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Intravenous fluids have become commonplace since their first use in 1831 during a cholera 
epidemic (1). In modern times, it is used to hydrate patients who are either not allowed or 
temporarily unable to eat, restore or maintain intravascular volume, or as a dilutive agent 
for intravenous medication. In the critically ill patient, intravenous fluid therapy and its 
management strategies are nothing short of a medical intervention. Nevertheless, fluid type 
selection, dosage and indication for fluids remain highly variable (2,3), despite two decades 
of research on fluid type and treatment guidelines. 
For fluid type, the discussion revolved around crystalloid versus colloid solutions and 
balanced versus unbalanced solutions. Crystalloid intravenous solution are generally 
a water and a salt solution, whereas colloid solutions add an insoluble protein (starch, 
gelatin, albumin) into a water and salt mixture to increase the colloid osmotic pressure of 
the intravenous fluid. Colloids were believed to reduce the volume of intravenous fluids 
needed, though the actual reduction was far less than hypothesized (4-8). Furthermore, 
governing bodies have issued warnings and discontinued the use of starch-based colloids 
in critically ill and septic patients due to the increased risk for acute kidney injury (AKI), 
renal replacement therapy, and mortality (9,10). Balanced solutions – like Ringer’s Lactate – 
consist of a water and salt solution approximating human plasma in concentration, whereas 
unbalanced solutions – like 0.9% saline, which is the most commonly used intravenous fluid 
– are considered unphysiological due to their huge variance from human plasma. The high 
chloride concentration in 0.9% saline is feared to result in AKI, as shown by one before-after 
study (11).  However, more recent studies showed no difference in the occurrence of renal 
adverse events between a balanced and an unbalanced solution (12). 
Ever since the landmark study in 2001 on early goal-directed therapy by Rivers et al. 
(13), aggressive fluid resuscitation has become the foundation for early treatment in septic 
patients. The Surviving Sepsis Campaign, a collaboration between the European Society of 
Intensive Care Medicine and the Society of Critical Care Medicine, adapted the treatment 
algorithm formulated by Rivers et al. to decrease mortality in sepsis by streamlining 
the early management and care (14). In these guidelines, additional fluid challenges are 
recommended after the initial resuscitation if hemodynamic parameters keep improving 
i.e. as long as the patient remains fluid responsive. Since then, the fluid management 
guidelines from the Surviving Sepsis Campaign have become standard care in sepsis, and 
by extension are used in most – if not all – critically ill patients in some form. 
Consequences of fluid management
Despite the reported benefits, this aggressive approach may lead to fluid overload, which 
has been associated with organ dysfunction and mortality (15-21). Since fluid overload 
should be avoided, research has focused on targets to guide fluid management and safely 
administer fluids. Traditional markers such as heart rate, blood pressure have consistently 
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been shown to be unreliable to guide fluid management, and physical examination suggestive 
of hypovolemia or inadequate perfusion is a poor predictor of whether a fluid bolus will 
lead to improvement of these physical signs and restoration of adequate perfusion (22,23). 
Similarly, central venous pressure is a good indicator of preload, but not whether preload 
will increase after a fluid bolus (24). Nevertheless, at least 75% of clinicians still use central 
venous pressure to guide fluid management (3,25). 
Since the rationale behind giving fluid boluses to restore or improve perfusion is to 
increase cardiac output, fluid responsiveness is defined as an increase in cardiac output 
– or more precisely, stroke volume – after a fluid challenge. To accurately assess the 
effects of additional fluid boluses, cardiac output, stroke volume and other associated 
hemodynamic indices need to be measured. Currently, there are various methods to do so, 
though the transpulmonary thermodilution technique has become the main method due 
to its relative ease of use and the possibility to measure extravascular lung water, which 
when elevated signals lung edema. In chapter 2, we investigate the effects of positive 
fluid balance on extravascular lung water formation and whether being fluid responsive 
protects from increases in extravascular lung water. In chapter 3, we analyze whether the 
occurrence of delayed cerebral ischemia in patients with a subarachnoid hemorrhage is 
associated with fluid intake and balance, and whether invasive hemodynamic monitoring 
with the transpulmonary thermodilution technique can reduce the total fluid intake while 
maintaining adequate cardiac output.
Fluid management guided by targeting urine output
Fluid intake is not the only determinant of fluid balance. Urine output is the only significant 
physiological method for fluid loss, though in patients with AKI, renal replacement therapy 
may be used to clear fluids. For this reason, urine output is a widely targeted parameter in 
the critically ill (3,25), and expert opinion historically advocated to keep urine output above 
0.5 ml/kg/h (26). It is viewed as a surrogate marker for renal perfusion by most clinicians, 
and is commonly used to guide fluid management. The rationale behind this is that when a 
patient is hypovolemic, renal perfusion decreases, and glomerular filtration pressure drops, 
leading to less urine output. Neurohormonal systems – i.e. renin-angiotensin-aldosterone, 
antidiuretic hormone and sympathetic activity – are then activated to restore intravascular 
volume and maintain glomerular perfusion by increasing renal fluid retention (27). If the 
hypovolemic state with hypoperfusion persists, this may lead to sustained renal damage and 
AKI (28). Nevertheless, whether targeting urine output in fluid management strategies has 
any effect on outcome has not been directly investigated.
In chapter 4, we investigate the effects of targeting urine output on AKI occurrence 
in the available literature on goal-directed fluid management versus conventional fluid 
management strategies. In chapter 5, we investigate what the effects of targeting urine 
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output are on mortality in the available literature on goal-directed fluid management 
versus conventional fluid management strategies. To prevent fluid overload, restrictive 
fluid management strategies have been devised which reduce the total volume of fluids 
administered to patients. In chapter 6, we analyze the effects of targeting urine output on 
AKI in the available literature on restrictive fluid management versus conventional fluid 
management strategies.
Fluid management in oliguria
While oliguria may be due to hypovolemia, oliguria in critically ill patients also has 
other causes which are not responsive to fluids. Physical stress due to pain, surgery or 
hemodynamic changes may lead to adaptation by neurohormonal changes without the 
presence of hypovolemia (27). In sepsis, pro-inflammatory cytokines, immune cell activity 
and tubular stress due to microcirculatory dysfunction may also lead to oliguria (29-31). 
Simply put, administering fluids without an increase in urine output only further aggravates 
the disbalance between intake and loss. The inability differentiate between the cause of 
oliguria at the bedside increases the risk of fluid overload. 
For this reason, biomarkers such as neutrophil gelatinase associated lipocalin (NGAL) 
have been used to determine whether there is actual tubular injury. In chapter 7, we 
assessed whether NGAL can be used to identify treatable oliguric patients within the first 
few hours of intensive care admission. In chapter 8, we address whether fluid therapy 
affects isolated oliguria in the critically ill, and an increase in urine output after a fluid 
challenge is associated with cardiac fluid responsiveness or AKI, and the predictors for an 
increase in urine output and AKI in this population of oliguric critically ill patients.
Aim of the thesis
There appears to be a mismatch between intravenous fluid administration and fluid loss via 
urine output in the critically ill patient, which leads to fluid overload and related adverse 
events. The main aim of this thesis is to investigate whether additional fluid administration 
aimed at improving urine output has the desired effect, whether this effect can be predicted, 
and whether this effect impacts patients’ outcome.
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abstract
backgroUnd: Guidelines on the management of patients with aneurysmal subarachnoid 
haemorrhage (aSAH) recommend maintaining euvolaemia, but fluid loading beyond 
euvolaemia (hypervolaemia) may occur and has been suggested to cause harm. We aimed to 
investigate whether high early fluid input and balance are associated with delayed cerebral 
ischaemia (DCI), and if fluid input can be decreased using transpulmonary thermodilution 
(TPT) while maintaining adequate preload.
methods: We retrospectively included consecutively admitted aSAH patients to an 
academic intensive care unit (2007–2011; cohort 1) and with aSAH requiring invasive 
hemodynamic monitoring (2011-2013; cohort 2). Local guidelines recommended a standard 
fluid input of 3 liters daily. More fluids were administered when daily fluid balance fell below 
+500 ml. In cohort 2, fluid input in selected high-risk aSAH patients was guided by stroke 
volume and cardiac output measured by TPT per a strict protocol. Associations of fluid 
input and balance with DCI were analyzed with multivariable logistic regression (cohort 1) 
and changes in hemodynamic indices before and after institution of a TPT-protocol were 
assessed with linear mixed-models (cohort 2).
resUlts: We included 223 patients in cohort 1. Cumulative fluid input 0-72h after admission 
was associated with DCI (OR 1.19 per liter; 95% CI 1.07–1.32), whereas cumulative fluid 
balance was not associated with DCI (OR 1.06 per liter; 95% CI 0.97-1.17). In cohort 2 (23 
patients), using TPT fluid input could be decreased (day -2: 6.0±1.0L and day -1: 5.3±0.9L 
versus day 3: 3.4±0.3L, P=0.012 and P=0.008, respectively), while preload parameters and 
consciousness remained stable.
conclUsions: High early fluid input was associated with DCI. Invasive hemodynamic 
monitoring was feasible to safely and significantly reduce fluid input while maintaining 
adequate preload. Taken together these results indicate that fluid loading beyond a normal 
preload is prevalent, may increase DCI risk and can be minimized with a hemodynamic 
monitoring protocol. 
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introdUction
Delayed cerebral ischaemia (DCI) after aneurysmal subarachnoid haemorrhage (aSAH) affects 
approximately 30% of patients (1). DCI typically develops between days 4 and 14 after ictus 
(2), and may progress to cerebral infarction which is associated with poor outcome (3,4). 
Since hypovolemia is associated with DCI, standard management includes maintenance of 
euvolemia (5,6). Nevertheless, ascertainment of euvolemia is problematic in clinical practice 
but highly relevant for several reasons. Guidelines recommend using meticulous fluid 
balance monitoring to guide fluid management. However, fluid balance has been shown to 
be poorly indicative of volume status (7). In addition, euvolemia as a fluid management goal 
is subject to interpretation, which is illustrated by highly variable maintenance fluid practices 
in aSAH across neuro-critical care units (8-10). In clinical practice, many patients with aSAH 
receive excessive fluids with the aim to maintain a positive fluid balance. However, excessive 
fluid administration may result in more systemic complications, e.g. congestive heart failure 
and pulmonary deterioration (11-13). In addition, a recent overview of the current literature 
suggested that excessive fluids might also be detrimental to neurological outcomes (10). In 
contrast, hypervolaemic therapy - as part of triple-H therapy - has long been regarded as 
beneficial rather than potentially harmful in aSAH (10). Hypervolaemia, which may be defined 
as fluid input exceeding the amount necessary for adequate organ perfusion, may therefore 
be an ill-recognized cause of harm to the brain. Since fluid management in aSAH still relies 
importantly on fluid balance, it is clinically relevant to assess whether excessive fluids are 
beneficial or harmful with regard to neurological clinical course. When “hypervolaemia” as 
defined above is a frequently occurring and undesirable consequence of aiming for positive 
fluid balances, one may hypothesize that hemodynamic monitoring may help restricting 
fluid input without compromising adequate cardiac preload and cerebral blood flow.
The main objective of this study was therefore to investigate whether high early fluid 
input and fluid balances within 72 hours after admission are associated with the occurrence 
of DCI in aSAH patients. Our secondary objective was to report on the feasibility to decrease 
fluid input guided by cardiac output monitoring with transpulmonary thermodilution (TPT).
methods
Study design and population
In this report, we describe two thematically related but separate studies. A schematic 
representation of the design and aims of the separate cohorts is shown in Figure 3.1. The 
first study was a retrospective cohort study of consecutively admitted aSAH patients (cohort 
1) to a University hospital’s ICU (Erasmus MC, University Medical Center Rotterdam, the 
Netherlands) between October 2007 and October 2011 aiming to investigate whether high 
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early fluid input or positive fluid balances were associated with DCI. Because preliminary 
analyses of cohort 1 showed that high early fluid input was associated with DCI (14), we 
instituted a fluid management protocol using fluid responsiveness with TPT using the PiCCO 
device (Pulsion Medical Systems SE, Feldkirchen, Germany), assuming that a reduction in 
excessive fluid input while maintaining adequate cardiac preload might be possible. 
The second study (cohort 2) concerned the first series of aSAH patients (April 2011 
to September 2013, admitted to the same unit) managed with this newly instituted TPT 
protocol (Supplement 3.1) and was aimed at retrospectively assessing changes in fluid 
input and balances in the days before versus after TPT. 
The inclusion criteria for cohort 1 were: 18 years or older, aneurysmal subarachnoid 
haemorrhage, and admission to hospital ≤ 48 hours after ictus. The exclusion criteria were: 
heart failure known from medical history, renal insufficiency (creatinine > 150 µmol/L), 
pregnancy, death within 48 hours after admission. For cohort 2, the inclusion criteria were 
similar to the indications for TPT monitoring according to the fluid management protocol 
and concerned high-risk patients (detailed in Supplement 3.1 and 3.2). Briefly, these 
criteria concerned lower than expected blood pressure or highly negative fluid balance, 
signs of pulmonary or cardiac dysfunction or progressive neurological deterioration due 
Figure 3.1 Schematic representation of the study design.
TPT: transpulmonary thermodilution; aSAH: acute subarachnoid haemorrhage; ICU: intensive care unit; CVP: 
central venous pressure; CI: cardiac index; SVI: stroke volume index; EVLWI: extravascular lung water index; 
GEDVI: global end-diastolic volume index.
cohort of aSAH patients 
(all managed at an ICU, n=223) 
2007-2011 
cohort of high-risk aSAH patients 
(managed with TPT protocol at an 
ICU, n=23) 
2011-2013 
Implementation 
of TPT protocol 
No intervention 
Variables of interest: fluid input, fluid balance 
Cardiac output monitoring aiming 
for non fluid responsive patient 
Delayed cerebral ischemia 
Before and after start of TPT: 
1. Fluid intake and balance 
2. CVP, CI, SVI, EVLWI, GEDVI 
To assess whether fluid input and balance is 
associated with delayed cerebral ischemia  
To assess the impact of TPT on 
fluid input and balance 
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to DCI. Patients in both cohorts were identified through a hospital health service code 
indicating subarachnoid haemorrhage. The Institutional Medical Ethics Committee approval 
for both cohort studies was obtained and informed consent was not necessary given the 
observational nature of the studies and anonymization of patient data in accordance with 
Dutch legislation. Due to the retrospective nature, we did not perform a power analysis and 
used a sample size of convenience.
Diagnosis and patient management
All patients were routinely managed at an ICU. In both cohorts, patients were evaluated 
with head CT and CT angiography on admission. When no blood was seen on CT, a 
lumbar puncture was performed > 12 hours after ictus for spectrophotometric analysis 
of cerebrospinal fluid (CSF). During the inclusion period for cohort 1, coiling procedures 
were performed by a regional team of interventional neuroradiologists. Stable patients 
were temporarily transferred to a different hospital for endovascular treatment when an 
interventional neuroradiologist was not available within 24 hours in the admitting hospital 
(Erasmus MC). A detailed description of patient management during the ICU admission in 
the two cohorts is given in Supplement 3.2. 
Data collection and outcomes
For both cohorts, data were collected from the ICU patient data management system and 
electronic patient records. Fluid input included all infusion fluids (including pharmaceuticals, 
blood products and intraoperative fluids), tube feeding and normal diet. Fluid losses 
included urine output, intraoperative blood loss, gastric retentions and cerebrospinal fluid 
from intrathecal drains. Insensible loss was not accounted for in the analyses. Fluid balance 
was calculated by subtracting fluid loss from input. 
In cohort 1, fluid input, loss and balance of the first 3 days after admission (day 1: 
0-24 hours, day 2: 24-48 hours, day 3: 48-72 hours) were collected. Admission CT scans 
were evaluated for Hijdra sum scores (15). The primary outcome was DCI, defined by 
CT infarction, clinical deterioration or both without other cause, according to recently 
proposed consensus criteria (1,16). Two authors (LJMV and MvdJ) assessed the primary 
outcome. During outcome assessments, the authors were blinded to the daily fluid data. 
Consensus on the outcomes was obtained by discussion in case of initial disagreement. 
Glasgow Outcome Score (GOS) was assessed between 3 and 6 months after admission to 
the hospital as a secondary outcome. When GOS could not be retrieved from our electronic 
patient records, we sent a letter to the general practitioner to request the relevant 
information. 
In cohort 2, fluid data and Glasgow Coma Score (GCS) were collected over a period 
from up to three days before until three days after initiation of TPT. TPT parameters – 
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cardiac index (CI), stroke volume index (SVI), global end-diastolic volume index (GEDVI), 
and extravascular lung water index (EVLWI) – were collected during the study period, and 
the daily average values recorded. Central venous pressure (CVP) measurements were 
collected at least from the day before TPT initiation until three days after. In this cohort, DCI 
was assessed as defined in cohort 1 by one author (ME) who was blinded for other clinical 
data. In contrast to cohort 1, the primary outcome was the difference in fluid parameters 
before versus after start of TPT monitoring.
Statistical analysis
Data were summarized as number with percentage (categorical), as median with 
interquartile range (ordinal), and as mean ± standard error (continuous). Imputation of 
missing values in the fluid parameters and Hijdra sum scores in cohort 1 was performed with 
single imputation with regression based on relevant covariates and outcome (Supplement 
3.3). Patients with DCI and without DCI in cohort 1 were compared using the student’s t-test, 
Mann-Whitney U test, or Chi2 or Fisher’s exact test. In cohort 1, logistic regression models 
were created with cumulative fluid input or cumulative fluid balance during the first 24, 48 
and 72 hours of ICU admission and previously identified independent predictors for DCI 
as covariables: age, gender, World Federation of Neurosurgical Societies [WFNS] grading 
score at admission, and Hijdra sum scores on initial CT scan (17,18). Hijdra scores were 
dichotomized at their median and WFNS was dichotomized in good (WFNS, 1-3) and poor 
(WFNS, 4-5) grades for the analyses. Sensitivity analyses with cerebral infarction on CT due 
to DCI with or without clinical signs and a secondary analysis with GOS as outcome were 
done. Interaction between variables were assessed in each model. To assess whether the 
relation between fluid input or balance was non-linear, i.e. whether there was a specific cut-
off in the effect of fluid on outcome, we did similar analyses with fluid input as covariables 
dichotomized on a cut-off of 3, 4 and 5 liters daily. In cohort 2, fluid and hemodynamic 
parameters were compared before and after TPT using linear mixed-models with day 3 after 
initiation of TPT as the reference. The course of patients’ Glasgow Coma Scales before and 
after TPT was assessed with Wilcoxon signed rank test. A 2-sided P value of less than 0.05 
was considered statistically significant. All statistical analyses were performed using SPSS 
20.0.0 (IBM, Chicago, IL, USA).
resUlts
Cohort 1
We included 223 consecutive aSAH patients, of whom 91 (41%) developed DCI. General 
characteristics of patients with and without DCI are reported in Table 3.1. In total, 119 
observations (18%) of fluid input data, 119 observations (18%) of fluid loss data, 8 (3.6%) 
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Table 3.1 General characteristics of cohort 1
Variable no dci dci p
n 132 91
Female 82 (62) 61 (67) 0.480
Age (year) 55 ± 1.1 57 ± 1.5 0.289
Loss of consciousness at ictus 53 (41) 55 (61) 0.003
ICU admission within 24 hours 125 (95) 85 (94) 0.761
Admission GCS 14 (13 - 15) 13 (6 - 15) 0.001
Transferred for intervention within 72 hours 59 (45) 29 (32) 0.054
Aneurysm location
Anterior circulation 101 (77) 72 (79) 0.744
Posterior circulation 23 (17) 17 (19) 0.860
No aneurysm found 8 (6) 2 (2) 0.206
Hijdra cistern sum score 16 (9 - 20) 20 (14 - 23) 0.001
Hijdra ventricular sum score 2 (0 - 4) 3 (0 - 6) 0.010
Treatment day 1.8 ± 0.2 2.0 ± 0.4 0.911
Aneurysm treatment mode
Coiling 85 (64) 44 (48) 0.019
Clipping 31 (24) 25 (28) 0.532
No occlusion 16 (12) 22 (24) 0.029
Day of DCI diagnosis 8 ± 0.5
DCI diagnosis based on
CT only 34 (37)
Clinical signs only 31 (34)
Both CT and clinical signs 26 (29)
Daily mean arterial pressure (mm Hg)
Day 1 93.7 ± 1.1 99.3 ± 1.4 0.002
Day 2 97.2 ± 1.2 101.0 ± 1.8 0.072
Day 3 101.0 ± 1.3 104.0 ± 1.7 0.170
Mean hemoglobin (mmol/L)
Day 1 7.97 ± 0.08 7.82 ± 0.10 0.251
Day 2 7.45 ± 0.08 7.15 ± 0.13 0.050
Day 3 7.35 ± 0.09 6.95 ± 0.10 0.009
Mean heart rate (beats per minute)
Day 1 71.8 ± 1.1 73.8 ± 1.5 0.303
Day 2 69.7± 1.1 71.4 ± 1.7 0.389
Day 3 71.5 ± 1.2 72.8 ± 1.7 0.535
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Lowest peripheral oxygen saturation (%)
Day 1 89.8 ± 0.95 89.6 ± 0.98 0.875
Day 2 92.7 ± 0.52 91.7 ± 0.88 0.336
Day 3 91.6 ± 0.58 91.6 ± 0.58 0.943
GOS follow-up (months) 3.5 ± 0.1 2.8 ± 0.2 0.008
GOS <0.001
Death 11 (9) 33 (39)
Persistent vegetative state 0 1 (1)
Severe disability, dependent 2 (2) 16 (19)
Moderate disability, independent 21 (17) 10 (12)
Good recovery 88 (72) 25 (29)
6-month mortality 11 (9) 33 (38) <0.001
Data is reported as mean ± standard error, median (interquartile range) or number (percentage) where 
appropriate.  DCI: delayed cerebral ischemia; ICU: intensive care unit; GCS: Glasgow Coma
Variable no dci dci p
Figure 3.2 Daily fluid parameters in cohort 1.
Data are represented as mean with 95% CI as one-sided error bar. Differences between patients with and 
without DCI are indicated in Figures: * P<0.01. ICU: intensive care unit; DCI: delayed cerebral ischaemia.
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Table 3.1 General characteristics of cohort 1 (continued)
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Hijdra cistern sum scores, and 12 (5.4%) of Hijdra ventricle sum scores were missing and 
imputed. Mean hemoglobin (Hb) level at day 2 and 3 were lower and blood pressure at day 
1 and 2 were higher in patients who developed DCI versus those who did not.
In patients who later developed DCI, fluid input was higher on day 1 after admission (DCI: 
4.9 ± 0.19 L; no DCI: 4.4 ± 0.13 L; P=0.005) and day 2 (DCI: 5.0 ± 0.21 L; no DCI: 4.2 ± 0.12 L; 
P=0.004, Figure 3.2). Fluid balance did not differ between groups. In multivariable logistic 
regression models, cumulative fluid input was associated with an increased risk of DCI (0-
24h: OR 1.22 per liter, 95% CI 1.01 – 1.46; 0-48h: OR 1.26 per liter, 95% CI 1.10 – 1.44; and 
0-72h: OR 1.19 per liter, 95% CI 1.07 – 1.32, Table 3.2). There was no association between 
cumulative fluid balances and DCI (0-24h: OR 1.09 per liter, 95% CI 0.90 – 1.32; 0-48h: OR 
1.07 per liter, 95% CI 0.95 – 1.21; and 0-72 hours: OR 1.06 per liter, 95% CI 0.97 – 1.17). 
Table 3.2 Multivariable logistic regression models for cumulative fluid input and balance data from 
cohort 1 with DCI as outcome
fluid input Fluid balance
Variable or 95% CI Variable or 95% CI
Age (year) 1.01 0.99 – 1.04 Age (year) 1.01 0.99 – 1.03
Gender (female) 1.33 0.73 – 2.43 Gender (female) 1.24 0.69 – 2.24
Admission WFNS (> 3) 2.30 1.24 – 4.27 Admission WFNS (>3) 2.62 1.43 – 4.81
Hijdra Cistern score (≥ 17) 2.23 1.25 – 3.98 Hijdra Cistern score (≥ 17) 2.17 1.22 – 3.86
Hijdra Ventricular score (≥ 2) 1.11 0.60 – 2.05 Hijdra Ventricular score (≥ 2) 1.14 0.62 – 2.10
Fluid input 0 – 24h L 1.22 1.01 – 1.46 Fluid balance 0 – 24h (L) 1.09 0.90 – 1.32
Age (year) 1.01 0.99 - 1.04 Age (year) 1.01 0.99 – 1.03
Gender (female) 1.33 0.72 - 2.45 Gender (female) 1.24 0.68 – 2.23
Admission WFNS (> 3) 2.25 1.21 - 4.20 Admission WFNS (>3) 2.54 1.39 – 4.66
Hijdra Cistern score (≥ 17) 2.22 1.23 - 3.99 Hijdra Cistern score (≥ 17) 2.15 1.21 – 3.81
Hijdra Ventricular score (≥ 2) 1.14 0.61 - 2.12 Hijdra Ventricular score (≥ 2) 1.15 0.63 – 2.10
Fluid input 0 – 48h (L) 1.26 1.10 - 1.44 Fluid balance 0 – 48h (L) 1.07 0.95 – 1.21
Age (year) 1.01 0.99 - 1.04 Age (year) 1.01 0.99 – 1.03
Gender (female) 1.39 0.75 - 2.58 Gender (female) 1.24 0.69 – 2.25
Admission WFNS (> 3) 2.45 1.31 - 4.56 Admission WFNS (>3) 2.50 1.36 – 4.59
Hijdra Cistern score (≥ 17) 2.27 1.26 - 4.08 Hijdra Cistern score (≥ 17) 2.20 1.24 – 3.91
Hijdra Ventricular score (≥ 2) 1.17 0.63 - 2.18 Hijdra Ventricular score (≥ 2) 1.11 0.60 – 2.04
Fluid input 0 – 72h (L) 1.19 1.07 - 1.32 Fluid balance 0 – 72h (L) 1.06 0.97 – 1.17
WFNS: World Federation of Neurosurgical Societies grading score
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The logistic regression models including fluid input dichotomized at 3, 4 or 5 liters are 
reported in Table 3.3. Higher fluid input was still associated with increased risk for DCI in 
these analyses although specific cut-offs were not evident. The univariable analysis for the 
fluid variables is shown in Table 3.4. Adding Hb level and blood pressure as covariables 
to the multivariable analyses did not change the associations between fluid intake and 
DCI (data not shown). No significant interactions were found between the independent 
variables. 
Table 3.3 Multivariable logistic regression models (cohort 1) with fluid input, in the first 24 to 72 hours, 
dichotomized at various cutpoints, as predictors for delayed cerebral ischemia.
Variable or 95% CI or 95% CI or 95% CI
Fluid input cutoff 3 L 4 L 5 L
Age (year) 1.01 0.99 – 1.03 1.01 0.99 – 1.03 1.01 0.99 – 1.04
Gender (female) 1.25 0.69 – 2.26 1.26 0.70 – 2.27 1.32 0.72 – 2.41
Admission WFNS (> 3) 2.54 1.38 – 4.67 2.50 1.36 – 4.61 2.40 1.30 – 4.44
Hijdra Cistern score (≥ 17) 2.15 1.21 – 3.80 2.13 1.20 – 3.76 2.05 1.15 – 3.66
Hijdra Ventricular score (≥ 2) 1.17 0.64 – 2.14 1.16 0.63 – 2.12 1.13 0.61 – 2.09
Fluid input 0 – 24h (L) 1.40 0.56 – 3.52 1.29 0.71 – 2.35 2.18 1.17 – 4.04
Fluid input cutoff 6 L 8 L 10 l
Age (year) 1.01 0.99 – 1.03 1.01 0.99 – 1.04 1.01 0.99 – 1.03
Gender (female) 1.26 0.70 – 2.28 1.26 0.69 – 2.30 1.28 0.70 – 2.32
Admission WFNS (> 3) 2.51 1.37 – 4.61 2.48 1.34 – 4.58 2.51 1.37 – 4.63
Hijdra Cistern score (≥ 17) 2.19 1.23 – 3.89 2.15 1.20 – 3.85 2.13 1.20 – 3.79
Hijdra Ventricular score (≥ 2) 1.17 0.64 – 2.13 1.13 0.61 – 2.09 1.20 0.65 – 2.20
Fluid input 0 – 48h (L) 2.00 0.60 – 6.70 2.30 1.22 – 4.32 2.01 1.10 – 3.69
Fluid input cutoff 9 l 12 L 15 L
Age (year) 1.01 0.99 – 1.04 1.02 0.99 – 1.04 1.01 0.99 – 1.03
Gender (female) 1.23 0.68 – 2.23 1.27 0.70 – 2.31 1.27 0.69 – 2.32
Admission WFNS (> 3) 2.53 1.38 – 4.64 2.55 1.38 – 4.71 2.45 1.32 – 4.54
Hijdra Cistern score (≥ 17) 2.24 1.26 – 3.98 2.21 1.24 – 3.95 2.27 1.26 – 4.09
Hijdra Ventricular score (≥ 2) 1.12 0.61 – 2.05 1.13 0.61 – 2.08 1.24 0.67 – 2.31
Fluid input 0 – 72h (L) 3.89 0.42 – 36.1 1.93 1.02 – 3.65 2.60 1.39 – 4.89
Each set of variables shows the multivariate regression model for the specified cutoff value for cumulative fluid 
input.
WFNS: World Federation of Neurosurgical Societies grading score; OR: odds ratio; CI: confidence interval.
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Table 3.4 Univariable logistic regression models for data from cohort 1 with DCI as outcome
Variable or 95% confidence interval
Age (year) 1.01 0.99 – 1.03
Gender (female) 1.24 0.71 – 2.17
Admission WFNS score 2.81 1.59 – 4.96
Hijdra Cistern score 1.06 1.02 – 1.10
Hijdra Ventricular score 1.13 1.04 – 1.23
Fluid input 0–24h (L) 1.25 1.05 – 1.49
Fluid input 0–48h (L) 1.28 1.12 – 1.45
Fluid input 0–72h (L) 1.17 1.06 – 1.29
Fluid balance 0–24h (L) 1.08 0.91 – 1.29
Fluid balance 0–48h (L) 1.10 0.98 – 1.24
Fluid balance 0–72h (L) 1.08 0.99 – 1.18
WFNS: World Federation of Neurosurgical Societies grading score
The sensitivity analysis with DCI infarction as the outcome yielded similar results as 
those with DCI, but cumulative fluid balances 0-48 hours and 0-72 hours after admission 
were associated with cerebral infarction due to DCI (0-48h: OR 1.15 per liter, 95% CI 1.00 – 
1.33, and 0-72 hours: OR 1.12 per liter, 95% CI 1.01 – 1.25, Table 3.5. Secondary outcome 
analysis for Glasgow Outcome Score showed similar results as the analysis for fluid input 
and DCI (Table 3.6).
Cohort 2
We included the first 23 patients with aSAH who had an indication for TPT according to the 
protocol (Appendix 3.1). Table 3.7 shows some pertinent characteristics on demographics, 
aneurysm management and outcomes. Eleven patients (48%) died within 30 days after 
ICU admission and this high mortality relates to the inclusion of high-risk patients for TPT, 
including those with recent signs of DCI. Fluid data from day -3 until day 3 relative to TPT 
initiation were available for 11, 10, 21, 23, 21, 20 and 20 patients, respectively (e.g. only 
11/23 patients had been admitted with available fluid data, 3 days before TPT initiation).
Daily fluid parameters and daily GCS are shown in Figure 3.3. Compared to day 3 
(reference) after TPT initiation (fluid input: 3.4 ± 0.3 L), fluid input was higher on day -2 
(6.0 ± 1.0 L; P=0.012) and day -1 (5.3 ± 0.9 L; P=0.008). Daily fluid loss was lower on day 
-3 when compared to day 3 (2.7 ± 0.5 L versus 3.4 ± 0.4 L; P=0.049). As a result, daily fluid 
balance was higher on day -3 (1.8 ± 0.6 L; P=0.003), day -2 (2.9 ± 1.4 L; P<0.001) and day 
-1 (1.4 ± 0.4 L; P=0.014) when compared to day 3 (0.0 ± 0.2 L). Median daily GCS on day 
-1 was not significantly lower than the median daily GCS on day 3 (GCS of 7 [5.5 – 7.5] 
versus 9 [6 – 14]; P=0.18). Most hemodynamic parameters as measured during TPT (CVP, 
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Table 3.5 Multivariable logistic regression models for cumulative fluid input and balance data with DCI 
infarction as outcome from cohort 1.
fluid input Fluid balance
Variable or 95% CI Variable or 95% CI
Age (year) 0.97 0.95 – 1.00 Age (year) 0.97 0.95 – 1.00
Gender (female) 0.98 0.51 – 1.91 Gender (female) 0.91 0.47 – 1.74
Admission WFNS (> 3) 3.25 1.66 – 6.35 Admission WFNS (>3) 3.81 1.97 – 7.39
Hijdra Cistern score (≥ 17) 1.60 0.83 – 3.07 Hijdra Cistern score (≥ 17) 1.57 0.82 – 3.00
Hijdra Ventricular score (≥ 2) 1.12 0.56 – 2.24 Hijdra Ventricular score (≥ 2) 1.10 0.55 – 2.20
Fluid input 0 – 24h (L) 1.24 1.02 – 1.51 Fluid balance 0 – 24h (L) 1.16 0.94 – 1.45
Age (year) 0.97 0.95 – 1.00 Age (year) 0.97 0.95 – 1.00
Gender (female) 0.98 0.50 – 1.91 Gender (female) 0.89 0.46 – 1.72
Admission WFNS (> 3) 3.26 1.66 – 6.40 Admission WFNS (> 3) 3.63 1.87 – 7.05
Hijdra Cistern score (≥ 17) 1.52 0.79 – 2.94 Hijdra Cistern score (≥ 17) 1.57 0.82 – 3.00
Hijdra Ventricular score (≥ 2) 1.14 0.56 – 2.29 Hijdra Ventricular score (≥ 2) 1.09 0.54 – 2.19
Fluid input 0 – 48h (L) 1.26 1.08 – 1.47 Fluid balance 0 – 48h (L) 1.15 1.00 – 1.33
Age (year) 0.97 0.95 – 1.00 Age (year) 0.97 0.95 – 1.00
Gender (female) 1.02 0.52 – 1.99 Gender (female) 0.92 0.47 – 1.78
Admission WFNS (> 3) 3.58 1.83 – 7.01 Admission WFNS (> 3) 3.62 1.86 – 7.05
Hijdra Cistern score (≥ 17) 1.55 0.80 – 2.99 Hijdra Cistern score (≥ 17) 1.61 0.84 – 3.09
Hijdra Ventricular score (≥ 2) 1.16 0.58 – 2.33 Hijdra Ventricular score (≥ 2) 1.06 0.53 – 2.13
Fluid input 0 – 72h (L) 1.18 1.05 – 1.32 Fluid balance 0 – 72h (L) 1.12 1.01 – 1.25
WFNS: World Federation of Neurosurgical Societies grading score
CI, SVI) remained within the range of normal values in spite of significant reductions of fluid 
input and balances after start of TPT, except GEDVI and EVLWI which were higher than the 
normal ranges of 650-800 ml/m2 and 3.0-7.0 ml/kg respectively (Figure 3.4).
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Table 3.6 Multivariate logistic regression models for cumulative fluid input and balance data from cohort 
1 with Glasgow Outcome Score as outcome.
fluid input Fluid balance
Variable or 95% CI Variable or 95% CI
Age (year) 1.04 1.01 – 1.07 Age (year) 1.04 1.01 – 1.07
Gender (female) 1.24 0.62 – 2.47 Gender (female) 1.16 0.59 – 2.29
Admission WFNS (> 3) 3.55 1.78 – 7.10 Admission WFNS (> 3) 4.05 2.06 – 7.95
Hijdra Cistern score (≥ 17) 1.51 0.77 – 2.94 Hijdra Cistern score (≥ 17) 1.43 0.74 – 2.77
Hijdra Ventricular score (≥ 2) 1.07 0.53 – 2.17 Hijdra Ventricular score (≥ 2) 1.16 0.58 – 2.33
Fluid input 0 – 24h L 1.22 1.00 – 1.49 Fluid balance 0 – 24h (L) 0.96 0.77 – 1.19
Age (year) 1.04 1.01 – 1.07 Age (year) 1.04 1.01 – 1.07
Gender (female) 1.18 0.59 – 2.35 Gender (female) 1.16 0.59 – 2.29
Admission WFNS (> 3) 3.67 1.84 – 7.30 Admission WFNS (> 3) 4.04 2.05 – 7.95
Hijdra Cistern score (≥ 17) 1.46 0.75 – 2.84 Hijdra Cistern score (≥ 17) 1.44 0.74 – 2.79
Hijdra Ventricular score (≥ 2) 1.12 0.55 – 2.26 Hijdra Ventricular score (≥ 2) 1.14 0.57 – 2.29
Fluid input 0 – 48h (L) 1.14 1.01 – 1.29 Fluid balance 0 – 48h (L) 1.00 0.87 – 1.15
Age (year) 1.05 1.02 – 1.08 Age (year) 1.04 1.02 – 1.07
Gender (female) 1.22 0.61 – 2.46 Gender (female) 1.12 0.56 – 2.23
Admission WFNS (> 3) 3.86 1.94 – 7.67 Admission WFNS (> 3) 3.96 1.99 – 7.84
Hijdra Cistern score (≥ 17) 1.47 0.75 – 2.89 Hijdra Cistern score (≥ 17) 1.50 0.77 – 2.92
Hijdra Ventricular score (≥ 2) 1.12 0.55 – 2.27 Hijdra Ventricular score (≥ 2) 1.07 0.53 – 2.16
Fluid input 0 – 72h (L) 1.12 1.00 – 1.25 Fluid balance 0 – 72h (L) 1.00 0.89 – 1.11
WFNS: World Federation of Neurosurgical Societies grading score
N=207, for 16 patients the outcome could not be retrieved.
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Table 3.7 General characteristics at start of invasive hemodynamic monitoring in cohort 2.
Variable
n 23
Female 19 (83)
Age (year) 55 ± 3.4
GCS 8 (6 - 13)
DCI (infarction, clinical and both) 10 (44)
Hijdra cistern sum score 14.6 ± 1.2
Hijdra ventricular sum score 4.4 ± 0.9
Treatment mode
Coiling 9 (39)
Clipping 11 (48)
No occlusion 3 (13)
IHM initiated (days after admission) 1.4 ± 0.4
30-day mortality 11 (48)
Data is reported as mean ± standard error, median (interquartile range) or number (percentage) where 
appropriate.  DCI: delayed cerebral ischemia; GCS: Glasgow Coma Score; IHM: invasive hemodynamic monitoring 
by transpulmonary thermodilution.
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Figure 3.3 Daily fluid parameters and associated course of Glasgow Coma Scale in cohort 2.
Data are represented as mean with standard error as one-sided error bar and median with interquartile range 
for GCS. TPT day 3 is used as the reference value (R) for the comparisons. + P<0.05; * P<0.01; ** P<0.001. TPT: 
transpulmonary thermodilution. GCS: Glasgow Coma Scale
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discUssion
The main finding of this study in patients with aSAH is that early high daily fluid input was 
independently associated with DCI and poor outcome. In addition, we showed that fluid 
loading beyond normal preload occurred in clinical practice and that it was feasible to 
significantly restrict fluid input while maintaining adequate preload with TPT in selected 
high-risk aSAH patients. Taken together, these results corroborate the potential harm from 
fluid overload in aSAH patients with regard to DCI and support further study on potential 
benefit of fluid restriction guided by hemodynamic monitoring.
We found that early high fluid input was associated with DCI. However, our cohort data, 
and specifically the analyses for fluid input of 3, 4 or 5 liters daily, did not indicate a specific 
cut-off for fluid input beyond which DCI-risk was increased. Therefore, firm conclusions 
about upper limits of fluid input for this cohort are not possible in spite of the robust finding 
that more fluids associate with DCI-risk, indicating that fluid titration in aSAH should still 
be individualized. In a sensitivity analysis with cerebral infarction on CT as the outcome, 
Figure 3.4 Hemodynamic data in cohort 2.
Data is represented as mean with standard error as two-sided error bar. TPT day 3 is used as the reference 
value (R) for the comparisons: there were no significant differences over time. Because the placement of a 
jugular or subclavian central venous catheter at admission for aSAH is not standard practice in our institution, 
data for central venous pressure is only available from at least TPT day -1 until TPT day 3. TPT: transpulmonary 
thermodilution.
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positive net fluid balances also showed an association. Furthermore, the hemodynamic 
data in cohort 2 seem to indicate a state of hypervolaemia, since GEDVI was higher than 
reference values. There are several possible explanations why high fluid input is associated 
with DCI (10). First, increased “fluid throughput” may cause fluids to accumulate in the 
interstitial space when the blood-brain-barrier is damaged, which may impede local oxygen 
diffusion to neurons (19-21). Second, haemodilution as a consequence of fluid loading may 
decrease shear-stress in the cerebral arteries, which may be detrimental to the integrity 
of the blood-brain-barrier (22), and lower hemoglobin levels may contribute to DCI due to 
decrease oxygen transport capacity of the blood, in line with our findings. Lastly, in cohort 
1, as fluid input increased, fluid loss did not increase equally to match the higher fluid input 
(data not shown). Conversely, in cohort 2, when fluid input decreased, diuresis seemed to 
increase. Both observations may theoretically be explained by (renal) venous congestion 
(i.e. high CVP) (23). It has been postulated that venous congestion may also impede 
cerebral venous outflow and lead to intracranial pressure increase (24). Furthermore, 
several studies in brain injured critically ill patients have found CVP to be higher in patients 
with worse neurological outcomes (11,13,25). Similarly, a recent study found that higher 
CVP was associated with lower brain tissue oxygen saturation and worse outcome in 
post-cardiac arrest patients (26). We acknowledge that these data do not provide proof 
and should be regarded as hypothesis-generating regarding the pathophysiologic role of 
venous congestion in DCI due to excessive fluids.
Our findings substantiate previous findings. Several investigators have described early 
mean daily fluid input varying from 3.3 to 6.6 liters and daily fluid balances varying from 
-0.6 to +2.1 liters (7,25,27-30). However, studies investigating the relation between fluid 
management and DCI are scarce (25,29,31,32). Two studies investigating the effect of early 
goal-directed hemodynamic management reported that mean daily fluid input was 2.7 
liters in the first three days with mean fluid balances between -0.5 to 0.5 liters when using 
TPT (33,34). Using goal-directed hemodynamic management, less fluid was infused and 
fewer patients suffered from DCI than in the conventional treatment group in line with our 
findings (34). The association of fluid input but not fluid balance with DCI is also in line with 
previous reports (23,28).
Some limitations of our study should be considered. Due to the retrospective nature, 
potential unmeasured confounding factors and retrieval of relevant patient data are an 
inherent threat to the associations found in cohort 1. Consequently, causality between 
high fluid input and DCI cannot be proven with this retrospective study. Another limitation 
is the fact that we did not differentiate between or adjust for crystalloids versus synthetic 
colloids, since DCI has been associated with use of synthetic colloids (29,35). However, 
these compounds were administered mainly in case of clinical deteriorations due to DCI 
as per out protocol at the time of the study period and not typically in the first three 
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days when fluid data were collected for this study. Furthermore, we did not adjust fluid 
parameters for weight. In cohort 2, due to the variable start of the TPT protocol, in relation 
to clinical admission, missing/unavailable values were unavoidable (e.g. when TPT was 
initiated soon after admission). Finally, our institutional fluid management protocol used 
in cohort 2 is based on our best clinical practice and the scarce literature available (33,34), 
but has not been validated outside our ICU. The patients in cohort 2 are those more likely 
to develop DCI, so the generalizability of our protocol to low risk aSAH patients is uncertain. 
Because both cohorts are from a single center and due to the sample size used, the overall 
generalizability may be limited.
The strengths of our study include a consecutive series of patients managed at an ICU 
with detailed data on fluid management and prognostic factors, as well as assessment 
of the primary outcome (DCI) according to recently proposed criteria (1,16). Second, we 
imputed missing data with multiple imputations enhancing the statistical power. Finally, 
our data are in line with the recent notion that excessive fluid input is an established risk 
factor for adverse outcome in non-neurological critically ill patients(36) and aSAH patients 
in particular (11,29,33,34,37).
A guideline endorsed by the American Heart Association advised to maintain euvolemia 
(5). However, establishing euvolemia is difficult when clear definitions are absent. This is 
reflected by the fact that mean daily fluid input and fluid balance in cohort 1 exceeded 
the predefined targets in our institutional protocol. Similarly, the hemodynamic data 
in cohort 2 suggested patients were hypervolemic when TPT was initiated. A multi-
disciplinary consensus statement recommended use of hemodynamic monitoring devices 
in aSAH, only in hemodynamically unstable patients (38). A practical approach based on 
previous literature (10,39) and our results may be to aim for euvolemia by giving 2.5-3.5 
L/day in most patients with a fluid balance around zero. Invasive monitoring may then be 
considered in patients in whom deviations from euvolemia are suspected and considered 
highly detrimental, or in case of signs of stress cardiomyopathy, neurogenic pulmonary 
edema, excessive diuresis or progressive DCI. Of note, when monitoring is applied, the 
ambiguous term “euvolemia” might best be replaced by “adequate preload”.
conclUsion
High early daily fluid input is associated with DCI after aSAH. We showed the feasibility 
of a protocol using TPT to significantly reduce fluid input and balance without negatively 
impacting on preload parameters and Glasgow Coma Scale. Further study seems warranted 
to determine whether and when hemodynamic monitoring can help establishing both 
restricted fluid management and improved clinical outcomes.
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Supplement 3.1 Invasive hemodynamic monitoring protocol using transpulmonary 
thermodilution.
SAH fluid management protocol with transpulmonary thermodilution. Basic tenets 
underlying the protocol: 
• Hypovolemia is to be avoided and increases DCI risk.
• Cardiac wall motion abnormalities (CWMA) are frequent but clinically evident signs of 
heart failure much less so.
• Hypotension after SAH (systole<100mmHg or MAP<65mmHg) is unusual and requires an 
investigation into its cause and prompt management.
• Neurogenic pulmonary edema (NPE) and cardiac wall motion abnormalities pose risks to 
adequate CBF and oxygenation and are associated with worse outcomes and occurrence 
of DCI.
• In general a diagnosis of NPE or CWMA requires invasive hemodynamic monitoring 
(IHM).
• IHM to assess volume status after SAH is focused on fluid responsiveness as a primary 
dynamic hemodynamic parameter, instead of only static parameters.
• It is not advised to start inotropes in case of NPE or CWMA without the concurrent 
initiation of IHM to guide their use.
• In patients with a Glasgow Coma Scale (GCS) >8, improvements of consciousness are 
also an important end-point of fluid management next to the hemodynamic parameters.
• Considering the previous point, a perfectly awake patient with a GCS=15 is considered to 
be “euvolemic” with regard to CBF.
PiCCO algorithm SAH*
When EVLWI≥13 and PEEP≥10
and oxygen saturation<92% with 
FiO2>50%
and not fluid responsive: consider 
diuretics
CI ?
Fluid bolus (250ml Voluven in 15 minutes)
Start dobutamine until CI≥4
(alternatively: enoximone
when HR>100)+
*In case of DCI:
In case of improvement of GCS≥2 or
improving focal neurogical deficit a 
next step in the flowchart may be 
deferred
+dobutamine up to 5 
mcg/kg/min and enoximone up 
to 2 mcg/kg/min
STOP algorithm
Consider aborting PiCCO 
monitoring after 24 hours
START PiCCO
CI<4
CI<4
STOP
no
yes
yes
yes
no
no
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Supplement 3.2 Appendix on patient management in each cohort.
Cohort 1:
Routine fluid input at the ICU was started at a total of 3 liters of fluid per 24 hours as per the 
local SAH management protocol. This included all oral fluids plus, if necessary, 0.9% saline 
intravenously. Additional fluids were given (6% hydroxyethyl starch 130/0.4 or 0.9% saline), 
when fluid balance became less than +500 ml daily or when body temperature exceeded 
38°C (0.5 liters of 0.9% saline for every degree Celsius per 24 hours). All patients were treated 
with oral nimodipine 6 x 60 mg for 21 days. When endovascular coiling of the ruptured 
aneurysm was feasible this was done as soon as possible. Surgical treatment was scheduled 
when coiling was technically not feasible and as soon as the patient had a World Federation 
of Neurosurgical Societies (WFNS) grade I or II. Otherwise, surgery was postponed until day 
12 after the initial bleed. Immediate treatment of the ruptured aneurysm was postponed 
when the patient had an admission WFNS grade V and treatment was scheduled as soon as 
WFNS grade improved.
Cohort 2:
Cohort 2 consisted of patients managed according to a fluid management protocol guided by 
cardiac output monitoring with transpulmonary thermodilution (Supplemnent 3.1). Briefly, 
the inclusion criteria for cohort 2 were equal to the entry characteristics for the protocol 
and were GCS < 15 and at least one of the following characteristics: hypotension (systolic 
blood pressure < 100 mmHg or MAP < 65 mmHg), not responsive to fluid administration; 
(neurogenic) pulmonary edema or clinically relevant cardiac dysfunction (as judged by 
attending ICU physician); negative fluid balance (-1L/day); DCI as judged by attending 
neurologist and either a persisting negative fluid balance (-500 mL/day) or progressive 
neurological deterioration despite extra fluid loading (aimed at mean arterial pressure of 
at least 80 mmHg and positive fluid balance). If cardiac index was < 4.0 L/min/m2, a fluid 
bolus of 250 mL 6% hydroxyethyl starch 130/0.4 (Voluven) was infused and repeated until 
cardiac index increased to > 4.0 L/min/m2 or did not further increase. If cardiac index did 
not increase after a fluid bolus, dobutamine was started and titrated until cardiac index 
increased to target or dosage reached 5 µg/kg/min. If a patient had an indication for 
dobutamine but a heart rate of > 100 beats per minute, enoximone was started and titrated 
similarly to a maximum dosage of 2 µg/kg/min (Supplement 3.1). 
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Supplement 3.3 Imputation assumptions and formula used in the Aregimpute function in R
(1) the number of missing values for each variable or the number of complete vs incomplete 
cases 
In total, 119 observations (18%) of fluid input data, 119 observations (18%) of fluid loss data, 
8 (3.6%) Hijdra cistern sum scores, and 12 (5.4%) of Hijdra ventricle sum scores were missing 
and imputed. There were 146 complete cases prior to imputation (65%).
(2) The outcome was available for all patients and the missing number of key exposure 
variables have already been mentioned. Below is a comparison table between the fluid 
volumes of the measured values and the imputed values.
no dci dci
Complete cases (n) Imputed cases (n) Complete cases (n) Imputed cases (n)
fluid input
day 1 4.4 ± 0.13 (110) 4.4 ± 0.13 (132) 5.0 ± 0.20 (82) 4.9 ± 0.19 (91)
day 2 4.2 ± 0.12 (107) 4.2 ± 0.12 (132) 4.8 ± 0.22 (82) 5.0 ± 0.21 (91)
day 3 4.5 ± 0.17 (92) 4.6 ± 0.15 (132) 4.7 ± 0.18 (77) 4.8 ± 0.17 (90)*
fluid loss
day 1 2.8 ± 0.13 (110) 2.9 ± 0.13 (132) 3.3 ± 0.19 (82) 3.3 ± 0.17 (91)
day 2 3.2 ± 0.16 (107) 3.2 ± 0.14 (132) 3.5 ± 0.22 (82) 3.6 ± 0.23 (91)
day 3 3.9 ± 0.18 (92) 3.9 ± 0.15 (132) 3.9 ± 0.21 (77) 3.8 ± 0.19 (90)*
Hijdra sum score
Cistern 16 (9 - 20) (127) 16 (9 - 20) (132) 20 (14 - 23) (88) 20 (14 - 23) (91)
Ventricular 2 (0 - 4) (124) 2 (0 - 4) (132) 3 (0 - 6) (87) 3 (0 - 6) (91)
Fluid in liters ± standard error. Score with interquartile range. DCI: delayed cerebral ischemia. *One patient died 
at day 3 and data for this patient was therefore not imputed.
(3) The main reason contributing to occurrence of missing data in cohort 1 is due to the 
transferral of patients for endovascular interventions, see the methods section. Transferals 
were at random, based on in which hospital the on-call intervention neuroradiologist was 
based in.
(4) The data are assumed to be missing at random to allow statistical imputation. 
(5) The imputation was performed with the AregImpute function in R statistical software 
using the following variables in the model: sex, age, admission GCS, aneurysm location, 
treatment mode, GOS, death within 6 months, Hijdra cistern score, Hijdra ventricle score, 
intracranial hemorrhage, diastolic/systolic/mean blood pressure at admission, fluid input on 
day 1 to 3 and fluid loss day 1 to 3. The specific formula used in the Aregimpute function is 
shown below.
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Formula:
sex + age + admissionGCS + as.factor(aneurloc.m) + as.factor(treatment_mode.m) + I(GOS.m) 
+ death_within_6months.m + HIJDRA_CIST_SUMSCORE.m + HIJDRA_VENTR_SUMSCORE.m 
+ ICH.m + DBPadmission.r + SBPadmission.r + MAPadmission.r + I(TEMPadmission.m) + 
FL_INTAKE_D1.m + FL_INTAKE_D2.m + FL_INTAKE_D3.m + FL_EXCRETION_D1.m + FL_
EXCRETION_D2.m + FL_EXCRETION_D3.m 
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part ii
fluid management guided 
by targeting urine output

CHAPTER 4
targeting oliguria 
reversal in goal 
directed hemodynamic 
management does not 
reduce renal dysfunction 
in perioperative and 
critically ill patients: a 
systematic review and 
meta-analysis
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abstract
backgroUnd: We investigated whether resuscitation protocols including oliguria reversal 
as a target – to achieve and maintain urine output above a predefined threshold – prevent 
acute renal failure (ARF).
methods: We performed a systematic review and meta-analysis using studies found by 
searching MEDLINE, EMBASE, and references in relevant reviews and articles. We included 
all studies which compared “conventional fluid management” (CFM) with “goal-directed 
therapy” (GDT) using cardiac output, urine output, or oxygen delivery parameters, and 
reported the occurrence of ARF in critically ill or surgical patients. We divided studies in 
groups with and without oliguria reversal as a target for hemodynamic optimization. We 
calculated combined odds ratio (OR) and 95% confidence intervals (CI) using random-effects 
meta-analysis.
resUlts: We based our analyses on 28 studies. In the overall analysis, GDT resulted in less 
ARF than CFM (OR 0.58; 95% CI 0.44 to 0.76; P<0.001; I2= 34.3%; N=28). GDT without oliguria 
reversal as a target resulted in less ARF (OR 0.45; 95% CI 0.34 to 0.61; P<0.001; I2=7.1%; 
N=7) when compared with CFM with oliguria reversal as a target. The studies comparing 
GDT with CFM in which reversal of oliguria was targeted in both or in neither group did not 
provide enough evidence to conclude a superiority of GDT (targeting oliguria reversal in 
both protocols: OR 0.63; 95% CI 0.36 to 1.10; P=0.09; I2=48.6%; N=9, in neither protocol: OR 
0.66; 95% CI 0.37 to 1.16; P=0.14; I2=20.2%; N=12).
conclUsions: Collectively, current literature favors targeting circulatory optimization 
by GDT without targeting oliguria reversal to prevent ARF. Future studies are needed to 
investigate the hypothesis that targeting oliguria reversal does not prevent ARF in critically 
ill and surgical patients.
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introdUction
Intravenous fluids are administered to compensate for losses during or after surgery, and to 
increase intravascular volume in hypovolemic patients. Textbooks frequently recommend 
using urine output to help guide fluid therapy (1-3). Oliguria is often viewed as a marker 
of decreased kidney and organ perfusion, and as a trigger to administer fluids to prevent 
acute renal failure (ARF) and organ damage. However, oliguria may not solely be caused by 
a suboptimal hemodynamic status, but may also be attributed to medications or hormonal 
effects, which reduces its value as a fluid loading criterion. Large observational studies have 
found no relation between intraoperative urine output and subsequent ARF (4-6). Even 
in the critically ill, oliguria lacks utility to predict subsequent ARF (7). Thus, fluids may be 
administered unnecessarily, which in turn could lead to fluid overloading. Several studies 
suggest that excess fluid administration is associated with adverse clinical outcomes in 
patients with ARF (8-11). 
Goal-directed therapy (GDT) strategies in the perioperative and critical care settings 
target specific hemodynamic parameters related to cardiac output or oxygen delivery along 
with intensive monitoring. In high risk surgical or critically ill patients, such strategies are 
increasingly being used to guide fluid therapy and have been associated with less morbidity 
and mortality (12-16). This effect may even be greater when hemodynamic targets are not 
achieved by additional fluid administration but with inotropic agents (16). 
We hypothesized that including oliguria reversal as a target – defined as achieving and 
maintaining urine output above a predefined threshold – does not prevent ARF, especially 
when used alongside cardiac output or oxygen delivery related hemodynamic parameters. 
In this systematic review and meta-analysis, we focused on whether including oliguria 
reversal as a target in the protocols of studies comparing GDT strategies with conventional 
fluid management (CFM) strategies reduced the incidence of renal dysfunction in surgical 
and critically ill patients.
methods
We performed a systematic literature search to identify all studies comparing GDT with CFM 
that reported ARF. We excluded all animal studies, articles not in English, studies unavailable 
as full-text, and studies with pediatric patients.
We defined GDT as any hemodynamic optimization strategy in the perioperative and 
critical care setting utilizing parameters related to cardiac output and oxygen delivery, 
irrespective of the device or method used to measure these parameters, and either 
exclusively or in combination with the classical parameters such as blood pressure, heart 
rate and urine output. To minimize the bias of protocol effect, the hemodynamic targets 
used in CFM had to be clearly defined. Due to variability in the definition of renal dysfunction 
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in the studies we evaluated, and to a very specific definition for the term acute kidney 
injury defined by the Acute Dialysis Quality Initiative (17), we used the term ARF to include 
a relative or absolute increase in serum creatinine, need for renal replacement therapy, 
any severity and duration of oliguria, or any combination of the previous - as defined in 
the selected studies. We defined targeting oliguria reversal as using fluids or vasoactive 
medication to achieve and maintain urine output above a previously defined threshold. 
The use of diuretics to increase urine output was not considered a resuscitation method 
to reverse oliguria, due to the difficulty in using urine output to assess oxygen delivery or 
blood flow after the administration of diuretics.  We used urine output thresholds as set by 
the selected studies.
We accessed the MEDLINE (1966 – present) database via PubMed and the EMBASE 
(1980 – present) database (last search March 2014) with no limits for publication date or 
language (Table S4.1). We used the ‘related articles’ function in PubMed to identify eligible 
studies that were not found by the main search queries. References of studies considered 
for inclusion and references of review articles were hand searched for eligible studies. We 
also used the ‘cited reference search’ function of Web of Knowledge (Thomson Reuters) to 
find potential studies. We screened the title and abstract of the studies found in the search 
to see whether GDT was compared with CFM, and whether the occurrence of ARF was 
reported. In case of doubt we screened the full-text article. Using a predefined study form, 
one author (M.E.) scored the following variables: total study population; group sizes; type of 
patients; definition of GDT and CFM; treatment targets in both groups; devices used in GDT 
to assess hemodynamic parameters; timing of intervention; fluid intake and balance during 
and after study period; definition of ARF used; and development of ARF.  Once included, the 
studies were scored according to the Jadad scale on: reporting whether it was randomized 
and by which method; the method and appropriateness of blinding used; and adequate 
reporting of withdrawals and dropouts (18).
Statistical analysis
All included studies were grouped on whether oliguria reversal was included as a target 
in the study protocol. Studies comparing GDT and CFM where neither treatment protocol 
involved oliguria reversal were designated as GDT- vs. CFM-, studies comparing GDT without 
oliguria reversal as a target with CFM with oliguria reversal as a target as GDT- vs. CFM+ 
and studies comparing GDT with CFM where both treatment arms had oliguria reversal as a 
target as GDT+ vs. CFM+. Odds ratios (OR) and 95% confidence intervals (CI) were calculated 
for each study based on their reported treatment arm specific sample size and observed 
frequencies of ARF.
In the primary analysis, we compared the number of patients with ARF in the two 
treatment arms in all studies as well as separately for each of the three study protocol 
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groups (GDT+ vs. CFM+, GDT- vs. CFM+, GDT- vs. CFM-) using random effects meta-analysis. 
To gain further insights into the role of the treatment period in which the protocol was 
used (pre-, vs intra-, or postoperative), we meta-analyzed studies in which the treatment 
protocol was used during the preoperative or intraoperative setting separately from 
studies in which the protocol was used during the postoperative or intensive care unit 
(ICU) setting, in a secondary analysis. Studies in which the treatment protocol was used 
during both periods were included in both analyses. Therefore, we performed a sensitivity 
analysis in which only studies were included that used the treatment protocol only during 
the postoperative and ICU setting.
To investigate potential sources of bias, we also identified subgroups of studies, which 
were defined based on ARF definition, type of monitoring, differences in fluid intake between 
GDT and CFM, year of publication, and Jadad score. We compared the ARF definition 
with the RIFLE and AKIN criteria and assigned the studies to one of three ARF subgroups: 
studies defining ARF using RIFLE and AKIN criteria (“exact”), studies defining ARF using a 
relative increase in serum creatinine near 50% or an absolute serum creatinine increase 
near 0.3 mg/dl (27 μmol/l) (“similar”) and studies using an absolute cut-off value for serum 
creatinine or the need for renal replacement therapy without other criteria (“other”). The 
categories for the type of monitoring were “invasive monitoring”, which included studies 
using pulmonary artery catheters or esophageal Doppler to guide therapy, “non-invasive”, 
which included studies using arterial wave-form or pulse contour analysis devices to guide 
therapy and “metabolic indices”, which included studies using oxygen saturation or lactate 
to guide therapy without also using devices from the two other groups. Difference in fluid 
intake between GDT and CFM was specified as one of three categories: studies in which 
more fluids were infused in GDT than in CFM (“more”), studies in which similar volumes of 
fluids were infused in GDT and CFM (“similar”), and studies in which less fluids were infused 
in GDT than in CFM (“less”). Additionally, we created a subgroup including all studies in 
which more colloids were infused in GDT than in CFM.  According to the year of publication, 
studies were divided into two subgroups: published before 2004 and published in or after 
2004. The year 2004 was chosen as cut-off point since the consensus definition and RIFLE 
criteria by the Acute Dialysis Quality Initiative Group were published in that year. Lastly, 
studies with a Jadad score greater than 2 formed another subgroup.
All meta-analyses were conducted as random effects meta-analysis in R (version 
3.1.3) (19) using the package metafor (version 1.9.5) (20). Specifically, the Sidik-Jonkman 
estimator (21) was used in combination with the Knapp & Hartung adjustment (22) to get 
better estimates of the heterogeneity variance. In studies with a count of zero in one of the 
treatment arms, 0.5 was added to all frequencies of that study. Heterogeneity between 
studies was analyzed using the I2 statistic and interpreted using thresholds as defined in the 
Cochrane Handbook (23). Funnel plots were analyzed visually in order to detect possible 
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publication bias. In the subgroup analysis, pooled OR and CI were calculated without taking 
heterogeneity between studies into account, and p-values were determined using Fisher’s 
exact test. Odds ratios were considered statistically significant when their 95% CI did not 
include 1.00 and the corresponding p-value was less than 0.05.
resUlts
Our search strategy resulted in 1062 articles, of which 588 remained after excluding 
duplicates (Figure 4.1). Of those, 525 were either animal studies, pediatric studies, not in 
English, not available as full-text, or comparing different fluid types, and were excluded. After 
reading all full-text articles for eligibility, we excluded another 34 studies because either the 
hemodynamic parameters were not defined in the conventional arm or no data on ARF was 
presented. One study which did report ARF occurrence (24) was excluded, because it was 
not possible to distinguish new occurrences of ARF in each group from those with ARF at 
randomization. Table 4.1 shows the characteristics of the resulting 28 included studies, and 
Table 4.2 shows the hemodynamic monitoring utilized in each of the selected studies. 
Figure 4.1 Flow chart of study selection.
ARF: acute renal failure.
Records identified through
database search and reviews
Nn = 1062A
Records screened after 
duplicates removed
Nn = 588A
Records meeting exclusion criteria
Nn = 525A
Full-text articles assessed
for eligibility
Nn = 63A
Studies included in review
Nn = 28A
Full-text articles excluded:
Hemodynamic targets not 
defined
Nn = 18A
No data on ARF
Nn = 16A
Data on new onset ARF 
not extractable
Nn = 1A
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Table 4.1 Characteristics of studies included
Study group total 
number
Type of 
patient
Exclusion 
of renal 
conditions
timing Definition of ARF
Berlauk 1991 (25) GDT- 
vs.CFM-
89 Vascular pre UO < 0.5 mL/kg/hr 
for 5 hours and/or a 
change in baseline 
sCr more than 44 
μmol/l.
Valentine 1998 (26) GDT- 
vs.CFM-
120 Vascular 
Abdominal
pre, intra, 
post
not mentioned in 
original publication
Wilson 1999 (27) GDT- 
vs.CFM-
138 General, 
Vascular, 
Abdominal
pre increase in BUN > 5 
mmol / l from pre 
levels .
Polonen 2000 (28) GDT- 
vs.CFM-
393 Cardiac post UO < 750 mL/24 h 
or increase of  sCr  
>150 μmol/l from 
previous normal 
levels
Bonazzi 2002 (29) GDT- 
vs.CFM-
100 Vascular, 
Abdominal
Yes, 
advanced 
CKD
pre worsening of pre 
renal function with 
accompanying 
oliguria requiring 
high doses of 
furosemide (>250 
mg/day) and/or RRT
Wakeling 2005 (30) GDT- 
vs.CFM-
128 Abdominal Yes, renal 
insufficiency
intra UO < 500 mL/d, 
increase in sCr > 
30%, or urinary 
catheter in place for 
a nonsurgical reason
Forget 2010 (31) GDT- 
vs.CFM-
86 Abdominal Yes, dialysis intra RRT or UO <0.5 mL/
kg for >2 hours
WenKui 2010 (32) GDT- 
vs.CFM-
214 Abdominal intra, 
post
RRT
Cecconi 2011 (33) GDT- 
vs.CFM-
40 Orthopedic intra UO < 500 mL/d, 
increase in sCr > 
30%, or urinary 
catheter in place for 
a nonsurgical reason
Bartha 2013 (34) GDT- 
vs.CFM-
149 Orthopedic intra 50% increase of 
baseline sCr or/and 
UO < 0.5 ml/h
Bisgaard 2013 (35) GDT- 
vs.CFM-
70 Vascular, 
Abdominal
Yes, ESRD intra, 
post
not mentioned in 
original publication
Goepfert 2013 (36) GDT- 
vs.CFM-
92 Cardiac Yes, dialysis intra AKIN
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Study group total 
number
Type of 
patient
Exclusion 
of renal 
conditions
timing Definition of ARF
Bishop 1995 (37) GDT- 
vs.CFM+
115 Orthopedic ICU, post sCr ≥ 177 μmol/l, 
or with pre-existing 
renal disease a  sCr 
2x that on admission
Gan 2002 (38) GDT- 
vs.CFM+
100 General, 
Abdominal
Yes, 
significant 
renal 
dysfunction
intra UO < 500 ml/day, 
increase in  sCr > 
30%
McKendry 2004 (39) GDT- 
vs.CFM+
174 Cardiac post not mentioned in 
original publication
Benes 2010 (40) GDT- 
vs.CFM+
120 High Risk, 
Abdominal
intra UO < 500 ml/day 
or  sCr > 170 μmol/l 
or RRT
Mayer 2010 (41) GDT- 
vs.CFM+
60 High Risk Intra UO < 500 ml/day 
or RRT
Zhang 2013 (42) GDT- vs. 
CFM+
80 Pulmonary intra not mentioned in 
original publication
Pro CI 2014 (43) GDT- vs. 
CFM+
885 Sepsis ICU RRT
Shoemaker 1988 (44) GDT+ 
vs.CFM+
88 High Risk intra, 
post
BUN >18 mmol/l, sCr 
>265 μmol/l
Boyd 1993 (45) GDT+ 
vs.CFM+
107 High Risk Yes, ARF pre, intra, 
post, ICU
UO <500 mL/24 h
Gattinoni 1995 (46) GDT+ 
vs.CFM+
762 High Risk ICU sCr ≥ 177 μmol/l, 
RRT, or both
Lobo 2000 (47) GDT+ 
vs.CFM+
37 High Risk, 
General, 
Abdominal, 
Vascular
intra, 
post
renal SOFA ≥ 3
Donati 2007 (48) GDT+ 
vs.CFM+
135 Vascular, 
Abdominal
Intra sCr > 177 μmol/l 
or RRT
Kapoor 2008 (49) GDT+ 
vs.CFM+
27 Cardiac post not mentioned in 
original publication
Jammer 2010 (50) GDT+ 
vs.CFM+
241 Abdominal Yes, sCr > 177 
μmol/l
intra sCr increase > 33%
Jhanji 2010 (51) GDT+ 
vs.CFM+
135 Abdominal post, ICU AKIN
Brandstrup 2012 (52) GDT+ 
vs.CFM+
150 Abdominal intra, 
post
RRT
GDT-: goal-directed therapy without oliguria reversal as a target; GDT+: goal-directed therapy with oliguria 
reversal as a target; CFM-: conventional fluid therapy without oliguria reversal as a target; CFM+: conventional 
fluid therapy with oliguria reversal as a target; CKD: chronic kidney disease; ESRD: end-stage renal disease; pre: 
preoperative; intra: intraoperative; post: postoperative; ICU: intensive care unit; ARF: acute renal failure; sCr: 
serum creatinine; UO: urine output; RRT: renal replacement therapy; SOFA: Sequential Organ Failure Assessment 
score; BUN: Blood urea nitrogen.
Table 4.1 Characteristics of studies included (continued)
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Table 4.2 Hemodynamic monitoring used in selected studies
Study group Device Hemodynamic Target UO criteria Intervention
Berlauk 1991 
(25)
GDT- 
vs.CFM-
PAC PAOP, CI, SVR fluids, 
vasoactive 
medication
Valentine 1998 
(26)
GDT- 
vs.CFM-
PAC PCWP, CI, SVR crystalloids, 
dopamine, 
vasoactive 
medication
Wilson 1999 
(27)
GDT- 
vs.CFM-
PAC PAOP fluids, 
adrenaline, 
dopexamine
Polonen 2000 
(28)
GDT- 
vs.CFM-
SvO2, Lactate fluids, 
dobutamine, 
vasoactive 
medication
Bonazzi 2002 
(29)
GDT- 
vs.CFM-
PAC CI, PCWP, SVR, DO2 crystalloids, 
vasoactive 
medication
Wakeling 2005 
(30)
GDT- 
vs.CFM-
esophageal 
Doppler
SV colloids
Forget 2010 
(31)
GDT- 
vs.CFM-
Masimo pulse 
oximeter
PVI colloids, 
vasoactive 
medication
WenKui 2010 
(32)
GDT- 
vs.CFM-
Lactate crystalloids, 
colloids, 
dopamine, 
ephedrine
Cecconi 2011 
(33)
GDT- 
vs.CFM-
FloTrac 
sensor/
Vigileo
SV colloids, 
vasoactive 
medication, 
dobutamine
Bartha 2013 
(34)
GDT- 
vs.CFM-
LiDCO SV, DO2I fluids, 
vasoactive 
medication
Bisgaard 2013 
(35)
GDT- 
vs.CFM-
LiDCO SVI colloids,  
dobutamine, 
vasoactive 
medication
Goepfert 2013 
(36)
GDT- 
vs.CFM-
PiCCOplus SV, GEDI, ELVI, CI fluids, 
vasoactive 
medication
Bishop 1995 
(37)
GDT- 
vs.CFM+
PAC DO2I, VO2I , CI UO 30-50 ml/h volume, 
dobutamine
Gan 2002 (38) GDT- 
vs.CFM+
esophageal 
Doppler
SV, Ftc UO < 0.5 ml/kg/h colloids
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Study group Device Hemodynamic Target UO criteria Intervention
McKendry 2004 
(39)
GDT- 
vs.CFM+
oesophageal 
Doppler
SI UO,  no specific 
goal mentioned
colloids, blood, 
vasoactive 
medication
Benes 2010 (40) GDT- 
vs.CFM+
FloTrac 
sensor/
Vigileo
SVV UO > 0.5 ml/kg/h colloids, 
dobutamine
Mayer 2010 (41) GDT- 
vs.CFM+
FloTrac 
sensor/
Vigileo
CI, SVI UO > 0.5 ml/kg/h crystalloids, 
colloids, 
norepinephrine, 
dobutamine, 
vasodilators
Zhang 2013 (42) GDT- vs. 
CFM+
FloTrac 
sensor/ 
Vigileo
SVV, CI UO > 0.5 ml/kg/h crystalloids, 
colloids, 
vasoactive 
medication
Pro CI 2014 (43) GDT- vs. 
CFM+
ScvO2, CVP UO, no specific 
goal mentioned
crystalloids, 
colloids, 
vasoactive 
medication
Shoemaker 
1988 (44)
GDT+ 
vs.CFM+
PAC Hct, PvO2, PAP, SVR, 
PWP, PVR, DO2, VO2
UO > 30 ml/h crystalloids, 
colloids, 
vasoactive 
medication
Boyd 1993 (45) GDT+ 
vs.CFM+
PAC DO2I UO > 0.5 ml/kg/h gelatin, 
dopexamine
Gattinoni 1995 
(46)
GDT+ 
vs.CFM+
PAC CI or SvO2 UO > 0.5 ml/kg/h fluids, 
vasoactive 
medication
Lobo 2000 (47) GDT+ 
vs.CFM+
PAC DO2 UO < 0.5 ml/kg/h fluids, 
dobutamine
Donati 2007 
(48)
GDT+ 
vs.CFM+
SvO2, O2ERe UO > 0.5 ml/kg/h fluids, 
dobutamine
Kapoor 2008 
(49)
GDT+ 
vs.CFM+
FloTrac 
sensor/
Vigileo
CVP,SVV UO > 1 ml/kg/h colloids, 
dopamine or 
other inotropes
Jammer 2010 
(50)
GDT+ 
vs.CFM+
ScvO2 UO > 0.5 ml/kg/h crystalloids, 
colloid
Jhanji 2010 (51) GDT+ 
vs.CFM+
LiDCO SV UO > 25 ml/h fluids, 
dopexamine
Brandstrup 
2012 (52)
GDT+ 
vs.CFM+
esophageal 
Doppler
SV UO > 0.5 ml/kg/h colloid
PAC: pulmonary artery catheter; PAC+: pulmonary artery catheter with supranormal hemodynamic targets; 
pre: preoperative; intra: intraoperative; post: postoperative; ICU: intensive care unit; SV: stroke volume; DO2I: 
oxygen delivery index; PAOP: pulmonary artery occlusion pressure; CI: cardiac index; SVR: systemic vascular 
resistance; SVI: systemic vascular index; PCWP: pulmonary capillary wedge pressure; DO2: oxygen delivery; PVI: 
pleth variability index; GEDI: global end-diastolic volume index; ELVI: extravascular lung water index; SvO2: mixed 
venous oxygen saturation; PAWP: pulmonary artery wedge pressure; FTc: corrected flow time; PCWP: pulmonary 
Table 4.2 Hemodynamic monitoring used in selected studies (continued)
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capillary wedge pressure; SVV: stroke volume variation; VO2I: oxygen consumption index; SI: stroke index; O2ERe: 
oxygen extraction estimate; ScvO2: central venous oxygen saturation; CVP: central venous pressure; PvO2: venous 
oxygen pressure; PAP: pulmonary artery pressure; PWP: pulmonary wedge pressure; PVR: pulmonary vascular 
resistance; Hct: hematocrit; VO2: oxygen consumption; UO: urine output.
Twelve studies (25-36) did not include oliguria reversal as a target in either of the treatment 
protocols, GDT and CFM, and were allocated to the GDT- vs. CFM- group, seven studies 
in which only the CFM protocol included oliguria reversal were allocated to the GDT- vs. 
CFM+ group (37-43), and nine studies which included oliguria reversal as a target in both 
the GDT and CFM protocol were assigned to the GDT+ vs. CFM+ group (44-52). We did not 
find studies comparing GDT with oliguria reversal as a target with CFM without oliguria 
reversal as a target, or studies comparing GDT with and without oliguria reversal as a target 
or studies comparing CFM with and without oliguria reversal as a target. Eight of the 28 
studies had a score of less than 3 on the Jadad scale (Table 4.3). The allocation of the studies 
to the subgroups is shown in Table 4.4. None of the selected studies reported the use of 
nephrotoxic medication and only five studies reported the use of diuretics for reasons other 
than oliguria reversal (36,40,47,49,52).
Table 4.3 Risk of bias assessment in selected studies
Study group blinding 
score
Randomization 
score
Withdrawal 
score
Score on 
Jadad scale
Berlauk 1991 (25) GDT- vs.CFM- 0 2 1 3
Valentine 1998 (26) GDT- vs.CFM- 0 2 1 3
Wilson 1999 (27) GDT- vs.CFM- 2 2 0 4
Polonen 2000 (28) GDT- vs.CFM- 0 2 0 2
Bonazzi 2002 (29) GDT- vs.CFM- 0 2 0 2
Wakeling 2005 (30) GDT- vs.CFM- 2 2 1 5
Forget 2010 (31) GDT- vs.CFM- 0 1 1 2
WenKui 2010 (32) GDT- vs.CFM- 0 2 1 3
Cecconi 2011 (33) GDT- vs.CFM- 0 1 1 2
Bartha 2013 (34) GDT- vs.CFM- 0 2 1 3
Bisgaard 2013 (35) GDT- vs.CFM- 0 2 1 3
Goepfert 2013 (36) GDT- vs.CFM- 0 2 1 3
Bishop 1995 (37) GDT- vs.CFM+ 0 1 0 1
Gan 2002 (38) GDT- vs.CFM+ 0 2 1 3
McKendry 2004 (39) GDT- vs.CFM+ 2 2 1 5
Benes 2010 (40) GDT- vs.CFM+ 0 2 1 3
Mayer 2010 (41) GDT- vs.CFM+ 0 2 1 3
Zhang 2013 (42) GDT- vs. CFM+ 0 2 0 2
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Pro CI 2014 (43) GDT- vs. CFM+ 0 2 1 3
Shoemaker 1988 (44) GDT+ vs.CFM+ 0 2 0 2
Boyd 1993 (45) GDT+ vs.CFM+ 0 1 0 1
Gattinoni 1995 (46) GDT+ vs.CFM+ 0 2 1 3
Lobo 2000 (47) GDT+ vs.CFM+ 0 2 1 3
Donati 2007 (48) GDT+ vs.CFM+ 0 2 1 3
Kapoor 2008 (49) GDT+ vs.CFM+ 0 2 1 3
Jammer 2010 (50) GDT+ vs.CFM+ 0 2 1 3
Jhanji 2010 (51) GDT+ vs.CFM+ 0 2 1 3
Brandstrup 2012 (52) GDT+ vs.CFM+ 2 2 1 5
GDT-: goal-directed therapy without oliguria reversal as a target; GDT+: goal-directed therapy with oliguria 
reversal as a target; CFM-: conventional fluid therapy without oliguria reversal as a target; CFM+: conventional 
fluid therapy with oliguria reversal as a target.
Primary analysis. 
Meta-analysis of all 28 studies showed that overall, GDT was associated with a lower 
occurrence of ARF than CFM (OR 0.58; 95% CI 0.44 to 0.76; P < 0.001; I2 = 34.3%; N = 28). 
In the GDT- vs. CFM+ group, patients that received GDT were less likely to develop ARF 
than patients treated with CFM (OR 0.45; 95% CI 0.34 to 0.61; P < 0.001; I2 = 7.1%; N = 7). 
The studies in the other two protocol groups did not provide enough evidence to conclude 
a superiority of GDT compared to CFM. Forest plots of the primary analysis are shown in 
Figure 4.2. The heterogeneity in this analysis ranged from low to moderate. The funnel plot 
of the overall analysis showed no marked asymmetry, suggesting the absence of publication 
bias (Figure S4.1).
Study group blinding 
score
Randomization 
score
Withdrawal 
score
Score on 
Jadad scale
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Figure 4.2 Forest plot of studies reporting occurrence of acute renal failure when comparing goal-
directed therapy with conventional fluid management.
GDT: goal-directed therapy; CFM: conventional fluid therapy; ARF: acute renal failure; OR: odds ratio; CI: 
confidence interval; GDT- vs. CFM-: Goal-directed therapy versus conventional fluid therapy both without 
oliguria reversal as a target; GDT- vs. CFM+: Goal-directed therapy without oliguria reversal as a target versus 
conventional fluid therapy with oliguria reversal as a target; GDT+ vs. CFM+: Goal-directed therapy versus 
conventional fluid therapy both with oliguria reversal as a target.
Secondary analysis. 
Results from the meta-analysis of those studies that targeted oliguria reversal during the 
pre- and intraoperative setting are shown in Figure 4.3. Here, the combined analysis showed 
that GDT was associated with a lower occurrence of ARF compared to CFM (OR 0.62; 95% 
CI 0.42 to 0.89; P = 0.01; I2 = 25.1%; N = 21). All three protocol group specific meta-analyses 
estimated ORs smaller than one, however none of the estimates were significantly different 
from 1.00.
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Meta-analysis of the studies that used the fluid management protocols during the 
postoperative and ICU setting showed that GDT reduced the number of ARF cases (OR 0.56; 
95% CI 0.39 to 0.80; P = 0.004, I2 = 42.6%; N = 14).  The corresponding forest plot is displayed 
in Figure 4.4. Here, the OR in the GDT- vs. CFM+ group was significantly smaller than 1.00 
(OR 0.46; 95% CI 0.31 to 0.70; P = 0.015; I2 = 1.2%; N = 3), while results in the other two 
groups were inconclusive. Funnel plots for the secondary analyses showed no asymmetry 
and hence suggested no publication bias (Figure S4.2 and S4.3).
Figure 4.3 Forest plot of studies reporting occurrence of acute renal failure when comparing goal-
directed therapy with conventional fluid management in the preoperative and intraoperative setting.
GDT: goal-directed therapy; CFM: conventional fluid therapy; ARF: acute renal failure; OR: odds ratio; CI: 
confidence interval; GDT- vs. CFM-: Goal-directed therapy versus conventional fluid therapy both without 
oliguria reversal as a target; GDT- vs. CFM+: Goal-directed therapy without oliguria reversal as a target versus 
conventional fluid therapy with oliguria reversal as a target; GDT+ vs. CFM+: Goal-directed therapy versus 
conventional fluid therapy both with oliguria reversal as a target.
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Seven studies (28,37,39,43,46,49,51) in which the treatment protocol was first used in 
the postoperative or the ICU setting and not in the pre- or intraoperative setting were 
included in the sensitivity analysis. Here, meta-analysis showed that GDT resulted in less 
ARF than CFM (OR 0.58; 95% CI 0.37 to 0.90; P = 0.02; I2 = 30.6%; N = 7, Figure S4).
Figure 4.4 Forest plot of studies reporting occurrence of acute renal failure when comparing goal-
directed therapy with conventional fluid management in the postoperative setting and intensive care 
unit.
GDT: goal-directed therapy; CFM: conventional fluid therapy; ARF: acute renal failure; OR: odds ratio; CI: 
confidence interval; GDT- vs. CFM-: Goal-directed therapy versus conventional fluid therapy both without 
oliguria reversal as a target; GDT- vs. CFM+: Goal-directed therapy without oliguria reversal as a target versus 
conventional fluid therapy with oliguria reversal as a target; GDT+ vs. CFM+: Goal-directed therapy versus 
conventional fluid therapy both with oliguria reversal as a target.
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Additional analysis. 
Since we did not find any studies directly comparing targeting oliguria reversal with not 
targeting oliguria reversal in each treatment, we conducted additional, pooled analyses 
based on the subgroups of studies described above (see Table 4.4). The results from this 
analysis are reported in detail in Table 4.5.  
Table 4.4 Allocation of the selected studies to subgroups 
Study Type of monitoring Relation to 
rifle/akin 
criteria
colloids infused 
in GDT relative 
to cfm
fluids infused in 
GDT relative to 
cfm
Berlauk 1991 (25) Invasive monitoring Similar
Valentine 1998 (26) Invasive monitoring More
Wilson 1999 (27) Invasive monitoring Other
Polonen 2000 (28) Metabolic indices Other More More
Bonazzi 2002 (29) Invasive monitoring Other More
Wakeling 2005 (30) Invasive monitoring Similar More More
Forget 2010 (31) Metabolic indices Other Less
WenKui 2010 (32) Metabolic indices Other More
Cecconi 2011 (33) Non-invasive monitoring Similar More
Bartha 2013 (34) Non-invasive monitoring Exact Less
Bisgaard 2013 (35) Non-invasive monitoring Similar
Goepfert 2013 (36) Non-invasive monitoring Exact More More
Bishop 1995 (37) Invasive monitoring Other More
Gan 2002 (38) Invasive monitoring Similar More More
McKendry 2004 (39) Invasive monitoring More More
Benes 2010 (40) Non-invasive monitoring Other More More
Mayer 2010 (41) Non-invasive monitoring Other More Similar
Zhang 2013 (42) Non-invasive monitoring Less
Pro CI 2014 (43) Metabolic indices Other Less
Shoemaker 1988 (44) Invasive monitoring Other
Boyd 1993 (45) Invasive monitoring Other Similar
Gattinoni 1995 (46) Invasive monitoring Other
Lobo 2000 (47) Invasive monitoring Other Similar
Donati 2007 (48) Metabolic indices Other Similar
Kapoor 2008 (49) Invasive monitoring More
Jammer 2010 (50) Metabolic indices Other Less
Jhanji 2010 (51) Non-invasive monitoring Exact Similar
Brandstrup 2012 (52) Invasive monitoring Other More Similar
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Invasive monitoring: the use of pulmonary artery catheters or esophageal Doppler. Non-invasive monitoring: 
the use of arterial wave-form or pulse contour analysis devices to estimate cardiac parameters. Metabolic 
indices: the use of oxygen saturation or lactate to guide therapy. GDT: goal-directed therapy; CFM: conventional 
fluid management.
Table 4.5 Direct comparison between targeting and not targeting oliguria reversal in goal-directed 
therapy and conventional fluid management.
Targeting oliguria 
reversal
Not targeting 
oliguria reversal
Analysis fms arf total arf total OR (95% CI) p
Main [25-52]
GDT 301 1003 46 1543 13.94 (10.05 - 19.7) <0.001
CFM 237 1398 28 754 5.29 (3.52 - 8.22) <0.001
Pre/intraoperative 
[25-27,29-36,38,40-
42,44,45,47,48,50,52]
GDT 25 390 26 826 2.11 (1.15 - 3.85) 0.013
CFM 45 538 25 557 1.94 (1.15 - 3.36) 0.009
Postoperative/ICU 
[26,28,32,35,37,39,43-
47,49,51,52]
GDT 288 814 29 918 16.76 (11.22 - 25.87) <0.001
CFM 209 1041 13 394 7.36 (4.14 - 14.23) <0.001
Jadad > 2 [25-
27,30,32,34-36,38-
41,43,46-52]
GDT 291 892 38 1156 14.23 (9.96 - 20.81) <0.001
CFM 207 1219 25 446 3.44 (2.23 - 5.53) <0.001
Relation to RIFLE AKIN definitions
Exact RIFLE/AKIN 
definition [34,36,51]
GDT 7 90 4 120 2.44 (0.6 - 11.72) 0.21
CFM 10 45 9 118 3.43 (1.15 - 10.4) 0.014
Similar definition 
[25,30,33,38]
GDT 0 0 6 202
CFM 4 50 3 105 2.93 (0.48 - 20.84) 0.21
Other definitions [27-
29,31,32,37,40,41,43-
48,50,52]
GDT 293 900 27 1010 17.55 (11.64 - 27.45) <0.001
CFM 219 1174 9 439 10.95 (5.59 - 24.48) <0.001
Type of hemodynamic monitoring used in the GDT group
Invasive monitoring 
[25-27,29,30,37-39,44-
47,49,52]
GDT 281 724 19 523 16.8 (10.33 - 28.79) <0.001
CFM 179 647 7 241 12.76 (5.93 - 32.73) <0.001
Non-invasive 
monitoring [33-36,40-
42,51]
GDT 7 90 12 292 1.96 (0.63 - 5.62) 0.17
CFM 20 165 15 170 1.42 (0.66 - 3.11) 0.37
Metabolic indices 
[28,31,32,43,48,50]
GDT 13 189 15 728 3.5 (1.5 - 8.06) 0.002
CFM 38 586 6 343 3.89 (1.61 - 11.38) 0.001
Difference in fluids infused between GDT and CFM 
More colloids in GDT 
[28,30,36,38-41,52]
GDT 0 71 14 535 0.26 (0.015 - 4.38) 0.39
CFM 19 304 13 307 1.51 (0.69 - 3.39) 0.28
Less fluids in GDT 
[31,34,42,43,50]
GDT 11 121 14 527 3.65 (1.46 - 8.93) 0.003
CFM 31 549 1 113 6.69 (1.09 - 275.29) 0.029
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Similar volume 
[35,41,45,47,48,51,52]
GDT 14 301 5 62 0.56 (0.18 - 2.06) 0.34
CFM 32 293 6 32 0.53 (0.19 - 1.7) 0.24
More fluids in GDT 
[26,28-30,32,33,36-
40,49]
GDT 1 13 24 794 2.67 (0.06 - 19.47) 0.34
CFM 29 274 17 542 3.65 (1.9 - 7.22) <0.001
Year of publication
< 2004 [25-
29,37,38,44-47]
GDT 280 640 16 566 26.67 (15.8 - 48.16) <0.001
CFM 173 469 8 374 26.66 (12.94 - 63.77) <0.001
≥ 2004 [30-36,39-
43,48-52]
GDT 21 363 30 977 1.94 (1.04 - 3.55) 0.025
CFM 64 929 20 380 1.33 (0.78 - 2.36) 0.32
For each analysis, the pooled data from all relevant studies targeting oliguria reversal was compared to the 
pooled data from studies not targeting oliguria reversal – separating data from goal-directed therapy protocols 
from conventional fluid management protocols. Odds ratio and 95% confidence intervals were then calculated 
and the P-value was calculated using the Fisher’s exact test to test whether there was a difference in acute renal 
failure occurrence between targeting and not targeting oliguria reversal in each protocol. When cells with 0 
caused problems in calculating odds ratio or associated confidence interval, 0.5 was added to all cells. 
FMS: fluid management strategy; ARF: acute renal failure; OR: odds ratio; CI: confidence interval; ICU: intensive 
care unit. GDT: goal-directed therapy; CFM: conventional fluid management
discUssion
In the present study, we performed meta-analyses on 28 studies and found that GDT is 
superior to CFM with regards to preventing ARF. This effect was the strongest in studies that 
included oliguria reversal as a target in CFM but not in GDT. Even though the comparison 
of GDT with CFM where both treatments included or excluded oliguria reversal as a target 
suggested superiority of GDT, available evidence was inadequate to allow a definite 
conclusion. This lack of clarity may partially be due to the small number of studies that were 
available for analysis.
In the additional, pooled analysis (Table 4.5), GDT and CFM strategies targeting oliguria 
reversal increased the odds of developing ARF when compared to GDT and CFM strategies 
not targeting oliguria reversal. This finding may partially explain the larger difference 
between treatments observed in the primary analysis of GDT- vs. CFM+. We found that 
when GDT- and CFM- groups were compared, the effect on ARF was not different than 
between GDT+ and CFM+ groups.  When combined with the lack of benefit in targeting 
oliguria reversal in the additional pooled analysis, this difference suggests that targeting 
oliguria reversal may not reduce the incidence of ARF when compared to strategies that do 
not target oliguria reversal. Our data support the hypothesis that preventing ARF may not 
be achieved by striving toward a predefined urine output target.
Targeting oliguria 
reversal
Not targeting 
oliguria reversal
Analysis fms arf total arf total OR (95% CI) p
Table 4.5 Direct comparison between targeting and not targeting oliguria reversal in goal-directed 
therapy and conventional fluid management. (continued)
4Targeting oliguria reversal and acute renal failure
81
Several reasons are possible for why urine output may have limited effectiveness as a 
hemodynamic management goal. Urine output is a parameter that takes time to change 
and is influenced by factors other than the hemodynamic status. Thus, oliguria can be 
due to causes which are unaffected by fluid administration or have already been resolved. 
Therefore, patients may be at risk for fluid overload due to superfluous fluid administration 
targeted only at urine output. On the other hand, strategies that do not target oliguria 
reversal may limit fluid overload by more precisely targeting variables related to cardiac 
output or oxygen delivery. Once the hemodynamic status has already been optimized, any 
subsequent occurrence of oliguria is unlikely to be due to hemodynamic causes, favoring 
the exclusion of oliguria reversal as a target. 
GDT patients received a similar or larger volume of fluids than CFM patients in most of 
the included studies (Table 4.4), and even in the GDT- vs. CFM+ group most studies used 
an equal or larger fluid volume in GDT than in CFM. However, in the subset of trials where 
GDT resulted in less fluid administered than in CFM, targeting oliguria reversal had a larger 
impact in the CFM than in the GDT group. These data suggest that in GDT trials that focus 
on limiting fluid administration, targeting oliguria reversal may play a role. For example, 
additional fluid resuscitation targeted at increasing urine output may result in hypervolemia 
and subsequent ARF. In contrast, when GDT results in equal or larger fluid volumes than 
CFM to achieve the predefined hemodynamic targets, any effects of targeting oliguria 
reversal on the occurrence of ARF may be relatively minor due possibly to the volume of 
fluids already administered.
Based on our findings, GDT is better suited than CFM to prevent ARF in the preoperative 
or intraoperative setting. Furthermore, GDT might also reduce ARF occurrence in the 
postoperative or ICU setting, but when we excluded studies in which GDT and CFM were 
already started during the preoperative or intraoperative setting the data were too limited 
to draw a definite conclusion. Similar to our findings, the meta-analysis performed by 
Brienza et al. (12) reported that patients treated with GDT in the postoperative setting 
had less ARF. However, their meta-analysis differed from ours in several ways. Firstly, they 
assigned studies according to commencement of hemodynamic optimization. Secondly, 
they pooled the intraoperative and postoperative commencement into one analysis (12). 
Finally, they excluded studies with late optimization, i.e. more than 12 hours postoperative 
or after onset of organ failure. It has been previously suggested that intraoperative and 
postoperative optimization should be separated due to differences in etiology and 
hemodynamic goals (53). Consequently, while our study supports the findings of Brienza et 
al. for the early postoperative phase, our findings also suggest that GDT may prevent ARF 
when used during the late postoperative phase or in the ICU.
While we found that GDT was associated with less ARF when oliguria reversal was not 
included as a target, the effects of such strategies on mortality remain unclear. Due to the 
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relatively low numbers of available studies reporting both ARF and mortality, we considered 
the risk of selection bias too high and therefore did not perform analyses to investigate the 
effects of targeting oliguria reversal on mortality.
Our study has several limitations. Firstly, as shown in Table 4.1, not all of the included 
studies shared the same definition for ARF. While the heterogeneity found in most of 
the analyses – as assessed by the I2 statistic – is low to moderate, most of the included 
studies are likely to underestimate the occurrence of ARF. Most definitions included a rise 
in serum creatinine values; a form of oliguria; some form of renal replacement therapy; or 
a combination of these criteria, and as such are quite similar to the RIFLE or AKIN criteria. 
However, due to the relatively short observation periods, the relatively high cut-off points 
for serum creatinine or the need for renal replacement therapy in most studies, smaller 
increases in serum creatinine may have been overlooked. These small increases are 
clinically relevant due to the associated increase in adverse outcomes (54), and are one 
of the reasons why the Acute Kidney Injury Network included small increments in serum 
creatinine in the RIFLE criteria (55). We found that the definition used for ARF affects the 
relation between ARF and targeting oliguria reversal. Studies using the RIFLE and AKIN 
criteria identified less ARF possibly related to targeting oliguria reversal than using the 
outdated definitions. It is possible that the RIFLE and AKIN criteria diagnosed more patients 
with less severe ARF, which would have been missed by the outdated definitions.  
Secondly, the hemodynamic parameters targeted in the GDT protocols and the methods 
used to evaluate them varied greatly among the included studies (Table 4.2). This variance 
was due partly to the large time span between some studies, which has led to pulmonary 
artery catheters and esophageal Doppler monitoring being replaced by calibrated or 
uncalibrated arterial pressure derived continuous cardiac output devices. Our subgroup 
analyses suggest that while all these methods assess parameters related to cardiac output 
or oxygen delivery, the differences between these devices and their practical limitations 
could have affected patient management and treatment options. Even when using similar 
devices, the correct interpretation of these indices is also important. Starting treatments 
based on an erroneous interpretation of hemodynamic parameters could result in more 
harm to patients in terms of ARF or other outcomes rather than the intended benefit. 
Furthermore, the potential change in the risk of ARF from earlier studies might also be 
attributable to improvements in conventional health care practice throughout the decades.
Another limitation of our meta-analysis is the different underlying conditions in the 
included studies. It is likely, for example, that surgical and septic patients differ regarding 
goals for hemodynamic optimization. Nevertheless, achieving an optimal hemodynamic 
state through intensive monitoring of cardiac output or oxygen delivery derived 
parameters should result in a similar benefit despite the underlying conditions. Thus, once 
the hemodynamic status has been optimized, the development of ARF should mostly be 
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determined by risk factors associated with the underlying condition. Furthermore, any 
additional fluids given after the hemodynamic status has been optimized can lead to 
deleterious effects due to fluid overload, which in turn increases the risk of developing ARF.
 Finally, the methods used to optimize hemodynamic status differed among the studies. 
As shown in Table 4.2, the use of vasopressors and inotropic drugs as well as type of fluid 
was not consistent. Colloids such as hetastarch, for example, have been associated with 
an increased risk for acute kidney injury (56,57). In most of the selected studies, colloids 
were used as the primary intervention fluid to achieve and maintain hemodynamic 
goals – including urine output. While unlikely, it is possible that asymmetry in colloid use 
between groups may have affected our results. In recent years, an association between 
hyperchloremic solutions and an increased risk for acute kidney injury has also been 
suggested (58,59). This effect also could have influenced our findings due to differences in 
fluid compositions used within studies or between studies. Furthermore, it is important to 
note that standard random effects meta-analysis methods may not accurately estimate the 
between study variation when only few studies are included in the analysis. We attempted 
to minimize this problem by using a more robust estimator; nevertheless, results from 
analyses with only few studies should be interpreted with great care. 
conclUsion
Collectively, our data favor targeting circulatory optimization by GDT without targeting oliguria 
reversal to prevent ARF. This effect of GDT- on ARF is present even during the perioperative 
period or in the ICU. Our findings support the hypothesis that ARF is not prevented by 
striving toward a predefined urine output target. However, randomized controlled trials are 
needed to investigate whether targeting oliguria reversal has a deleterious effect on the 
occurrence of ARF and whether – as our findings suggest – resuscitation protocols which 
prioritize cardiac output and oxygen delivery are better able to reduce the risk of ARF than 
those including oliguria reversal as a target.
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Table S4.1 Search strategy
#44 (#36 AND #43) 543
#43 (#39 OR #42)
#42 (#41 OR #40)
#41 “controlled trial”
#40 trial
#39 (#37 OR #38)
#38 “randomised”
#37 “randomized”
#36 (#35 AND #26)
#35 (#11 AND #34)
#34 (#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33)
#33 fluid
#32 “fluid resuscitation”
#31 “fluid loading”
#30 “fluid administration”
#29 “fluid management”
#28 “fluid therapy”
#27 “fluid therapy”[MeSH]
#26
(#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 
OR #24 OR #25)
#25 outcome
#24 “urinary output”
#23 “urine production”
#22 “urine output”
#21 “diuresis”
#20 “acute renal failure”
#19 “acute kidney injury”[MeSH]
#18 “acute kidney injury”
#17 creatinine
#16 kidney
#15 renal
#14 “organ dysfunction”
#13 “complications”
#12 “organ failure”
#11 (#1 OR #2 OR #3 # OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
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#10 “supranormal”
#9 “goal-directed therapy”
#8 optimisation
#7 optimization
#6 “cardiac index”
#5 “stroke volume”
#4 “cardiac output”
#3 “hemodynamic target”
#2 “goal-directed”
#1 “goal directed”
Figure S4.1 Funnel plots used to assess the presence of publication bias in the analysis from Figure 4.2.
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Figure S4.2 Funnel plots used to assess the presence of publication bias in the analysis from Figure 4.3.
Figure S4.3 Funnel plots used to assess the presence of publication bias in the analysis from Figure 4.4.
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Figure S4.4 Forest plot reporting the sensitivity analysis of GDT and CFM commenced during the 
postoperative or ICU setting.
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CHAPTER 5
targeting urine output 
and 30-day mortality in 
goal-directed therapy: a 
systematic review with 
meta-analysis and meta-
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abstract
backgroUnd: Oliguria is associated with a decreased kidney- and organ perfusion, 
leading to organ damage and increased mortality. While the effects of correcting oliguria 
on renal outcome have been investigated frequently, whether urine output is a modifiable 
risk factor for mortality or simply an epiphenomenon remains unclear. We investigated 
whether targeting urine output, defined as achieving and maintaining urine output above a 
predefined threshold, in hemodynamic management protocols affects 30-day mortality in 
perioperative and critical care.
methods: We performed a systematic review with a random-effects meta-analyses and 
meta-regression based on search strategy through MEDLINE, EMBASE and references in 
relevant articles. We included studies comparing conventional fluid management with 
goal-directed therapy and reporting whether urine output was used as target or not, and 
reporting 30-day mortality data in perioperative and critical care.
resUlts: We found 36 studies in which goal-directed therapy reduced 30-day mortality (OR 
0.825; 95% CI 0.684-0.995; P=0.045). Targeting urine output within goal-directed therapy 
increased 30-day mortality (OR 2.66; 95% CI 1.06-6.67; P=0.037), but not in conventional 
fluid management (OR 1.77; 95% CI 0.59-5.34; P=0.305). After adjusting for operative setting, 
hemodynamic monitoring device, underlying etiology, use of vasoactive medication and 
year of publication, we found insufficient evidence to associate targeting urine output with 
a change in 30-day mortality (goal-directed therapy: OR 1.17; 95% CI 0.54-2.56; P=0.685; 
conventional fluid management: OR 0.74; 95% CI 0.39-1.38; P=0.334).
conclUsions: The principal finding of this meta-analysis is that after adjusting for 
confounders, there is insufficient evidence to associate targeting urine output with an effect 
on 30-day mortality. The paucity of direct data illustrates the need for further research on 
whether permissive oliguria should be a key component of fluid management protocols.
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backgroUnd
Textbooks and guidelines frequently recommend urine output as a parameter to guide fluid 
administration, since decreased organ perfusion may decrease urine output in an attempt 
to maintain intravascular volume (1-3). However, a suboptimal hemodynamic status is 
not always the cause of oliguria. In recent years, the concept of an association between 
intraoperative urine output and postoperative acute kidney injury has been challenged 
(4-6). As a result, advocacy for permissive oliguria has increased, for example to include 
permissive oliguria in the early recovery after surgery (ERAS) protocols (7-9). 
Our group has previously published meta-analyses concerning the effects of targeting 
urine output on acute renal failure or acute kidney injury (10,11). A frequent remark on these 
meta-analyses was that while targeting urine output may not have an effect on preventing 
acute kidney injury, there is increasing evidence that reduced urine output is a risk factor 
for mortality (12-16). Especially in critically ill patients, the occurrence and severity of 
oliguria is associated with an increase in mortality. Whether the association between urine 
output and outcome is due to a causal relation or rather an epiphenomenon is yet to be 
determined. Nevertheless, fluids and vasoactive medication are often administered to 
patients with a decrease in urine output to guarantee and maintain adequate perfusion. 
However, whether urine output is a useful target for fluid management remains doubtful, 
especially when direct measures related to cardiac output and oxygen delivery are available.
We hypothesize that including urine output as a target does not decrease 30-day 
mortality in perioperative and critical care. This study aims to investigate whether including 
urine output as a target in fluid management protocols reduces 30-day mortality in 
perioperative and critical care.
methods
Search strategy
We conducted a systematic literature search of MEDLINE by using PubMed (1966 – present) 
and EMBASE (1980 – present). There were no studies directly investigating the effect on 
30-day mortality by urine output as fluid management target in a perioperative or critical 
care protocol. Therefore, to determine the effect of urine output as a target, all studies 
comparing goal-directed therapy (GDT) and conventional fluid management (CFM) and 
reporting within 30-day mortality were identified. The last search was performed in May 
2016. No limits for publication date or language were used. Table S5.1 and S5.2 show the 
strategy for the MEDLINE and EMBASE database. The ‘related articles’ function in PubMed 
provided us with the opportunity to identify eligible studies that were not found by the 
main search queries. All references of the identified articles and review articles were hand 
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searched to avoid missing relevant trials. We screened the title and abstract of the studies 
found in the databases to determine whether GDT was compared to CFM and to establish 
whether mortality was reported. We used the full text of the article in case of uncertainty 
about the therapy or mortality. 
Study selection
The search was performed by two authors (E.Z., M.E.). Disagreements were resolved by 
consensus or if necessary by a third author (ABJG). We included randomized controlled trials 
during perioperative or critical care into our main analysis, whereas observational studies 
have been collected and are reported in the supplement. Animal studies, pediatric trials 
(<18 years), articles written in another language than English, studies unavailable as full-
text, and studies in which mortality data was not clearly described were excluded. Due to 
the difficulty of using urine output as a parameter after administration of diuretics, the use 
of diuretic drugs to increase urine output was not allowed during the intervention period. 
Therefore, studies using diuretics during the intervention period were excluded. Although a 
full description of the protocol was not required, the hemodynamic targets in the CFM arm 
had to be clearly reported. We excluded studies which described the CFM arm as ‘standard 
treatment’ without further elaboration. Quality assessment was performed using the 
Cochrane Collaboration’s tool for assessing risk of bias (17).
Definitions
Goal-directed therapy was defined as any hemodynamic optimization strategy in the 
perioperative and critical care setting, utilizing parameters related to cardiac output and 
oxygen delivery, either exclusively or in combination with classical parameters such as 
blood pressure and heart rate, irrespective of the device or method used to measure these 
parameters. Urine output as a target was defined as achieving and maintaining urine output 
using fluids and vasoactive medication above a predefined threshold. We did not redefine 
the urine output thresholds and used the thresholds as set by the respective studies. We 
defined mortality as death by all causes within 30 days after inclusion. In case mortality 
was reported as ‘intensive care mortality’ or ‘in-hospital mortality’, we used the respective 
length of stay data to determine the survival duration. Studies in which more than 75% 
of the patients were admitted for less than 30 days were considered for reporting 30-day 
mortality.
Data collection
Two authors (E.Z., M.E.) extracted the following variables: total study population, size of 
GDT arm, size of CFM arm, type of patients, timing of the intervention period, definition of 
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GDT and CFM, urine output target criteria, intraoperative and postoperative urine output 
data, treatment targets in both study arms, definition of mortality and number of deaths. 
Data synthesis
All selected studies were divided into three groups for the main forest plot based on whether 
oliguria reversal was included as a target in a study protocol: trials comparing GDT and CFM 
in which both the GDT protocol and the CFM protocol did not include urine output as a 
target, articles in which urine output was only targeted in the CFM protocol, and articles 
in which GDT and CFM treatment arms both included urine output as target.  We analyzed 
whether there was a difference in 30-day mortality between the two treatment arms and 
in the targeting urine output subsets. A funnel plot was conducted to identify asymmetry. 
If publication bias was detected, possible missing studies were identified by using the ‘trim 
and fill’ method. 
To investigate the effect of targeting urine output in CFM and in GDT on mortality, a meta-
regression model was performed to estimate a regression equation with 30-day mortality 
as outcome and the use of urine output as a target as a variable for GDT and CFM. This 
meta-regression model was then adjusted with study setting, hemodynamic monitoring 
device used, underlying etiology, use of vasoactive medication and year of publication as 
covariates in the regression equation. The year of publication variable was centered on the 
mean year of publication, which was 2008.
Due to the various threshold values used as the urine output target, we performed 
a sensitivity analysis excluding studies utilizing a urine output target different from the 
conventional standard of 0.5 ml/kg/h. This sensitivity analysis was performed for both the 
meta-analysis as well as the meta-regression analysis. 
Statistical analysis 
For each study odds ratios (OR) and 95% confidence intervals (CI) were calculated, based 
on their sample sizes of the GDT and CFM and the reported mortality in those treatment 
arms. All meta-analyses were conducted as random effect meta-analyses in R (version 3.2.1) 
using the metafor package (18,19). The Sidik-Jonkman estimator was used in combination 
with Knapp & Hartung adjustment to improve estimates of the heterogeneity variance due 
to the low number of studies included (20,21). In studies with a count of zero in one of the 
treatment arms, 0.5 was added to all frequencies. Heterogeneity between the trials was 
analyzed using the I2 statistic and interpreted using thresholds as defined in the Cochrane 
Handbook (22). A trial sequence analysis was performed to account for random error. 
Optimal sample size – i.e. information size – was determined using alpha=0.05 and power 
of 0.80 for a relative risk reduction of 25%. Due to the Knapp-Hartung adjustment utilizing 
a t-distribution, we converted the t-value to a z-score using a nominal p-value approach for 
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the trial sequence analysis. Quality of evidence was assessed using the GRADE system (23). 
We used a random-effects meta-regression model with targeting urine output, study setting, 
hemodynamic monitoring device used, underlying etiology, use of vasoactive medication 
and year of publication as covariates and fluid management protocol (GDT or CFM) as the 
inner grouping variable and study as the outer grouping variable to test the effect of the 
moderators on 30-day, using a bivariate approach which has been described earlier (24). 
This method resulted in separate regression equations for the 30-day mortality risk in GDT 
and in CFM. For the sensitivity analysis for studies with a urine output target of 0.5 ml/kg/h, 
we repeated the meta-analysis and meta-regression analysis. Odds ratios were considered 
statistically significant when their 95% CI did not include 1.00 and the corresponding P-value 
was less than 0.05.
resUlts
Our search strategy resulted in 1435 articles. A total of 326 remained after excluding duplicates 
and irrelevant articles. After removing studies which met our exclusion criteria, 83 articles 
remained. An additional 41 studies were excluded based on the usage of diuretics, or the 
absence of a description of the hemodynamic parameters in the CFM arm (Figure 5.1). 
Figure 5.1 Flow chart of study selection
CFM: conventional fluid management; RCT: randomized controlled trial
Exclude:
Unclear description CFM(28)
Diuretics (5)
Only included in one arm (8)
1435 articles
Exclude: duplicate and 
irrelevant articles f11097
326 articles
83 articles
36 RCT and 6 observational
Exclude:
 Animal studies f1167
Pediatric studies f517
Not English f187
No full text f377
Unclear mortality data f57
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Table 5.1 shows the characteristics of the remaining 36 randomized controlled trials. 
Thirteen studies (25-37) did not target urine output in either GDT or CFM; seven studies 
(38-44) only targeted urine output in the CFM protocol; and sixteen studies (45-60) targeted 
urine output in both protocols. 
Table 5.1 Characteristics of studies included
Study total number Type of patient timing Mortality follow up
Not targeting urine output in either protocol
Sinclair 1997 [23] 40 Orthopedic intra 30 days
Polonen 2000 [24] 393 Cardiac post 28 days
Rhodes 2002 [25] 201 Critically ill ICU 28 days
Pearse 2005 [26] 122 High risk post 28 days
Szakmany 2005 [27] 40 Abdominal Intra 3 days postoperative
Wakeling 2005 [28] 128 Abdominal intra 30 days
Forget 2010 [29] 86 Abdominal intra 30 days
WenKui 2010 [30] 214 Abdominal intra, post 30 days
Cecconi 2011 [31] 40 Orthopedic intra 28 days
Challand 2012 [32] 236 Abdominal Intra 30 days
Bartha 2013 [33] 149 Orthopedic intra 30 days
Bisgaard 2013 [34] 70 Abdominal intra, post 30 days
Lai 2015 [35] 221 Abdominal Intra 30 days
Targeting urine output only in CFM
Bishop 1995 [36] 115 Trauma post, ICU in-hospital (95% < 15 days)
McKendry 2004 [37] 174 Cardiac post 30 days
Benes 2010 [38] 120 High Risk intra 30 days
Mayer 2010 [39] 60 High Risk Intra in-hospital (95% < 30 days)
McKenny 2013 [40] 101 Abdominal Intra 30 days
Zakhaleva 2013 [41] 74 Abdominal Intra 30 days
Osawa 2016 [42] 126 Cardiac Intra, post 30 days
Targeting urine output in both protocols
Shoemaker 1988 [43] 88 High Risk intra, post in-hospital (95% < 29 days)
Boyd 1993 [44] 107 High Risk
pre, intra, post, 
ICU
28 days
Gattinoni 1995 [45] 762 High Risk ICU 30 days
Lobo 2000 [46] 37 High Risk intra, post 28 days,
Rivers 2001 [47] 263 Sepsis ICU 28 days
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Chytra 2007 [48] 162 Trauma ICU n-hospital (75% <29 days)
Donati 2007 [49] 135 Abdominal Intra in-hospital (95% < 30 days)
Kapoor 2008 [50] 27 Cardiac post in-hospital (95% < 13 days)
Senagore 2009 [51] 43 Abdominal Intra 2 days
Jammer 2010 [52] 241 Abdominal intra 30 days
Jansen 2010 [53] 348 Critically ill ICU 28 days
Jhanji 2010 [54] 135 Abdominal post, ICU in-hospital (75% < 28 days)
Bisgaard 2013 [55] 40 Vascular Intra, post 30 days
Zheng 2013 [56] 60 Abdominal Pre, intra, post in-hospital (75% <27 days)
Peng 2014 [57] 80 Orthopedic Intra in-hospital (95% <28 days)
Correa-Gallego 2015 
[58]
135 Abdominal Intra, post 30 days
Pre: preoperative; intra: intraoperative; post: postoperative; ICU: intensive care unit.
Hemodynamic monitoring devices and parameters used in the included studies are reported 
in Table 5.2. 
Table 5.2 Hemodynamic monitoring used in selected studies
Study Device Hemodynamic 
targets
Urine output 
threshold
Intervention
Not targeting urine output in either protocol
Sinclair 1997 
[23]
esophageal Doppler SV colloids
Polonen 2000 
[24]
SvO2, Lactate fluids, dobutamine, vasoactive 
medication
Rhodes 2002 
[25]
PAC PAWP fluid boluses, vasoactive 
agents
Pearse 2005 
[26]
LiDCO plus SV, DO2I colloid, dopexamine
Szakmany 2005 
[27]
PiCCO ITBVI crystalloid, colloid 
Wakeling 2005 
[28]
esophageal Doppler SV colloids
Forget 2010 
[29]
Masimo pulse 
oximeter
PVI colloids, vasoactive medication
WenKui 2010 
[30]
Lactate crystalloids, colloids, 
dopamine, ephedrine
Cecconi 2011 
[31]
FloTrac/Vigileo SV colloids, vasoactive 
medication, dobutamine
Challand 2012 
[32]
esophageal Doppler SV colloid
Study total number Type of patient timing Mortality follow up
Table 5.1 Characteristics of studies included (continued)
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Bartha 2013 
[33]
LiDCO SV, DO2I fluids, vasoactive medication
Bisgaard 2013 
[34]
LiDCO SVI colloids, dobutamine, 
vasoactive medication
Lai 2015 [35] LiDCO SVV Colloids
Targeting urine output only in CFM
Bishop 1995 
[36]
PAC DO2I, VO2I, CI 30-50 ml/h volume, dobutamine
McKendry 2004 
[37]
esophageal Doppler SI no specific goal 
mentioned
colloids, blood, vasoactive 
medication
Benes 2010 [38] FloTrac/Vigileo SVV 0.5 ml/kg/h colloids, dobutamine
Mayer 2010 
[39]
FloTrac/Vigileo CI, SVI 0.5 ml/kg/h crystalloids, colloids, 
norepinephrine, dobutamine, 
vasodilators
McKenny 2013 
[40]
esophageal Doppler SV 0.5 ml/kg/h colloids
Zakhaleva 2013 
[41]
esophageal Doppler SV, SVR, CO, FTc 0.5-1.0 ml/kg/h colloids
Osawa 2016 
[42]
LIDCO CI, SVI 0.5 ml/kg/h crystalloid, dobutamine
Targeting urine ouput in both protocols
Shoemaker 
1988 [43]
PAC Hct, PvO2, PAP, 
SVR, PWP, PVR, 
DO2, VO2
30 mL/h crystalloids, colloids, 
vasoactive medication
Boyd 1993 [44] PAC DO2I 0.5 mL/kg/h gelatin, dopexamine
Gattinoni 1995 
[45]
PAC CI or SvO2 0.5 mL/kg/h fluids, vasoactive medication
Lobo 2000 [46] PAC DO2 0.5 mL/kg/h fluids, dobutamine
Rivers 2001 
[47]
computerized 
spectrophotometer
ScvO2, MAP 0.5 mL/kg/h crystalloid dobutamine, blood 
transfusions
Chytra 2007 
[48]
esophageal Doppler SV, FTc 1 mL/kg/h colloids
Donati 2007 
[49]
SvO2, O2ERe 0.5 mL/kg/h fluids, dobutamine
Kapoor 2008 
[50]
FloTrac/Vigileo CVP, SVV 1 mL/kg/h colloids, dopamine or other 
inotropes
Senagore 2009 
[51]
esophageal Doppler SV 0.5 mL/kg/h colloid
Jammer 2010 
[52]
ScvO2 0.5 mL/kg/h crystalloids, colloid
Jansen 2010 
[53]
CeVOX Lactate, ScvO2 0.5 mL/kg/h fluids, vasodilator therapy
Study Device Hemodynamic 
targets
Urine output 
threshold
Intervention
Table 5.2 Hemodynamic monitoring used in selected studies (continued)
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Jhanji 2010 [54] LiDCO SV 25 mL/h fluids, dopexamine
Bisgaard 2013 
[55]
LiDCO DO2I, SVI 0.5–1.0 mL/
kg/h
colloid, dobutamine
Zheng 2013 
[56]
FloTrac/Vigileo CI, SVI, SV 0.5 mL/kg/h balanced salt solution, colloid,  
dopamine /
norepinephrine, nitroglycerin / 
ephedrine
Peng 2014 [57] FloTrac/Vigileo SVV 0.5 mL/kg/h Crystalloid, colloid,
Correa-Gallego 
2015 [58]
FloTrac/Vigileo SVV 25
mL/h for 2 
consecutive 
hours
Crystalloid, colloid, albumin 
bolus infusions
PAC: pulmonary artery catheter; PAC+: pulmonary artery catheter with supranormal hemodynamic targets; 
pre: preoperative; intra: intraoperative; post: postoperative; ICU: intensive care unit; ITBVI: intrathoracic blood 
volume index; SV: stroke volume; DO2I: oxygen delivery index; PAOP: pulmonary artery occlusion pressure; 
CI: cardiac index; CO: cardiac output; SVR: systemic vascular resistance; SVI: systemic vascular index; PCWP: 
pulmonary capillary wedge pressure; DO2: oxygen delivery; PVI: pleth variability index; GEDI: global end-diastolic 
volume index; ELVI: extravascular lung water index; SvO2: mixed venous oxygen saturation; PAWP: pulmonary 
artery wedge pressure; FTc: corrected flow time; PAWP: pulmonary artery wedge pressure;  SVV: stroke volume 
variation; VO2I: oxygen consumption index; SI: stroke index; O2ERe: oxygen extraction estimate; ScvO2: central 
venous oxygen saturation; CVP: central venous pressure; PvO2: venous oxygen pressure; PAP: pulmonary artery 
pressure; PWP: pulmonary wedge pressure; PVR: pulmonary vascular resistance; Hct: hematocrit; VO2: oxygen 
consumption; UO: urine output.
The amount of fluids infused during GDT and CFM in each study is reported in Table S5.3. 
The risk of bias assessment is shown in Figure 5.2. Of the 23 studies which included urine 
output as a target, fifteen studies had a threshold of 0.5 ml/kg/h (Table 5.2). For the limited 
number of studies in which urine output was reported, the urinary data are reported in 
Table S5.4. The data on the six observational studies (61-66) are reported in Table S5.5 and 
S5.6.
Study Device Hemodynamic 
targets
Urine output 
threshold
Intervention
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Figure 5.2 Risk of bias assessment
Risk of bias assessment performed with the Cochrane Collaboration tool.(17) 
Because there are two studies by Bisgaard et al published in 2013, 1 marks reference (36), and 2 marks reference 
(57). Gray circle: low risk of bias; blank: unclear risk of bias; white circle: high risk of bias.
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Meta-analysis
Because there was no direct data on the effect of targeting urine output on mortality, we 
first pooled the studies comparing GDT with CFM based on the presence of urine output as 
a target in either fluid management protocols. Overall, GDT was associated with a decrease 
in 30-day mortality (OR 0.83; 95% CI 0.68 to 1.00; P = 0.04; I2 = 28%; N = 36) (Figure 5.3). 
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Figure 5.3 Forest plot of 36 studies reporting 30-day mortality when comparing goal-directed therapy 
with conventional fluid management. 
+: mortality follow-up was shorter than 28 days. *: mortality reported as in-hospital mortality. **: mortality data 
extracted from Kaplan-Meier curve.
GDT: goal-directed therapy; CFM: conventional fluid therapy; OR: odds ratio; CI: confidence interval.
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However, there was insufficient evidence for a decrease in 30-day mortality due to GDT 
in all the subgroups. The heterogeneity was low to moderate. The funnel plot is shown in 
Figure S5.1. A slight asymmetry was detected; and identification of eight possible missing 
studies altered the point estimate (OR 0.75; 95% CI 0.56 to 1.00; P = 0.05; I2 = 32.8%). The 
trial sequential analysis is shown in Figure S5.2. Despite reaching statistical significance, the 
required information size of 7400 was not reached and the cumulative Z-score did not cross 
the monitoring boundaries. This suggests that the results for the beneficial effects of GDT 
on mortality in this meta-analysis are inconclusive, and the quality of evidence – as assessed 
by GRADE – is limited.
Meta-regression analysis
To assess the effects of urine output as a fluid management target from the available data, 
we performed a meta-regression analysis to estimate a regression line for GDT and CFM with 
targeting urine output as a secondary variable. There was insufficient evidence to suggest 
that targeting urine output influences 30-day mortality in a CFM protocol (OR 1.77; 95% CI 
0.59-5.34; P=0.305). However, targeting urine output increased 30-day mortality when using 
GDT (OR 2.66 95% CI 1.06-6.67; P=0.037). After adjusting for study setting, hemodynamic 
monitoring device, underlying etiology, use of vasoactive medication and year of publication 
(Table 5.3), there was insufficient evidence to associate targeting urine output with an effect 
on 30-day mortality when using a CFM protocol (OR 0.74; 95% CI 0.39-1.38; P=0.334) and a 
GDT protocol (OR 1.17; 95% CI 0.54-2.56; P=0.685).
Table 5.3 Meta-regression model with 30-day mortality as outcome for conventional and goal-directed 
fluid therapy
Variable cfm gdt
Targeting urine output 0.74 (0.39-1.38) 1.17 (0.54-2.56)
Intensive Care setting (reference)
Intraoperative setting 0.15 (0.08-0.28) 0.12 (0.05-0.28)
Postoperative setting 0.06 (0.02-0.15) 0.12 (0.03-0.51)
Transpulmonary thermodilution (reference)
Esophageal Doppler 0.67 (0.21-2.11)
Pulmonary artery catheter 0.79 (0.27-2.27)
Other monitoring devices 1.27 (0.25-6.35)
Other etiologies (reference)
Abdominal 0.32 (0.15-0.69) 0.76 (0.32-1.77)
High risk 2.13 (0.94-4.81) 2.19 (0.74-6.51)
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Inotropic use 1.40 (0.72-2.69) 1.01 (0.4-2.53)
Publication year a 0.97 (0.93-1.02) 1.00 (0.91-1.10)
aPublication year was inputted as the years from the mean publication year (2008).
Data reported as odds ratio and 95% confidence interval.
Sensitivity analysis
In the sensitivity analysis excluding studies with a urine output threshold different from 
the conventional standard of 0.5 ml/kg/h in the targeting urine output group, GDT was 
associated with a decrease in 30-day mortality (OR 0.78; 95% CI 0.63 to 0.97; P = 0.03; I2 = 
31.8%; N = 29, Figure S5.3). In the bivariate meta-regression analysis, we found insufficient 
evidence to suggest that targeting urine output with a threshold of 0.5 ml/kg/h was 
associated with an increase in 30-day mortality when using a CFM protocol (OR 1.90; 95% 
CI 0.56 to 6.50; P=0.300) and in a GDT protocol (OR 2.46; 95% CI 0.80 – 7.59; P=0.114). After 
adjusting for covariates (Table 5.4), targeting urine output was not associated with a change 
in 30-day mortality when using a CFM protocol (OR 0.89; 95% CI 0.41 - 1.91; P=0.756) and a 
GDT protocol (OR 1.08; 95% CI 0.48 – 2.44; P=0.852).
Table 5.4 Meta-regression model of sensitivity analysis with 30-day mortality for conventional and goal-
directed fluid therapy
Variable cfm gdt
Targeting urine output 0.56 (0.29-1.11) 0.68 (0.34-1.36)
Intensive Care setting (reference)
Intraoperative setting 0.16 (0.08-0.30) 0.14 (0.08-0.24)
Postoperative setting 0.07 (0.03-0.16) 0.17 (0.05-0.57)
Transpulmonary thermodilution (reference)
Esophageal Doppler 0.61 (0.23-1.60)
Pulmonary artery catheter 0.21 (0.07-0.63)
Other monitoring devices 1.80 (0.51-6.33)
Other etiologies (reference)
Abdominal 0.48 (0.21-1.10) 1.14 (0.54-2.38)
High risk 2.36 (0.99-5.67) 1.19 (0.61-2.30)
Variable cfm gdt
Table 5.3 Meta-regression model with 30-day mortality as outcome for conventional and goal-directed 
fluid therapy (continued)
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Inotropic use 1.43 (0.67-3.07) 1.15 (0.47-2.81)
Publication year a 0.95 (0.9-1.00) 0.95 (0.88-1.03)
The sensitivity analysis excluded studies in which the urine output threshold was not 0.5 ml/kg/h. aPublication 
year was inputted as the years from the mean publication year (2008). Data reported as odds ratio and 95% 
confidence interval. 
discUssion
The principal finding of this meta-analysis is that while GDT might decrease 30-day mortality, 
including urine output as a target may increase 30-day mortality. However, after adjusting 
for confounders, there is insufficient evidence to associate targeting urine output with an 
effect on 30-day mortality. Additionally, using the common urine output threshold of 0.5 ml/
kg/h, there was insufficient evidence to suggest that targeting urine output affected 30-day 
mortality. Considering our previous findings that targeting urine output does not prevent 
acute renal failure (10,11), our current finding adds further evidence to strongly reconsider 
the use of urine output as a fluid management target.
Our data shows that GDT is associated with an overall decrease in 30-day mortality, 
although barely reaching significance. This is partially in agreement with previously 
published meta-analyses on GDT and mortality. While one meta-analysis in surgical patients 
reported that GDT was associated with a decrease in mortality (67), another meta-analysis 
in surgical patients found no such effect (68). The difference in mortality between these 
two meta-analyses may be due to studies published after the publication of the meta-
analysis by Brienza et al (67). The disagreement between the meta-analysis by Corcoran et 
al. (68) and our meta-analysis may be due to three reasons: the inclusion of newer studies, 
the addition of critical care studies, and the follow-up period for mortality. Additionally, 
the meta-analysis by Zhang et al. showed that patients with severe sepsis or septic shock 
receiving GDT had a similar risk of mortality compared with those in the control group (69). 
Nevertheless, as the optimal information size metric suggests, the currently available pool 
of studies may be insufficient to conclusively state any effect of GDT on mortality.
This meta-analysis supports the hypothesis that oliguria is likely an epiphenomenon 
rather than a modifiable risk factor. In a perioperative setting, low urine output is common 
in the first 24 hours after surgery and in the absence of other issues it does not reliably 
reflect fluid status (5). Moreover, urine output is influenced by factors other than the 
hemodynamic status (70,71). Surgical trauma and physical stress in critical illness cause 
the release of neuro-hormonal factors which influence glomerular filtration pressure or 
water reabsorption in the collecting duct, such as catecholamines, arginine vasopressin 
Variable cfm gdt
Table 5.4 Meta-regression model of sensitivity analysis with 30-day mortality for conventional and goal-
directed fluid therapy (continued)
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and the renin-angiotensin-aldosterone system. While these neuro-hormonal factors are 
also upregulated in hypovolemia resulting in oliguria, the perioperative or critical care 
setting itself promote the occurrence of oliguria. Additionally, anesthetic techniques and 
medication can affect neuro-hormonal factors as well as vasomotor tone. Moreover, 
using urine output to guide fluid management is inherently flawed due to the delayed 
response. Evaluating the urinary response to a fluid challenge is generally possible after 
at least 15-30 minutes and is limited by the lack of a clear dose-response relationship. In 
contrast, hemodynamic parameters such as cardiac output are dynamic variables which 
are influenced within a short interval after a fluid challenge is given and for most variables 
a dose-response relationship has been given. Thus, the primary cause of oliguria may not 
be affected by fluid administration or may already have been resolved by acting on another 
target. 
In light of this, the use of permissive oliguria has already been advocated in ERAS 
protocols, primarily to avoid excess fluid loading (7). In patients managed by hemodynamic 
targets with a better correlation to fluid status, the occurrence of oliguria due to 
hemodynamic causes is unlikely, which favors the exclusion of urine output as a target for 
fluid resuscitation. Considering this, the current paradigm that urine output reflects renal 
injury and – perhaps indirectly – increases mortality needs to be revisited (12,15). In most 
– if not all – cases, oliguria is most likely an epiphenomenon of an underlying problem. A 
recent study showed that after adjusting for confounders while intraoperative urine output 
was not associated with postoperative morbidity, total intraoperative fluid intake and 
postoperative fluid boluses for hypotension and low urine output were associated with an 
increase in postoperative morbidity (60). This strongly suggests that urine output should 
not be a target in a fluid management protocol to improve outcome.
This meta-analysis has several important limitations. The main limitation is the various 
sources of heterogeneity. The I2 statistic showed low to moderate heterogeneity in most 
analyses. However, considering the different hemodynamic targets, fluid types, vasopressor 
use, monitoring devices, underlying etiologies, clinical settings and mortality follow-up used 
in these studies, assuming that the heterogeneity is as low as suggested by the I2 statistic 
would be imprudent. Because data on fluids infused was not reported as a statistical 
measure and urinary data was rarely reported at all, further analysis of these data points 
was not possible. Despite the use of a random-effects model and a bi- and multivariate 
approach to a meta-regression analysis, the effects of between-trial differences are most 
likely not completely taken into account (20,21). Since our findings are based on between-
trial statistical analyses, given the large differences between the included studies, the 
interpretation of these findings – even after adjusting for operative setting, underlying 
etiology and other confounders - should be done with care. Understandably, given the 
absence of trials primarily investigating the effects of urine output as a target, to account 
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for all the possible sources of heterogeneity within the currently available literature would 
be impractical and the inability to do so is currently an inevitable limitation. However, after 
acknowledging this limitation, our findings are currently the only assessment of the effects 
of targeting urine output on mortality, and are supported by the observations from various 
trials (6,60).
Another important limitation is the low number of studies given the available literature 
on GDT. The potential for robust conclusions by using meta-regression is limited by the 
number of studies (72). However, to ensure that heterogeneity was limited as much as 
possible, several of the larger - and perhaps more convincing – trials were excluded. The 
three recent large studies - ARISE, PROCESS and PROMISE - were not included in this meta-
analysis, due to meeting our exclusion criterion of vague CFM protocols (73-75). While their 
exclusion may limit the generalization of our findings, the strict inclusion and exclusion 
criteria removes bias caused by some of the heterogeneity. Given that our main objective 
was to assess the effect of targeting urine output on 30-day mortality, removing as many 
sources of heterogeneity as possible strengthens our findings. Similarly, despite the 
absence of these large trials, the mortality rate in most studies is close to the estimated 
30-day mortality rate in elective – high risk – surgery (±7%) and critical care (±15%) (76-78). 
Additionally, a slight asymmetry was found in the funnel plot, and after applying the ‘trim 
and fill’ method, the effect size of eight possible missing studies were added to the analysis. 
In combination with the trail sequential analysis, this suggests insufficient evidence to 
support a difference in 30-day mortality between GDT and CFM, despite the analysis in 
Figure 5.3, and illustrates the dependence on adequate sample size to establish definite 
conclusions.
conclUsion
In conclusion, based on the currently available literature, we found that GDT might decrease 
30-day mortality, including urine output as a target may increase 30-day mortality. However, 
the principal finding of this meta-analysis is that after adjusting for confounders, there is 
insufficient evidence to associate targeting urine output with an effect on 30-day mortality. 
This suggests that oliguria is not a modifiable risk factor for mortality and using diuresis 
to guide fluid management may not affect survival. However, the paucity of direct data 
illustrates the need for further research on whether oliguria is just an epiphenomenon and 
whether ‘permissive oliguria’ should be a key component of fluid management protocols. 
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Table S5.1 Search strategy in MEDLINE database through PubMed
#49 ((#41 AND #48)) 446
#48 ((#44 OR #47))
#47 ((#45 OR #46))
#46 “controlled trial”
#45 trial
#44 ((#42 OR #43))
#43 “randomised”
#42 “randomized”
#41 ((#31 AND #40))
#40 ((#12 AND #39))
#39 ((#32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38))
#38 fluid
#37 “fluid resuscitation”
#36 “fluid loading”
#35 “fluid administration”
#34 “fluid management”
#33 “fluid therapy”
#32 “fluid therapy”[MeSH]
#31 ((#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR 
#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30))
#30 outcome
#29 “urinary output”
#28 “urine production”
#27 “urine output”
#26 “diuresis”
#25 “mortality rate”
#24 “loss of life”
#23 decease
#22 lethality
#21 fatality
#20 survival
#19 death
#18 mortality
#17 “mortality”[MeSH]
#16 “acute kidney injury”
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#15 “complications”
#14 “organ dysfunction”
#13 “organ failure”
#12 (#1 OR #2 OR #3 # OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#11 “supranormal”
#10 “goal directed therapy”
#9 “goal-directed therapy”
#8 optimisation
#7 optimization
#6 “cardiac index”
#5 “stroke volume”
#4 “cardiac output”
#3 “hemodynamic target”
#2 “goal-directed”
#1 “goal directed”
Table S5.2 Search strategy in EMBASE database
#47 #39 AND #46 890
#46 #42 OR #45
#45 #43 OR #44
#44 “controlled trial”
#43 trial
#42 #40 OR #41
#41 “randomised”
#40 “randomized”
#39 #30 AND #38
#38 #12 AND #37
#37 ((#31 OR #32 OR #33 OR #34 OR #35 OR #36))
#36 fluid
#35 “fluid resuscitation”
#34 “fluid loading”
#33 “fluid administration”
#32 “fluid management”
#31 “fluid therapy”
#30 ((#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR 
#24 OR #25 OR #26 OR #27 OR #28 OR #29))
#29 outcome
#28 “urinary output”
#27 “urine production”
#26 “urine output”
#25 “diuresis”
#24 “mortality rate”
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#23 “loss of life”
#22 decease
#21 lethality
#20 fatality
#19 survival
#18 death
#17 mortality
#16 “acute kidney injury”
#15 “complications”
#14 “organ dysfunction”
#13 “organ failure”
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#11 “supranormal”
#10 ‘goal-directed’
#9 ‘goal directed’
#8 optimisation
#7 optimization
#6 “cardiac index”
#5 “stroke volume”
#4 “cardiac output”
#3 “hemodynamic target”
#2 ‘goal-directed therapy’
#1 ‘goal directed therapy’
Table S5.3 Amount of fluids infused during the relevant study period.
Study Total fluid amount GDT (mL) Total fluid amount 
CFM (mL)
Not targeting urine output in either protocol
Sinclair 1997 1475 1000
Polonen 2000 3193 2772
Rhodes 2002 4953 4295
Pearse 2005 2962 2164
Szakmany 2005 5458 5298
Wakeling 2005 5000 4500
Forget 2010 5777 6835
WenKui 2010 2800 2800
Cecconi 2011 6229 3293
Challand 2012 5309 4010
Bartha 2013 1310 1197
Bisgaard 2013 7236 8953
Lai 2015 5369 4532
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Targeting urine output only in CFM
Bishop 1995 5496 6165
McKendry 2004 2020 1370
Benes 2010 3746 3729
Mayer 2010 4528 4494
McKenny 2013 2000 2500
Zakhaleva 2013 5300 5600
Osawa 2016 1056 894
Targeting urine output in both protocols
Shoemaker 1988 - -
Boyd 1993 5075 4845
Gattinoni 1995 - -
Lobo 2000 7200 6600
Rivers 2001 4981 3499
Chytra 2007 4516 3599
Donati 2007 4391 4285
Kapoor 2008 - -
Senagore 2009 3400 3000
Jammer 2010 3875 6490
Jansen 2010 3019 2390
Jhanji 2010 1879 1743
Bisgaard 2013 4314 3616
Zheng 2013 2650 3950
Peng 2014 2100 2600
Correa-Gallego 2015 2000 2900
Pre: preoperative; intra: intraoperative; post: postoperative; ICU: intensive care unit.
Study Total fluid amount GDT (mL) Total fluid amount 
CFM (mL)
Table S5.3 Amount of fluids infused during the relevant study period. (continued)
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Table S5.4 Available urine output data from the selected studies
Intraoperative urine output Postoperative urine output
Study gdt cfm p gdt cfm p
Not targeting urine output
Szakmany 2005 757 mL ± 533 755 mL ± 528 NS
Cecconi 2011 1225 mL (IQR 
650 - 1375)
300 mL (IQR 
100 - 475)
<0.0001
Challand 2012 655 mL ± 302 388 mL ± 355 <0.001
Bartha 2013 400 mL (range 
0 - 1900)
300 mL (range 
0 - 1300)
NS 400 mL (range 
0 - 2275) 
350 mL (range 
25 - 4800) 
NS
Targeting urine output
Gattinoni 1995 95.8 mL ± 50.1 CIG: 102 mL ± 
49.5
O2G: 95.5 mL 
± 49.5
0.274
Kapoor 2008 230* mL 140* mL NS
Jammer 2010 1.1 ml/kg/h ± 1.5 1.5 ml/kg/h 
± 1.5
0.020 83 mL 1 ± 445 1104 mL ± 449 <0.001
Zheng 2013 618 mL ± 239 800 mL ± 304 <0.001 518 mL ± 330 870 mL ± 304 <0.001
Peng 2014 1.98 ml/kg/h 
(IQR 1.29 - 2.63)
2.20 ml/kg/h 
(IQR 1.53 - 
3.25)
NS
Correa-Gallego 
2015
200 mL ± 100 300 mL ± 200 0.10 900 mL ± 600 1000 mL ± 500 0.07
Data as reported by the respective studies as either mean ± standard deviation or median (interquartile range 
(IQR) or range), in mL or mL/kg/h. *: approximated from figure. GDT: goal-directed therapy; CFM: conventional 
fluid management; CIG: cardiac index guided group; O2G: oxygen saturation guided group. NS: not statistically 
significant.
Table S5.5 Characteristics of observational studies included
Study total 
number
Type of patient timing Mortality (GDT vs CFM), follow up
Not targeting urine output in either protocol
Hussien 2011 25 Abdominal intra 1 vs 0, 10 days
See 2014 612 Critically ill ICU 90 vs 148, 30 days
Thomson 2014 264 Cardiac Post 0 vs 2 ,30 days
Cannesson 2015 330 Abdominal, pelvic intra 2 vs 1, 30 days
Targeting urine output in both protocols
Sivayoham 2012 174 Critically ill ICU 22 vs 33, 30 days
Reydellet 2013 50 Abdominal Intra, post 1 vs 4, 30 days
Pre: preoperative; intra: intraoperative; post: postoperative; ICU: intensive care unit.
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Table S5.6 Hemodynamic monitoring used in observational studies
Study Device Hemodynamic 
targets
Urine output 
threshold
Intervention
Not targeting urine output in either protocol
Hussien 2011 Oesophageal Doppler SV colloids
See 2014 PP, SV crystalloids
Thomson 2014 LiDCOplus SV colloids, cystalloids, 
blood products
Cannesson 2015 EV 1000, Edwards SV, SVV, CI crystalloids
Targeting urine output in both protocols
Sivayoham 2012 SVO2, CI, 0.5 ml/kg/h crystalloids, colloids, 
vasoactive medication
Reydellet 2013 FloTrac-Vigileo MAP, CO, CI, SV, 
SVV, ScvO2
no specific goal 
mentioned
colloids, crystalloids 
vasoactive medication
SV: stroke volume; PP: pulse pressure; SVV: stroke volume variation; CI: cardiac index; SvO2: mixed venous 
oxygen saturation; MAP: mean arterial pressure; CO: cardiac output; ScvO2: central venous oxygen saturation; 
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Figure S5.1: Funnel plot used to assess the presence of publication bias in the performed analysis. 
Fig S1: Funnel plot
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Figure S5.2: Trial sequential analysis for cumulative meta-analysis.
Data is analyzed cumulatively in order of year of publication, and the optimal information size (sample size) is 
7400 patients to find a 25% relative risk reduction with a power of 80% and an alpha of 0.05. 
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Figure S5.3: Forest plot of sensitivity analysis (urine output threshold 0.5 ml/kg/h) on 30-day mortality 
when comparing goal-directed therapy with conventional fluid management. 
+: mortality follow-up was shorter than 28 days. *: mortality reported as in-hospital mortality. **: mortality 
data extracted from Kaplan-Meier curve. GDT: goal-directed therapy; CFM: conventional fluid therapy; OR: odds 
ratio; CI: confidence interval. PDF.
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abstract
backgroUnd: Interest in perioperative fluid restriction has increased, but it could lead 
to hypovolemia. Urine output is viewed as surrogate for renal perfusion and is frequently 
used to guide perioperative fluid therapy. However, the rationale behind targeting oliguria 
reversal - achieving and maintaining urine output above a previously defined threshold by 
additional fluid boluses - is often questioned.
obJectiVe: We assessed whether restrictive fluid management had an effect on the 
occurrence of oliguria, acute renal failure (ARF), and fluid intake. We also investigated 
whether targeting oliguria reversal affected these parameters. 
design: Systematic review of randomized controlled trials with meta-analyses. We used the 
definitions of restrictive and conventional fluid management as provided by the individual 
studies.
data soUrces: We searched MEDLINE (1966 – present), EMBASE (1980 – present), and 
relevant reviews and articles.
eligibility criteria: We included randomized controlled trials with adult patients 
undergoing surgery comparing a restrictive fluid management against a conventional fluid 
management protocol and also reporting the occurrence of postoperative ARF. 
resUlts: We included fifteen studies with a total of 1594 patients. There was insufficient 
evidence to associate restrictive fluid management with an increase in oliguria (restrictive 
83/186 vs conventional 68/230; odds ratio 2.07; 95% confidence interval (CI) 0.97-
4.44; P=0.06;I2=23.7%;Nstudies=5). The frequency of ARF in restrictive and conventional 
fluid management was 20/795 and 20/799 respectively (odds ratio 1.07;95% CI 
0.60-1.92;P=0.8;I2=17.5%;Nstudies=15). There was no statistically significant difference in ARF 
occurrence between studies targeting oliguria reversal and not targeting oliguria reversal 
(odds ratio 0.31;95% CI 0.08-1.22;P=0.088). Intraoperative fluid intake was 1.89 liters lower 
in restrictive than in conventional fluid management when not targeting oliguria reversal 
(95% CI -2.59L to -1.20L P<0.001;I2=96.6%;Nstudies=7), and 1.63 liters lower when targeting 
oliguria reversal (95% CI -2.52L to -0.74L;P<0.001;I2=96.6%;Nstudies=6).
conclUsions: Our data suggests that, even though event numbers are small, perioperative 
restrictive fluid management does not increase oliguria or postoperative ARF, while 
decreasing intraoperative fluid intake, irrespective of targeting reversal of oliguria or not.
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introdUction
Interest in restrictive fluid management has increased over the past decade, mainly due 
to increasing evidence of adverse events associated with positive fluid balances in surgical 
and critically ill patients (1-4). The large fluid volumes in standard perioperative fluid 
management were intended to compensate for hypovolemia due to non-anatomical third-
space loss and  preoperative fasting (5), though in recent years both these concepts have 
been called into question (6-8). While several meta-analysis have associated restrictive fluid 
management with lower mortality and complication rates after abdominal and major surgery 
(9-11), the main argument against reducing intraoperative fluid intake was that it would 
lead to persistence of hypovolemia and thereby induce or aggravate renal injury. However, a 
recent meta-analysis by Boland et al. concluded that perioperative fluid restriction in major 
abdominal surgery had no effect on postoperative acute renal failure (ARF) (12).
Even so, clinicians widely use urine output as surrogate for renal perfusion to guide 
perioperative fluid therapy (13,14). Many perioperative care protocols include oliguria 
reversal as a resuscitation target to maintain urine output above a certain predefined 
threshold and advocate additional fluid boluses when oliguria occurs in an attempt 
to improve diuresis. However, the relation between perioperative urine output and 
postoperative ARF is weak at best (15). Oliguria is not always due to a decrease in renal 
perfusion pressure or glomerular perfusion and therefore will not necessarily benefit 
from fluid therapy aimed at improving cardiac output and systemic blood pressure. 
Intra-abdominal pressure during abdominal surgery and neurohormonal regulation due 
to surgical stress are likely fluid unresponsive causes of oliguria during surgery (16), and 
administering fluids to increase urine output in these cases may lead to fluid overload 
without any renal benefits. Conversely, if fluid boluses are withheld when oliguria occurs 
in a hypovolemic patient, the persistence of renal hypoperfusion may over time induce 
damage leading to ARF. Even though the rationale behind targeting oliguria reversal is often 
questioned, especially when hemodynamic monitoring tools which can estimate cardiac 
output are available, it still remains widely used.
Objectives
We investigated whether perioperative restrictive fluid management had an effect on the 
occurrence of oliguria, ARF, fluid intake and fluid balance. We also investigated whether 
targeting oliguria reversal influenced these parameters. We hypothesized that excluding 
oliguria reversal as target does not affect these parameters when used in a restrictive fluid 
management protocol.
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methods
Eligibility criteria
We performed a systematic literature search to identify all studies investigating restrictive 
fluid management and also reporting the occurrence of ARF. We included studies with adult 
surgical patients, performed as randomized controlled trials, and comparing restrictive with 
conventional fluid management in the perioperative period. Studies only using restrictive 
fluid management in the postoperative setting were also eligible for inclusion; however the 
intraoperative data - if available - was not pooled with the intraoperative data from the other 
studies. We excluded articles not in English or unavailable as full-text. We excluded studies 
directly comparing restrictive fluid management strategy against a goal-directed therapy 
strategy, because, while goal-directed therapy leads to the infusion of a fluid volume equal 
to conventional fluid management (17), the additional hemodynamic measurements would 
introduce bias. However, studies in which both the restrictive and the control group were 
treated using a goal-directed therapy strategy were included, and the control group was 
allocated to the conventional fluid management group. We excluded studies with protocols 
in which diuretics were administered when oliguria occurred to increase urine output; 
however studies that use diuretic for indications outside the fluid management protocol or 
for indications not related to the reversal of oliguria were not excluded.
Definitions
We used the definitions of restrictive and conventional fluid management as provided by 
the individual studies. We defined targeting oliguria reversal as the concept of achieving and 
maintaining urine output above a previously defined threshold by additional fluid boluses - 
in combination with vasoactive medication – guided by the occurrence of oliguria. Because 
the currently used term acute kidney injury is specifically linked to the RIFLE and later criteria 
(18), we used the term ARF for all definitions using a relative or absolute increase in serum 
creatinine, need for renal replacement therapy, or any combination of the previous with any 
severity and length of oliguria - as defined in the selected studies. 
Search strategy
We searched the MEDLINE (1966 – present) database via PubMed and the EMBASE 
(1980 – present) database (last search August 2015) using combinations of the following 
MESH terms and keywords; a full search strategy for the MEDLINE database is presented 
in Supplement Table S6.1 and for the EMBASE database in Supplement Table S6.2. We 
handsearched references of studies considered for inclusion and references of the review 
articles for eligible studies. We screened the title and abstract of the studies found in the 
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search to see whether the study fulfilled our inclusion criteria, and if the occurrence of ARF 
was not reported in the abstract, we screened the full-text article.
Data collection
Using a predefined study form, one author (M.E.) scored the following variables: total 
study population; group sizes; type of patients; presence or absence of oliguria reversal 
in treatment protocols; urine output threshold to define oliguria; occurrence of oliguria; 
definition of ARF; duration of postoperative period in which ARF was assessed; and 
occurrence of ARF; intraoperative fluid intake; postoperative fluid intake; postoperative 
fluid balance; operative periods in which the study was performed. Once included, the 
studies were scored according to the Jadad scale on: reporting whether randomized or not 
and by which method; the method of blinding used and whether this was appropriate; and 
adequate reporting of withdrawals and dropouts (19).
Data synthesis
To investigate whether targeting oliguria reversal had an effect on oliguria, ARF occurrence, 
fluid intake and fluid balance, we assigned all included studies to one of two groups based 
on whether oliguria reversal was included as a target in the study protocol: restrictive fluid 
management compared with conventional fluid management without oliguria reversal as 
a target in both protocols; and restrictive fluid management compared with conventional 
fluid management with oliguria reversal as a target in both protocols. 
We first analyzed whether there was a difference in the occurrence of intraoperative 
study-defined oliguria between restrictive and conventional fluid management. The 
second analysis was to investigate the difference in ARF occurrence between restrictive 
and conventional fluid management. We also performed a sensitivity analysis based on 
whether ARF was defined as need for renal replacement therapy or as an increase in 
serum creatinine levels. We then pooled studies reporting intraoperative fluid intake to 
investigate whether the mean fluid difference between restrictive and conventional fluid 
management differed between studies targeting and studies not targeting oliguria reversal. 
We similarly pooled studies reporting postoperative fluid intake and postoperative fluid 
balance. In studies reporting postoperative fluid balance as a change from preoperative 
weight, we made the assumption that 1 kilogram of weight gain was equal to a volume 
increase of 1 liter. 
Due to the lack of studies directly comparing the inclusion and exclusion of oliguria 
reversal as a target in a perioperative restrictive fluid management protocol, we performed 
an indirect comparison to assess the effects of targeting oliguria reversal. We compared 
the cumulative ARF occurrence of studies including oliguria reversal as a target with studies 
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without oliguria reversal as a target, grouped according to the use of either restrictive or 
conventional fluid management protocols.
Statistical analysis
We calculated the odds ratio (OR) and corresponding 95% confidence interval (CI) of each 
study for occurrence of ARF using the available dichotomous data. In studies with a count 
of zero in one of the treatment arms, 0.5 was added to all frequencies of that study.  For 
the continuous data, we used mean with standard deviation (SD). If mean with SD was not 
present, we calculated it from median and range using the methods described by Hozo et 
al (20). When only median with interquartile range (IQR) was presented in the study, we 
assumed a normal distribution in order to approximate mean with SD and used the median 
as mean. We calculated SD for each side of the IQR as where 0.67 is 
the Z-range for the 25th to 75th percentile where a equals the lower IQR value, and b equals 
the upper IQR value. Then we used the formula  to calculate the SD of 
the study population. In an indirect comparison, we calculated an OR and 95% CI for the 
difference in ARF occurrence in studies with and without oliguria reversal as a target based 
on the cumulative number of patients with ARF and the cumulative total number of patients 
in each fluid management protocol. We calculated the respective P value using the Fisher’s 
exact test.
All meta-analyses were performed as a random effects meta-analysis, and due to the 
expected heterogeneity between studies and the low number of included studies we used 
the Sidik-Jonkman estimator (21) in combination with the Knapp & Hartung adjustment 
(22) to get better estimates of the heterogeneity variance. Heterogeneity was analyzed 
using the I2 statistics, and the thresholds for interpretation were used as defined in 
the Cochrane Handbook. We used a random effects meta-regression model with a 
heteroscedastic compound symmetry variance structure using targeting oliguria reversal 
as the moderator to test for subgroup differences in ARF occurrence and mean differences 
in intraoperative fluid intake, and postoperative fluid balance between studies targeting 
and studies not targeting oliguria reversal. We did not perform a meta-regression analysis 
for oliguria and postoperative fluid intake due to low number of studies in one group and 
changes in postoperative fluid management strategies in both groups, respectively. We 
used R (version 3.2.1) (23) with the metafor package (version 1.9.7) (24) for the analyses 
and creating the forest and funnel plots. In case the funnel plot for the analysis on ARF 
occurrence suggested publication bias, we performed a trim and fill analysis to identify 
missing studies. We subsequently performed a new analysis which compensates for any 
missing trials identified and compared the results to the analysis on ARF occurrence with a 
meta-regression model. Pooled outcome data are presented as OR and 95% CI, and exact P 
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values are given unless P < 0.001. Statistical significance was defined as a 95% CI which did 
not include 1.00 and a P value less than 0.05.
resUlts
Study selection and characteristics
We found 477 articles, of which 30 full text articles remained after removing duplicates 
and articles which met our exclusion criteria, see Figure 6.1. We included fifteen studies 
and the characteristics are reported in Table 6.1. Six studies included oliguria reversal as 
a target in both the restrictive and conventional fluid management protocols (25-30), and 
nine studies excluded oliguria reversal as target in both protocols (31-39). One study only 
used restrictive fluid management during the postoperative period (34). Three studies did 
not exclude patients with chronic kidney disease or preoperative ARF (27,28,32). Only one 
of the included studies (28) had a score of less than 3 on the Jadad scale (Table 6.2).
Oliguria
Four studies (34,35,37,38) reported no difference in intraoperative urine output between 
restrictive and conventional fluid management, and in three studies (25,32,36) intraoperative 
urine output was lower in patients with restrictive fluid management. Five studies reported 
the occurrence of study-defined oliguria when using restrictive and conventional fluid 
management, ranging from urine output less than 0.5 ml/kg/h to less than 1.0 ml/kg/h 
(25,33,34,37,38). There was insufficient evidence to associate restrictive fluid management 
with an increase in study-defined oliguria, see Figure 6.2. Because of the limited number of 
studies in the targeting oliguria reversal subset, we did not test for differences in oliguria 
between targeting and not targeting oliguria reversal.
Figure 6.1 Flow chart of study selection.
ARF: acute renal failure, GDT: goal-directed therapy.
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Table 6.1 Characteristics of included studies
Study year Country number
Total (Restrictive 
| Conventional)
Type of 
patient
timing target 
oliguria 
reversal
renal 
exclusion
ARF definition Conventional protocol Restrictive protocol
Brandstrup 2003 Denmark 141 (69 | 72) Abdominal 
Elective
intraoperative Yes Renal 
insufficiency
Renal 
replacement 
therapy
Preloading 
500 mL HAES 6%.
Third space loss
7 mL/kg/h NS first hour;
5 mL/kg/h NS second and third hour; 
3 mL/kg/h NS following hours.
Maintenance:
500 mL of normal saline 0.9% 
Preloading
No preloading. 
Third space loss 
No replacement 
Maintenance:
500 mL of glucose 5%
Nisanevich 2005 Israel 152 (77 | 75) Abdominal 
Elective
Intraoperative Yes sCr > 97 
(female) or 
> 115 (male) 
µmol/l
sCr > 97 (female) 
or > 115 (male) 
µmol/l within 3 
postoperative 
days 
Before skin incision:
10 ml/kg RL
After skin incision;
12 ml/kg/h RL
4 ml/kg/h RL
MacKay 2006 UK 80 (39 | 41) Abdominal 
Elective
intraoperative, 
postoperative
No Significant 
renal 
impairment
Not clearly 
defined in the 
study
1L 0.9% NS + 2L 5% dextrose per day, until day 3 
unless decided otherwise by the consultant.
2L 4% dextrose/0,18% NS per day.  All 
intravenous fluids were stopped on day 1 after 
operation unless there was a clinical reason to 
maintain them.
Holte 2007 Denmark 32 (16 | 16) Abdominal 
Elective
intraoperative, 
postoperative
No Renal 
replacement 
therapy
Preload 
10 ml/kg RL
During surgery
18 ml/kg/h RL
7 mg/kg Voluven
After operation day of surgery:
10 ml/kg RL
Preload 
None
During surgery:
7 ml/kg/h RL first hour
5 ml/kg/h RL subsequent hours
7 mg/kg Voluven
After operation day of surgery
No fluids 
Gonzalez-
Fajardo
2009 Spain 40 (20 | 20) Vascular / 
Abdominal 
Elective
intraoperative, 
postoperative
No Impaired 
renal function
sCr > 97 (female) 
or > 115 (male) 
µmol/l ; oliguria 
not further 
specified
1000 ml of 5% dextrose and 1500 ml of 0.9% NS per 
day
1500 ml of 0.9% NS per day
McArdle 2009 Northern 
Ireland
21 (10 | 11) Vascular / 
Abdominal
Elective
intraoperative, 
postoperative
Yes Renal 
replacement 
therapy
Preload 
10 mL/kg NS
During surgery 
12 mL/kg/h HM 
Postoperative (day-of surgery) 
125 mL/h HM
Preload
No preload
During surgery
4 mL/kg/h HM 
Postoperative (day-of surgery) 
83 mL/h HM
Muller 2009 Switzerland 151 (76 | 75) Abdominal Intraoperative Yes Not clearly 
defined in the 
study
preoperative loading
2 mL/kg/h RL
during surgery.
10 mL/kg/h RL
preoperative loading
1 mL/kg/h RL
during surgery.
5 mL/kg/h RL
Vermeulen 2009 Netherlands 62 (30 | 32) Abdominal 
Elective
postoperative No Impaired 
renal function
Renal 
replacement 
therapy
1500 ml 0.9% NS and 1000 ml 5% glucose per day 1000 ml 0.9% NS and 500 ml 5% glucose IV per 
day
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Table 6.1 Characteristics of included studies
Study year Country number
Total (Restrictive 
| Conventional)
Type of 
patient
timing target 
oliguria 
reversal
renal 
exclusion
ARF definition Conventional protocol Restrictive protocol
Brandstrup 2003 Denmark 141 (69 | 72) Abdominal 
Elective
intraoperative Yes Renal 
insufficiency
Renal 
replacement 
therapy
Preloading 
500 mL HAES 6%.
Third space loss
7 mL/kg/h NS first hour;
5 mL/kg/h NS second and third hour; 
3 mL/kg/h NS following hours.
Maintenance:
500 mL of normal saline 0.9% 
Preloading
No preloading. 
Third space loss 
No replacement 
Maintenance:
500 mL of glucose 5%
Nisanevich 2005 Israel 152 (77 | 75) Abdominal 
Elective
Intraoperative Yes sCr > 97 
(female) or 
> 115 (male) 
µmol/l
sCr > 97 (female) 
or > 115 (male) 
µmol/l within 3 
postoperative 
days 
Before skin incision:
10 ml/kg RL
After skin incision;
12 ml/kg/h RL
4 ml/kg/h RL
MacKay 2006 UK 80 (39 | 41) Abdominal 
Elective
intraoperative, 
postoperative
No Significant 
renal 
impairment
Not clearly 
defined in the 
study
1L 0.9% NS + 2L 5% dextrose per day, until day 3 
unless decided otherwise by the consultant.
2L 4% dextrose/0,18% NS per day.  All 
intravenous fluids were stopped on day 1 after 
operation unless there was a clinical reason to 
maintain them.
Holte 2007 Denmark 32 (16 | 16) Abdominal 
Elective
intraoperative, 
postoperative
No Renal 
replacement 
therapy
Preload 
10 ml/kg RL
During surgery
18 ml/kg/h RL
7 mg/kg Voluven
After operation day of surgery:
10 ml/kg RL
Preload 
None
During surgery:
7 ml/kg/h RL first hour
5 ml/kg/h RL subsequent hours
7 mg/kg Voluven
After operation day of surgery
No fluids 
Gonzalez-
Fajardo
2009 Spain 40 (20 | 20) Vascular / 
Abdominal 
Elective
intraoperative, 
postoperative
No Impaired 
renal function
sCr > 97 (female) 
or > 115 (male) 
µmol/l ; oliguria 
not further 
specified
1000 ml of 5% dextrose and 1500 ml of 0.9% NS per 
day
1500 ml of 0.9% NS per day
McArdle 2009 Northern 
Ireland
21 (10 | 11) Vascular / 
Abdominal
Elective
intraoperative, 
postoperative
Yes Renal 
replacement 
therapy
Preload 
10 mL/kg NS
During surgery 
12 mL/kg/h HM 
Postoperative (day-of surgery) 
125 mL/h HM
Preload
No preload
During surgery
4 mL/kg/h HM 
Postoperative (day-of surgery) 
83 mL/h HM
Muller 2009 Switzerland 151 (76 | 75) Abdominal Intraoperative Yes Not clearly 
defined in the 
study
preoperative loading
2 mL/kg/h RL
during surgery.
10 mL/kg/h RL
preoperative loading
1 mL/kg/h RL
during surgery.
5 mL/kg/h RL
Vermeulen 2009 Netherlands 62 (30 | 32) Abdominal 
Elective
postoperative No Impaired 
renal function
Renal 
replacement 
therapy
1500 ml 0.9% NS and 1000 ml 5% glucose per day 1000 ml 0.9% NS and 500 ml 5% glucose IV per 
day
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Futier 2010 France 70 (36 | 34) Abdominal 
Elective
intraoperative No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
Within 2 
postoperative 
days: UO < 
500ml/d 
sCr > 30% from 
preoperative
Renal 
replacement 
therapy
12 mL/kg/h RL 6 mL/kg/h RL
Lobo 2011 Brazil 88 (45 | 43) High Risk intraoperative Yes sCr > 176 
µmol/l
sCr > 2x baseline 
value during 
discharge or 60 
days
12 ml/kg/hour RL 4 ml/kg/hour RL
Abraham-
Nordling
2012 Sweden 161 (79 | 82) Abdominal 
Elective
intraoperative, 
postoperative
No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
Not clearly 
defined in the 
study
before surgery:
 500–1000 ml RA 
during surgery
5 ml/kg/h RA
induction of anesthesia:
2 ml/kg/h buffered glucose 2.5% 
early postoperative period:
 1000 ml RA 
from early after operation until morning after 
surgery :
1 ml/kg/h glucose 10%
induction of anesthesia:
2 ml/kg/h buffered glucose 2.5% 
from early after operation until morning after 
surgery :
1 ml/kg/h glucose 10%
Matot 2012 Israel 107 (52 | 55) Abdominal 
Elective
intraoperative No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
sCr > 97 (female) 
or > 115 (male) 
µmol/l within 3 
postoperative 
days
10 mL/kg/h RL 4 mL/kg/h RL
Kalyan 2013 UK 239 (121 | 118) Abdominal 
Elective
Intraoperative,
postoperative
Yes sCr > 140  
µmol/l
Renal 
replacement 
therapy
Preloading 
500 mL HM
Third space loss
7 mL/kg/h HM  first hour;
5 mL/kg/h HM following hours.
Maintenance:
1.5 ml/kg/h
Preloading
No preloading. 
Third space loss 
No replacement 
Maintenance:
1.5 ml/kg/h during anesthesia
1 ml/kg/h 5% glucose until enteral intake
Matot 2013 Israel 102 (51 | 51) Thoracic 
Elective
intraoperative No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
sCr > 97 (female) 
or > 115 (male) 
µmol/l within 3 
postoperative 
days
8 mL/kg/h RL 2 mL/kg/h RL
Wuethrich 2014 Switzerland 166 (83 | 83) Urologic / 
Abdominal 
Elective
Intraoperative No Estimated 
glomerular 
filtration rate 
<60 ml/min
sCr >50% upper 
limit of normal 
value within 90 
days
Induction: 6 ml/kg/h RL
6 ml/kg/h RL until end of surgery
1 ml/kg/h RL until bladder removal
3 ml/kg/h RL after bladder removal
ARF: acute renal failure; sCr: serum creatinine; UO: urine output; NS: normal saline; RL: Ringer’s Lactate; RA: Ringer’s Acetate; 
HM: Hartmann’s solution; HAES: Hydroxyethyl starch.
Study year Country number
Total (Restrictive 
| Conventional)
Type of 
patient
timing target 
oliguria 
reversal
renal 
exclusion
ARF definition Conventional protocol Restrictive protocol
Table 6.1 Characteristics of included studies (continued)
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Futier 2010 France 70 (36 | 34) Abdominal 
Elective
intraoperative No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
Within 2 
postoperative 
days: UO < 
500ml/d 
sCr > 30% from 
preoperative
Renal 
replacement 
therapy
12 mL/kg/h RL 6 mL/kg/h RL
Lobo 2011 Brazil 88 (45 | 43) High Risk intraoperative Yes sCr > 176 
µmol/l
sCr > 2x baseline 
value during 
discharge or 60 
days
12 ml/kg/hour RL 4 ml/kg/hour RL
Abraham-
Nordling
2012 Sweden 161 (79 | 82) Abdominal 
Elective
intraoperative, 
postoperative
No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
Not clearly 
defined in the 
study
before surgery:
 500–1000 ml RA 
during surgery
5 ml/kg/h RA
induction of anesthesia:
2 ml/kg/h buffered glucose 2.5% 
early postoperative period:
 1000 ml RA 
from early after operation until morning after 
surgery :
1 ml/kg/h glucose 10%
induction of anesthesia:
2 ml/kg/h buffered glucose 2.5% 
from early after operation until morning after 
surgery :
1 ml/kg/h glucose 10%
Matot 2012 Israel 107 (52 | 55) Abdominal 
Elective
intraoperative No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
sCr > 97 (female) 
or > 115 (male) 
µmol/l within 3 
postoperative 
days
10 mL/kg/h RL 4 mL/kg/h RL
Kalyan 2013 UK 239 (121 | 118) Abdominal 
Elective
Intraoperative,
postoperative
Yes sCr > 140  
µmol/l
Renal 
replacement 
therapy
Preloading 
500 mL HM
Third space loss
7 mL/kg/h HM  first hour;
5 mL/kg/h HM following hours.
Maintenance:
1.5 ml/kg/h
Preloading
No preloading. 
Third space loss 
No replacement 
Maintenance:
1.5 ml/kg/h during anesthesia
1 ml/kg/h 5% glucose until enteral intake
Matot 2013 Israel 102 (51 | 51) Thoracic 
Elective
intraoperative No sCr > 97 
(female) or 
> 115 (male) 
µmol/l
sCr > 97 (female) 
or > 115 (male) 
µmol/l within 3 
postoperative 
days
8 mL/kg/h RL 2 mL/kg/h RL
Wuethrich 2014 Switzerland 166 (83 | 83) Urologic / 
Abdominal 
Elective
Intraoperative No Estimated 
glomerular 
filtration rate 
<60 ml/min
sCr >50% upper 
limit of normal 
value within 90 
days
Induction: 6 ml/kg/h RL
6 ml/kg/h RL until end of surgery
1 ml/kg/h RL until bladder removal
3 ml/kg/h RL after bladder removal
ARF: acute renal failure; sCr: serum creatinine; UO: urine output; NS: normal saline; RL: Ringer’s Lactate; RA: Ringer’s Acetate; 
HM: Hartmann’s solution; HAES: Hydroxyethyl starch.
Study year Country number
Total (Restrictive 
| Conventional)
Type of 
patient
timing target 
oliguria 
reversal
renal 
exclusion
ARF definition Conventional protocol Restrictive protocol
Chapter 6 Restrictive fluid management, oliguria and acute renal failure
136
Acute renal failure
The frequency of ARF in restrictive and conventional fluid management was 2.5% and 2.5%, 
respectively. In two studies targeting oliguria reversal (25,29) and five studies not targeting 
oliguria reversal (31,33,35,37,38), serum creatinine did not significantly increase from baseline 
during the following postoperative days. The overall analysis did not provide enough evidence 
to conclude that restrictive fluid management increased ARF occurrence (Figure 6.3). Though 
the heterogeneity in this analysis was low, six studies reported no occurrence of ARF in either 
restrictive or conventional fluid management. The funnel plot suggested possible publication 
bias (Figure 6.4). The trim and fill analysis suggested three missing studies, which are included 
in the funnel plot and forest plot in Figure 6.4 and Figure 6.5, respectively. The overall OR was 
Table 6.2 Risk of bias assessment in selected studies
Study year Randomization blinding Withdrawal Jadad 
Score
Concealment of allocation
Brandstrup 2003 2 1 1 4 Complications assessed 
both blinded and unblinded
Nisanevich 2005 2 2 1 5 Study personnel was 
blinded to allocation
MacKay 2006 2 1 1 4 Allocation concealed for 
consultant surgeon
Holte 2007 2 2 1 5 Concealment until end of 
study
Gonzalez-
Fajardo
2009 2 1 1 4 Study personnel were 
blinded to allocation
McArdle 2009 2 0 1 3 Only 1 investigator was 
blinded to allocation
Muller 2009 2 0 0 2 No concealment of 
allocation
Vermeulen 2009 2 2 1 5 Disclosure at the end of the 
operation
Futier 2010 2 1 1 4 Study personnel was 
blinded to allocation
Lobo 2011 2 0 1 3 Only 1 investigator was 
blinded to allocation
Abraham-
Nordling
2012 2 1 1 4 Only 2 investigator were not 
blinded to allocation
Matot 2012 2 2 0 4 Clinicians and investigators 
were blinded to allocation
Kalyan 2013 2 1 1 4 Surgeon: until end of 
operation.
Matot 2013 2 2 1 5 Clinicians and investigators 
were blinded to allocation
Wuethrich 2014 2 2 1 5 Clinicians and investigators 
were blinded to allocation
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1.07 (95% CI 0.60 to 1.92; P=0.84; I2=17.5%; Nstudies=18), which does not significantly differ from 
the analysis in Figure 6.2 (P=1.00).
The sensitivity analysis to investigate whether different ARF definitions influenced the 
results is reported in Figure 6.6. The estimated OR for need for renal replacement therapy 
was 0.89 (95% CI 0.22 to 3.61; P=0.82; I2=24.7%; Nstudies=5) and for serum creatinine 0.75 (95% 
CI 0.19 to 2.96; P=0.62; I2=22.4%; Nstudies=6) when comparing restrictive with conventional 
fluid management.
In studies with oliguria reversal as a target, the estimated OR for ARF occurrence was 
0.58 favoring restrictive fluid management, and in studies not targeting oliguria reversal 
Figure 6.2 Forest plot of studies reporting occurrence of study-defined oliguria when comparing 
restrictive with conventional fluid management.
IV: inverse variance; CI: confidence interval
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Figure 6.3 Forest plot of studies reporting occurrence of acute renal failure when comparing restrictive 
with conventional fluid management.
IV: inverse variance; CI: confidence interval.
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Figure 6.4: Funnel plot of studies reporting occurrence of acute renal failure when comparing restrictive 
with conventional fluid management, and a funnel plot which includes possible missing studies identified 
by the trim-and-fill analysis.
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Figure 6.5: Forest plot of studies reporting occurrence of acute renal failure when comparing restrictive 
with conventional fluid management which includes possible missing studies identified by the trim-and-
fill analysis.
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the estimated OR for ARF occurrence was 1.8 favoring conventional fluid management; 
however neither was significantly different from 1.00 (Figure 6.3). There was also insufficient 
evidence to suggest that targeting oliguria reversal decreased the occurrence of ARF (OR 
0.31; 95% CI 0.08 to 1.22; P=0.088). 
Fluid management
The fluid management protocols for each study are presented in Table 6.1. Two studies 
(25,28) reported that respectively 15% and 22% of the patients in the restrictive fluid 
management protocol had received more fluids than intended, and one study (34) reported 
that the actual volume administered during surgery was higher than intended in either 
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Figure 6.6: Forest plot of studies reporting occurrence of acute renal failure when comparing restrictive 
with conventional fluid management based on acute renal failure definition.
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protocol. One study (26) reported that restrictive fluid management was associated with 
more additional fluid boluses, and one study (29) reported no difference in additional fluid 
boluses between protocols. 
The mean difference in intraoperative fluid intake could be extracted and calculated for 
twelve studies (Figure 6.7). Less fluid was infused during the intraoperative period in those 
receiving restrictive fluid management than in those with conventional fluid management 
Figure 6.7 Forest plot of the mean difference in infused fluids in liters between restrictive and 
conventional fluid management during the intraoperative and postoperative period.
*: mean and standard deviation derived from median and interquartile range; **: mean and standard deviation 
derived from median and range. SD: standard deviation; IV: inverse variance; CI: confidence interval.
6Restrictive fluid management, oliguria and acute renal failure
143
irrespective of targeting oliguria. There was insufficient evidence to suggest that targeting 
oliguria reversal was associated with a smaller difference in fluid intake between restrictive 
and conventional fluid management (OR 1.32; 95% CI 0.47 to 3.77; P=0.56).
The mean difference in postoperative fluid intake could be extracted and calculated 
for seven studies (Figure 6.7). The studies without oliguria reversal as a target continued 
the use of the restrictive fluid management protocol into the postoperative period, while 
the studies with oliguria reversal as a target had the same postoperative fluid regime for 
both restrictive and conventional arms (Table 6.1). Postoperative fluid intake was lower in 
restrictive fluid management than in conventional fluid management in studies without 
oliguria reversal as a target and in studies with oliguria reversal as a target; however the 
differences were not statistically significant suggesting that factors other than postoperative 
fluid restriction affect fluid intake.
Nine studies (25-27,30-33,36,39) reported on postoperative fluid balance either in terms 
of volume or weight increase (Figure 6.7). Postoperative fluid balance was lower in those 
receiving restrictive fluid management than in those with conventional fluid management 
irrespective of targeting oliguria. There was insufficient evidence to suggest that targeting 
oliguria reversal was associated with a smaller difference in postoperative fluid balance 
between restrictive and conventional fluid management (OR 1.07; 95% CI 0.33 to 3.55; 
P=0.88). The heterogeneity in the fluid intake and fluid balance analyses were high.
Indirect comparison
Because there were no studies investigating targeting oliguria reversal with not targeting 
oliguria reversal, we performed an indirect comparison to analyze the effects of including 
targeting oliguria reversal or excluding targeting oliguria reversal on the occurrence of ARF 
(Table 6.3). Targeting oliguria reversal in a restrictive protocol does not appear to affect 
the occurrence of ARF, whereas targeting oliguria reversal in a conventional protocol may 
possibly even increase the occurrence of ARF.
Table 6.3 Indirect comparison of the effect of targeting oliguria reversal in restrictive and conventional 
fluid management.
Targeting oliguria reversal
yes no
Protocol ARF (%) total ARF (%) total OR (95% CI) P value
Restrictive 8 (2.0) 391 12 (2.97) 404 0.68 [0.24, 1.84] 0.50
Conventional 16 (4.1) 394 4 (0.98) 405 4.24 [1.35, 17.65] 0.006
For each analysis, the pooled data from all relevant studies targeting oliguria reversal was compared to the 
pooled data from studies not targeting oliguria reversal – separating data from restrictive fluid management 
protocols from conventional fluid management protocols. Odds ratio and 95% confidence intervals were then 
calculated and the P-value was calculated using the Fisher’s exact test to test whether there was a difference in 
acute renal failure occurrence between targeting and not targeting oliguria reversal in each protocol. 
ARF: acute renal failure; OR: odds ratio; CI: confidence interval.
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discUssion
In this meta-analysis, we found insufficient evidence to associate restrictive fluid management 
with an increase in oliguria and ARF occurrence. The difference in intraoperative fluid intake 
between conventional and restrictive fluid management was similar whether oliguria 
reversal was targeted or not. In line with our initial hypothesis, excluding targeting oliguria 
reversal in a restrictive fluid management protocol does not seem to be associated with an 
increase in ARF occurrence when compared with including oliguria reversal as a target.
Similar to the findings from the meta-analysis of major abdominal surgery by Boland 
et al. (12), we were unable to demonstrate an association between restrictive fluid 
management and an increase in the occurrence of postoperative ARF. Additionally, the 
FACCT trial in patients with acute lung injury was unable to demonstrate a difference in 
renal failure-free days between a restrictive and conventional fluid management strategy, 
though the restrictive fluid management strategy utilized diuretics when oliguria occurred 
(40). Even when looking at more specific ARF definitions, we found insufficient evidence 
that restrictive fluid management was associated with an increase in the need for renal 
replacement therapy or with a postoperative increase in serum creatinine concentrations. 
The latter, however, could be explained by a positive postoperative fluid balance diluting 
any increase to near preoperative levels.
We were unable to demonstrate an increase in the occurrence rate of oliguria due to 
the restrictive fluid management protocols, and targeting oliguria reversal did not seem 
to influence fluid intake. It is likely that patients given restrictive fluid management were 
already normovolemic during surgery since most postoperative fluid balances were near 
zero. This suggests that oliguria is the result of a physiological stress response during surgery 
to maintain an adequate intravascular volume through activity of several neurohormonal 
systems such as the renin-angiotensin-aldosterone axis and antidiuretic hormone (16,41). 
Hence, oliguria does not necessarily reflect absolute hypovolemia and additional fluid 
administration could increase urine output, but likely without any true benefit in terms of 
renal function.
Our findings suggest that excluding targeting oliguria reversal does not seem to increase 
ARF occurrence when using a restrictive fluid management protocol. However, since the 
postoperative fluid intake did not noticeably differ between restrictive and conventional 
fluid management in both studies targeting and not targeting oliguria reversal, we cannot 
exclude that the postoperative fluid protocols could have had an effect on the occurrence 
of ARF. It may be that protocols which restrict postoperative fluid intake do not compensate 
for patients being unable to manage their own fluid balance. Without an adequate 
postoperative fluid protocol to compensate for this fluid deficit, this may eventually lead 
to an increase in ARF occurrence by prolonged and recurrent episodes of hypovolemia. 
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Moreover, intravascular volume could change during the postoperative period, while the 
physiological stress response from surgery may continue and influence the activity of 
neurohormonal systems. It is therefore possible that to maintain an adequate intravascular 
volume during the postoperative period requires more fluids due to vasodilation-mediated 
volume redistribution. 
Lastly, it is important to note that in the indirect comparison groups are treated as a 
cohort based on the cumulative ARF occurrence in each fluid management protocol with 
or without targeting oliguria reversal therefore lacking the benefit of randomization. This 
indirect comparison is the best available surrogate effect estimate, since there were no 
trials available which either directly compared targeting with not targeting oliguria reversal, 
or compared restrictive fluid management without against conventional fluid management 
with targeting oliguria reversal. As a result, we recommend future studies to prospectively 
investigate the effects of targeting oliguria reversal on the occurrence of ARF.
Limitations
This meta-analysis has several limitations. The low event rates in the selected studies can 
be a cause for bias and are most likely caused by excluding patients with preoperative 
chronic kidney disease, and by the inconsistent ARF definition among the included studies 
as reported in Table 6.1. The funnel plot for ARF occurrence suggested possible publication 
bias. This may be due to the lack of published studies with ARF as an investigated outcome 
leading to selection bias or perhaps due to language bias from excluding trials not published 
in English. Since most of the studies only included patients with normal preoperative serum 
creatinine and undergoing elective surgery, the a priori risk of ARF in these patients was 
lower than for patients with chronic kidney disease or undergoing emergency surgery 
(42,43). Nevertheless, the incidence of postoperative ARF in this meta-analysis is well within 
the margins reported in current literature (15,43,44). However, it must be noted that the 
incidence of ARF may be an underestimation. The latest diagnostic criteria for acute kidney 
injury – the consensus definition which incorporates the whole spectrum of renal dysfunction 
(18) - incorporated small increases in serum creatinine (45). These small increases have been 
associated with an increased mortality rate (46,47), however it remains unknown whether 
these small changes are merely a marker of underlying pathology which are the cause of the 
mortality increase or whether these changes in serum creatinine represent fluctuations in 
kidney function with clinical importance (45).
Second, the fluid administration protocols greatly differed between the included studies. 
As described by the I2 in Figure 6.7, the heterogeneity in the fluid intake comparisons was 
very high. In addition, the adherence to the protocols during the study might have been 
poor. While only three studies actively reported deviations from protocol, it can be assumed 
that other studies had similar issues, which bias our findings. Nevertheless, restrictive fluid 
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management reduced intraoperative fluid intake irrespective of the use of oliguria reversal 
as a target. 
It is also important to note that unlike earlier meta-analyses (9,10) we did not redefine 
restrictive and conventional fluid management, but rather used the study definitions. 
This may introduce some bias since some restrictive fluid management protocols were 
considered to be either too restrictive or not restrictive enough. However, most of the 
restrictive fluid management protocols infused roughly 2 liters during surgery, which in 
the meta-analysis by Varadhan et al (10) was defined as a state of fluid balance for the 
average patient without ongoing fluid deficits or losses. Additionally, most of the studies 
reporting postoperative fluid management had a neutral fluid balance with restrictive fluid 
management, suggesting that in these studies restrictive fluid management was closer to 
an optimal fluid strategy than the conventional fluid management.
conclUsion
In conclusion, even though event numbers are small, we found insufficient evidence to 
associate restrictive fluid management with an increased occurrence of oliguria and risk 
for ARF. Intraoperative fluid intake and postoperative fluid balances remained lower with 
restrictive fluid management. Similarly, adding targeting oliguria reversal in both protocols 
did not influence ARF occurrence, fluid intake or fluid balance. There was insufficient 
evidence to suggest that restrictive fluid management in combination with oliguria reversal 
as a target influences ARF occurrence in either direction. However, this may be due to 
postoperative rather than intraoperative fluid management when oliguria occurs. Future 
studies are needed to confirm the effects of targeting oliguria reversal, though restrictive 
fluid management seems to be a safe and viable perioperative fluid strategy for the kidney, 
considering the currently available evidence.
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sUpplement
Table S6.1: Search strategy for MEDLINE database via PubMed
#1 restrictive
#2 conservative
#3 limited
#4 (#1 OR #2 OR #3)
#5 conventional
#6 liberal
#7 (#5 OR #6)
#8 “Fluid Therapy/methods”[Mesh]
#9 “Fluid Therapy”[Mesh]
#10 “fluid therapy”
#11 “fluid management”
#12 “fluid resuscitation”
#13 “maintenance fluid”
#14 (#8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 outcome
#16 “acute renal failure”
#17 “acute kidney injury”
#18 “oliguria”
#19 “urine output”
#20 “urinary output”
#21 “diuresis”
#22 “creatinine”
#23 (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)
#24 (#14 AND (#4 OR #7))
#25 randomized
#26 controlled
#27 trial
#28 “Randomized Controlled Trial” [Publication Type]
#29 #28 OR (#27 AND (#25 OR #26))
#30 (#23 AND #24 AND #29) 141
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Table S6.2: Search strategy for EMBASE database 
#1 restrictive
#2 conservative
#3 limited
#4 #1 OR #2 OR #3
#5 conventional
#6 liberal
#7 #5 OR #6
#8 ‘fluid therapy’
#9 ‘fluid therapy’/exp
#10 ‘fluid management’
#11 ‘fluid resuscitation’
#12 ‘maintenance fluid’
#13 #8 OR #9 OR #10 OR #11 OR #12
#14 outcome
#15 ‘acute renal failure’
#16 ‘acute kidney injury’
#17 ‘oliguria’
#18 ‘urine output’
#19 ‘urinary output’
#20 ‘diuresis’
#21 ‘creatinine’
#22 #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #13 AND (#4 OR #7)
#24 randomized 
#25 controlled
#26 trial
#27 #26 AND (#24 OR #25)
#28 #22 AND #23 AND #27 334
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abstract
backgroUnd Oliguria occurs frequently in critically ill patients, challenging clinicians to 
distinguish functional adaptation from serum-creatinine-defined acute kidney injury (AKIsCr). 
We investigated neutrophil gelatinase-associated lipocalin (NGAL)’s ability to differentiate 
between these two conditions.
methods This is a post-hoc analysis of a prospective cohort of adult critically ill patients. 
Patients without oliguria within the first six hours of admission were excluded. Plasma 
and urinary NGAL were measured at four hours after admission. AKIsCr was defined using 
the AKIN criteria with pre-admission serum creatinine or lowest serum creatinine value 
during the admission as the baseline value. Hazard ratios (HR) for AKIsCr occurrence within 
72 hours were calculated using Cox regression and adjusted for risk factors such as sepsis, 
pre-admission serum creatinine, and urinary output. Positive (PPV) and negative predictive 
values (NPV) were calculated for the optimal cutoffs for NGAL.
resUlts Oliguria occurred in 176 patients, and 61 (35%) patients developed AKIsCr. NGAL 
was a predictor for AKIsCr in univariate and multivariate analysis. When NGAL was added to 
a multivariate model including sepsis, pre-admission serum creatinine and lowest hourly 
urine output, it outperformed the latter model (plasma P=0.001; urinary P=0.048). Cutoff 
values for AKIsCr were 280 ng/mL for plasma (PPV 80%; NPV 79%), and 250 ng/mL for urinary 
NGAL (PPV 58%; NPV 78%). 
conclUsions NGAL can be used to distinguish oliguria due to functional adaptation from 
AKIsCr, directing resources to patients more likely to develop AKIsCr. 
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introdUction
Oliguria is defined as a drop in urine output to less than 0.5 mL/kg/h and frequently 
occurs in critically ill patients. Oliguria - in the absence of a serum creatinine increase – in 
a patient without invasive monitoring of cardiac output and fluid status is a challenge for 
the intensivist’s decision to either continue fluid resuscitation in order to treat presumed 
hypovolemia and thereby prevent the onset of acute kidney injury (AKI) (1) or to limit fluid 
intake to avoid the adverse effects of fluid overload. Indeed, a decrease in urine output can 
be due to hypovolemia, transiently inadequate perfusion, or renal cell injury (2). Accordingly, 
oliguria by itself is at best a moderate predictor for acute kidney injury defined as a serum 
creatinine increase (AKIsCr) (3,4). 
Traditionally, urinary markers such as the fractional excretion of sodium or urea are used 
to differentiate between prerenal or renal causes of AKI. However, its utility in critically ill 
patients has been challenged due to confounders such as fluid resuscitation, diuretics and 
vasoactive drugs, and by a poor correlation with severity of AKI (5). Recently, the advent 
of renal biomarkers has seen many studies investigating their use as early predictors for 
AKI (6). Neutrophil gelatinase-associated lipocalin (NGAL), one of those biomarkers, is 
produced in the distal nephron and its concentration increases when tubular cellular injury 
is present (7-9). The increase in NGAL levels in case of cellular damage – i.e. acute tubular 
injury – precedes a rise in serum creatinine (9-11). 
To address whether NGAL is able to identify those critically ill patients with early oliguria 
that will develop AKIsCr, we performed a post-hoc analysis in a previously described cohort 
(12). Our hypothesis was that low NGAL concentrations in oliguric critically patients are most 
likely due to hemodynamic or hormonal compensation mechanisms whereas a high NGAL 
concentration heralds AKIsCr. Our objective was to investigate whether NGAL, measured 
after the occurrence of oliguria, can identify AKIsCr within the first 72 hours in patients with 
oliguria occurring within six hours of intensive care unit (ICU) admission.
patients and methods
Patient selection
We performed a post-hoc analysis on a prospectively gathered biomarker dataset from a 
previously published cohort (12,13). The institutional review board of Erasmus MC, University 
Medical Center Rotterdam, The Netherlands, approved the initial study. All consecutive 
admitted patients between September 2007 and April 2008 were eligible for enrollment. 
The original exclusion criteria were age under 18 years, refusal of consent, nephrectomy, 
chronic kidney disease (glomerular filtration rate using pre-admission serum creatinine < 
60 mL/min/1.73m2), end-stage renal disease, and renal transplantation. Deferred consent 
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was used, and written informed consent was obtained from all participants or their health 
care proxy (14). From this dataset, we excluded readmissions and all patients who did not 
develop oliguria within the first six hours of the ICU admission (Figure 7.1). All patients 
without a recorded weight or without sufficient urine output data within six hours of ICU 
admission – i.e. only one recorded measurement during the six-hour period - were excluded.
Data collection and definitions
Data was retrospectively collected from our electronic patient data monitoring system (Picis 
Clinical Solutions, Massachusetts, USA). Urine output was prospectively recorded by the 
attending nurses in irregular intervals, depending on the urine output, ranging from one 
hour up to three hours. We assumed a constant rate of urine flow within each interval, 
and calculated the hourly urine output by averaging the volume over each hour in that 
interval. Oliguria was defined as urine output less than 0.5 mL/kg/h. Mean urine output 
and lowest hourly urine output were calculated from the urine output available in the first 
six hours. Furosemide and bumetanide were pooled together when looking at diuretics 
use. Serum creatinine was measured at admission and at least once daily at 6:00 AM. Pre-
admission serum creatinine was defined as the steady state level 4 weeks before admission 
(12). Patients who required renal replacement therapy were identified, which in our clinical 
setting is initiated for metabolic disorders due to AKI or diuretic-resistant fluid overload. 
We collected the following variables from the clinical chart: gender; age; Acute 
Physiology and Chronic Health Evaluation (APACHE) and the Sequential Organ Failure 
Assessment (SOFA) score at day of admission; presence of the systemic inflammatory 
response syndrome (SIRS) criteria was scored during the first six hours of ICU admission; the 
presence of sepsis at admission defined according to American College of Chest Physicians/
Society of Critical Care Medicine consensus criteria (1) and the presumed or confirmed 
source. The primary admission diagnosis was collected for each patient and categorized 
to either respiratory failure, gastrointestinal hemorrhage, liver failure, esophagectomy, 
vascular surgery, gastrointestinal surgery, liver transplant, multi-trauma, subarachnoid 
hemorrhage, neuro-trauma and neurosurgery. Admission diagnoses were then pooled 
according to medical, surgical or neurological etiologies.
Plasma and urinary NGAL samples were collected and measured in the original study 
at admission and at 7 time points thereafter (4, 8, 24, 36, 48, 60 and 72 hours) using the 
Triage® point-of-care immunoassay (Biosite Inc., San Diego, USA), which measures the 
NGAL monomer (12). AKIsCr was defined according to the acute kidney injury network 
(AKIN) serum creatinine criteria using the pre-admission serum creatinine as the baseline 
value (15). If pre-admission serum creatinine was not available, the lowest value during 
the admission was used as a surrogate (16). Patients who did not develop AKIsCr in the 
first 72 hours of ICU admission were allocated to the noAKIsCr group, and those who did 
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were allocated to the AKIsCr group. If in AKIsCr the lowest serum creatinine value during the 
admission was measured after the highest serum creatinine value within the first 72 hours, 
it was categorized as transient AKIsCr (16).
Statistical analysis
Since most data were not normally distributed (Kolmogorov-Smirnov test P<0.05), data was 
reported as median with interquartile range (IQR). Missing plasma and urinary NGAL data 
were imputed using multiple imputations with the MICE package, using predictive mean 
matching of NGAL at admission, 4 hours and 8 hours after admission with 25 imputations 
across 50 iterations (17). Categorical variables were summarized by numbers and 
percentages. Differences between the two groups were compared using the Mann-Whitney 
U test for continuous variables, and the Fisher’s exact test for categorical variables. 
NGAL measured 4 hours after admission was used for all analyses due to being the 
closest measured value after most occurrences of oliguria. Cox’s proportional hazard 
regression analysis was used to estimate the effect of NGAL, pre-admission serum 
creatinine, sepsis, mean urine output, lowest hourly urine output and duration of oliguria 
as predictors for AKIsCr. These variables were also inputted in a multivariate model, one for 
plasma NGAL and one for urinary NGAL and variables were subsequently eliminated using 
a stepwise backward selection method. A multivariate model without NGAL was created 
using a stepwise backward selection method to investigate the additive value of NGAL to 
the multivariate model. The continuous net reclassification improvement (NRI) and the 
integrated discrimination improvement (IDI) were calculated to quantify the improvement 
in AUROC after adding NGAL. The NRI statistic describes the proportion of patients based 
on the new model assigned a probability for AKIsCr closer to 1 for those with AKIsCr and closer 
to 0 for patients without AKIsCr. The IDI statistic describes the mean change in probabilities 
(increases for events and decreases in non-events) between the new and old model.
To assess whether NGAL - either univariate or in a multivariate model – leads to an 
improvement in AKIsCr prediction, we first compared the area under the receiver operating 
characteristics curves (AUROC) for the NGAL models against the AUROC of the multivariate 
model without NGAL at 24, 48 and 72 hours after admission. Optimal cutoff values at 24, 48 
and 72 hours after admission were estimated for univariate plasma and urinary NGAL and 
admission serum creatinine using Youden’s J-statistic (18). 
All analyses were performed using R statistical software package (R Foundation for 
Statistical Computing; Vienna, Austria) (19) and the time-dependent AUROCs for the Cox’s 
regression models were calculated and compared with the timeROC package (20). A P value 
< 0.05 was defined as significant, and exact P values were given unless P<0.001.
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resUlts
Of the 632 patients included in the original study and after excluding readmissions and records 
with insufficient urinary data from the original cohort (12), 439 patients remained with an 
AKIsCr incidence of 25% (Figure 7.1). After excluding patients without oliguria within the first 
six hours of ICU admission, 176 patients remained. In ten patients (5.7%) pre-admission 
serum creatinine was not available. The general characteristics are reported in Table 7.1. 
Sixty-one patients (35%) developed AKIsCr during the first 72 hours of ICU admission. AKIsCr 
occurred relatively early in the ICU admission (87% within 24 hours), and 16 patients had 
transient AKIsCr (Table 7.2). Plasma NGAL data was missing for 15 patients (AKIsCr 6, noAKIsCr 
9) and urinary NGAL data were missing 21 patients (AKIsCr 7, noAKIsCr 14), for which imputed 
data was used. Admission serum creatinine was higher in the AKIsCr group compared to the 
noAKIsCr group (P<0.001). Mean urine output and lowest hourly urine output during the first 
six hours were lower in AKIsCr than in noAKIsCr. Plasma and urinary NGAL were higher in AKIsCr 
compared to those in the noAKIsCr group (plasma NGAL: P< 0.001; urinary NGAL: P<0.001).
Figure 7.1 Inclusion flow chart
This figure shows the number of patients included in the original article (12), and the exclusion criteria and 
number of patients excluded from this post-hoc analysis. AKIsCr: serum creatinine defined acute kidney injury.
Original dataset
n = 632
Included into analysis
n = 176
AKIsCr
n = 61
no AKIsCr
n = 115
Readmission
n = 36
Insufficient urinary data
n = 155
No oliguria within 6 hours
n=263
Urinary data available
n = 439
AKIsCr
n = 109
no AKIsCr
n = 330
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Table 7.1 General characteristics
akiscr no akiscr p
n 61 115
Male 37 (61) 75 (65) 0.622
Age (year) 62 (47 - 72) 61 (49 - 71) 0.889
APACHE II score 22 (17 - 28) 16 (13 - 20) <0.001
SOFA score on day of admission 8 (6 - 12) 4 (1.5 - 6) <0.001
Pre-admission serum creatinine (µmol/L) 75 (60 - 90) 70 (60 - 80) 0.139
Admission serum creatinine (µmol/L) 115 (84 - 148) 68 (55.5 - 82) <0.001
Lowest serum creatinine during admission (µmol/L) 73 (53 - 108) 56 (46 - 68) <0.001
Admission type
Medical 39 (64) 36 (31) <0.001
Surgical 19 (31) 61 (53) 0.007
Neurological 3 (5) 18 (16) 0.049
admission diagnosis
Respiratory failure 14 (23) 10 (9) 0.011
Gastrointestinal hemorrhage 4 (7) 5 (4) 0.500
Liver failure 2 (3) 0 (0) 0.119
Esophagectomy 3 (5) 19 (17) 0.031
Vascular surgery 6 (10) 10 (9) 0.789
Gastrointestinal surgery 7 (11) 13 (11) 1.000
Liver transplant 2 (3) 1 (1) 0.276
Multitrauma 4 (7) 5 (4) 0.500
Subarachnoid hemorrhage 0 (0) 7 (6) 0.097
Neurotrauma 1 (2) 7 (6) 0.265
Neurosurgery (elective and emergency) 3 (5) 17 (15) 0.078
SIRS ≥ 2 criteria 52 (85) 81 (70) 0.042
Sepsis 23 (38) 12 (10) <0.001
Pulmonary 10 (16) 6 (5) 0.025
Abdominal 11 (18) 6 (5) 0.013
Urogenital 1 (2) 0 (0) 0.347
Soft tissue 4 (7) 1 (1) 0.050
Central nervous system 0 (0) 2 (2) 0.544
Length of stay (hours) 205 (85 - 416) 64 (25 - 158) <0.001
28 day mortality 17 (28) 12 (10) 0.005
Data is presented as median (interquartile range) or number (percentage) where appropriate.
AKIsCr: acute kidney injury by serum creatinine definition; SIRS: Systemic inflammatory response syndrome; more 
than one location could be recorded as the diagnostic site of (suspected) sepsis. 
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Table 7.2 Renal data
Variable akiscr no akiscr p
n 61 115
Urine output during first 6 hours
Time from admission to oliguria (hours) 2 (1 - 3) 1 (1 - 2) 0.080
Cumulative oliguria duration (hours) 4 (3 - 5) 3 (2 - 4) 0.003
Mean urine output (mL/kg/h) 0.48 (0.24 - 0.71) 0.66 (0.47 - 0.88) 0.001
Lowest hourly urine output (mL/kg) 0.25 (0.1 - 0.35) 0.33 (0.24 - 0.4) 0.002
Diuretics used during first 6 hours 0 (0) 3 (3) 0.552
AKI by serum creatinine criteria
Time from admission to AKIsCr (hours) 1 (0 - 14)
Transient AKIsCr 16 (26)
AKIsCr within 24 hours 53 (87)
Highest AKIsCr stage reached within 24 hours 43 (70)
Highest AKIsCr stage within 72 hours
AKIsCr stage 1 31 (51)
AKIsCr stage 2 20 (33)
AKIsCr stage 3 10 (16)
Renal replacement therapy
Need for renal replacement therapy 12 (20) 0 (0) <0.001
NGAL 4 hours after admission
Plasma NGAL (ng/mL) 349 (192 - 566) 150 (86 - 216) <0.001
Urine NGAL (ng/mL) 754 (186 - 4124) 99 (52 - 228) <0.001
Data is presented as median (interquartile range) or number (percentage) where appropriate.
Oliguria is defined as hourly urine output < 0.5 ml/kg. AKIsCr: acute kidney injury by serum creatinine criteria; 
NGAL: neutrophil gelatinase-associated lipocalin.
Multivariate models
In order to assess how the predictive ability of NGAL was related to other risk factors for AKIsCr, 
we performed univariate and multivariate Cox proportional hazards regression analyses. 
The univariate Cox analyses are reported in Table 7.3. In the multivariate model without 
NGAL – using stepwise backward elimination – pre-admission serum creatinine, sepsis and 
lowest hourly urine output were significant predictors for AKIsCr (Table 7.4). The addition of 
NGAL to the multivariate model – and subsequent stepwise backward elimination – resulted 
in pre-admission serum creatinine becoming a nonsignificant predictor of AKIsCr, and NGAL, 
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sepsis and lowest hourly urine output remained significant predictors. The AUROCs for the 
univariate NGAL and the multivariate models are shown in Table 7.5. NGAL as a univariate 
predictor was not inferior to the multivariate model without NGAL at all time points, whereas 
the addition of NGAL to the multivariate model slightly increased the AUROC of predicting 
AKIsCr at 24 and 72 hours after admission. Specifically, the improvement in AUROC by adding 
NGAL to the multivariate models seems mainly to be due to better classification of patients 
without AKIsCr within the first 24 hours (Table 7.6). While a similar effect is present in the 
multivariate urinary NGAL model for patients without AKIsCr within the first 72 hours, the 
multivariate plasma NGAL does not improve the classification of patients with and without 
AKIsCr within the first 72 hours.
Table 7.3 Univariate Cox regression analysis for AKIsCr  as the outcome
Univariate
Variable hr 95% CI p
Plasma NGAL (x 100 ng/mL) 1.278 1.196 - 1.365 <0.001
Urinary NGAL (x 100 ng/mL) 1.049 1.034 - 1.065 <0.001
Pre-admission serum creatinine (µmol/L) 1.010 0.998 - 1.022 0.103
Sepsis 3.259 1.938 - 5.482 <0.001
Mean urine output (mL/kg/h) 0.385 0.174 - 0.850 0.018
Lowest hourly urine output (mL/kg) 0.015 0.002 - 0.118 <0.001
Duration of oliguria (hours) 1.300 1.110 - 1.522 0.001
Admission serum creatinine (µmol/L)a 1.015 1.012 - 1.018 <0.001
a: Variable not included in the full multivariate model due to prediction bias. HR: hazard ratio; CI: confidence 
interval.  
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Table 7.6 Net reclassification index and integrated discrimination improvement
Multivariate model vs. Multivariate plasma NGAL Multivariate urinary NGAL
Outcome Estimate 95% CI p Estimate 95% CI p
akiscr within 24 hours
NRIevent 0.057 -0.212 - 0.325 0.680 -0.132 -0.399 - 0.135 0.332
NRInonevent 0.285 0.115 - 0.454 <0.001 0.789 0.680 - 0.897 <0.001
NRI 0.341 0.023 - 0.659 0.035 0.657 0.368 - 0.945 <0.001
IDI 0.051 0.011 - 0.090 0.012 0.075 0.029 - 0.121 0.001
akiscr within 72 hours
NRIevent 0.082 -0.168 - 0.332 0.521 -0.180 -0.427 - 0.067 0.152
NRInonevent 0.165 -0.015 - 0.345 0.072 0.722 0.595 - 0.848 <0.001
NRI 0.247 -0.061 - 0.555 0.116 0.541 0.264 - 0.818 <0.001
IDI 0.047 0.012 - 0.081 0.008 0.067 0.026 - 0.109 0.001
The NRI statistic describes the proportion of patients based on the new model assigned a probability for AKIsCr 
closer to 1 for those with AKIsCr and closer to 0 for patients without AKIsCr. The IDI statistic describes the mean 
change in probabilities (increases for events and decreases in non-events) between the new and old model. AKIsCr: 
acute kidney injury by serum creatinine criteria; NRI: net reclassification index; IDI: integrated discriminatory 
improvement.
Optimal cutoff and test characteristics
Because plasma and urinary NGAL as a univariate predictor for AKIsCr was not inferior to the 
multivariate model, we calculated the test characteristics of the optimal cutoff values for 
NGAL as predictors of AKIsCr occurrence within 24, 48 and 72 hours of ICU admission. The 
result of this analysis is shown in Table 7.7, and the 2x2 tables for the optimal cutoff values 
for NGAL are reported in Tables 7.8-7.10. The optimal cutoff for plasma NGAL across the 
different time points resulted in positive likelihood ratios ranging from 4.6 to 8.2, whereas 
the optimal cutoff values for urinary NGAL led to positive likelihood ratios ranging from 2.2 
to 2.6. For AKIsCr within 48 and 72 hours, plasma NGAL was able to correctly predict 80% of 
patients with and without AKIsCr based on the optimal cutoff. 
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Table 7.8 2x2 tables for distribution of patients based on the optimal cutoff values for NGAL at 24 hours 
after admission. 
akiscr noakiscr
Plasma NGAL > 340 ng/mL 29 13
Plasma NGAL ≤ 340 ng/mL 24 110
Urinary NGAL > 270 ng/mL 37 30
Urinary NGAL ≤ 270 ng/mL 16 93
Table 7.9 2x2 tables for distribution of patients based on the optimal cutoff values for NGAL at 48 hours 
after admission. 
AKIsCr noAKIsCr
Plasma NGAL > 370 ng/mL 29 8
Plasma NGAL ≤ 370 ng/mL 29 110
Urinary NGAL > 230 ng/mL 43 29
Urinary NGAL ≤ 230 ng/mL 15 89
Table 7.10 2x2 tables for distribution of patients based on the optimal cutoff values for NGAL at 72 hours 
after admission. 
AKIsCr noAKIsCr
Plasma NGAL > 280 ng/mL 36 19
Plasma NGAL ≤ 280 ng/mL 25 96
Urinary NGAL > 250 ng/mL 42 26
Urinary NGAL ≤ 250 ng/mL 19 89
discUssion
The main finding of this post-hoc analysis is that NGAL can be used in a clinical setting to 
discriminate between oliguric critically ill patients with AKIsCr within the first 72 hours from 
oliguric patients with a functional reversible glomerular adaptation. In an oliguric patient with 
known risk factors, the addition of NGAL improves the ability to rule out AKIsCr. Furthermore, 
univariate NGAL is not inferior to a multivariate model of known risk factors, and NGAL can 
be used to identify or exclude AKIsCr in oliguric patients even when pre-admission serum 
creatinine value and other risk factors are unknown. Given these findings, clinicians can use 
NGAL to identify patients with oliguria due to functional adaptation during the early ICU 
admission. In other words, when oliguria occurs, low NGAL values may rule out structural 
cellular damage signifying AKIsCr.
Our results partly agree with previous literature on oliguria and AKI in the critically ill. 
A recent study in critically ill patients with new-onset oliguria strongly suggests that not 
all episodes of oliguria carry the same risk for worsening renal function (21). In contrast to 
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our analysis, only patients with six consecutive hours of oliguria at some point during the 
ICU admission were included and worsening renal outcome was defined as both serum 
creatinine and urine output defined AKI. However, as the occurrence of oliguria takes place 
farther from the initial renal hit, biomarkers with a time course similar to NGAL may become 
less informative (11). In our study, this is illustrated by the decrease in NRI and IDI for plasma 
NGAL when predicting AKIsCr within 72 hours when compared with the prediction of AKIsCr 
within 24 hours after admission. 
This study has several strengths: First, we showed that NGAL measurements in a patient 
group with a high pre-test probability, such as oliguric patients, are of additional value for 
the early diagnosis of AKIsCr and can be done in a clinically practical manner. Limiting NGAL 
measurements to a high pre-test probability population improves the cost-effectiveness 
of biomarkers for AKI (22). Secondly, considering its time course, NGAL only improves the 
differentiation between functional oliguria and oliguria due to renal injury within a relative 
short time after the initial renal injury. Thus, NGAL is best suited for use early during the 
ICU admission or shortly after an event leading to the initial renal injury. Lastly, in oliguric 
patients NGAL can be used to identify those without AKIsCr without having to wait for a 
second serum creatinine measurement or search for a pre-admission serum creatinine 
value. Given the lag time, the measurement frequency of serum creatinine, and the paucity 
of available pre-admission data, NGAL provides early information on renal outcome.
This study has several potential limitations: Firstly, because this study was a post-hoc 
analysis of a prior prospective dataset, future studies are needed to validate our findings. 
Secondly, the lack of an adequate gold standard to diagnose AKIsCr distorts the performance 
of any biomarker (23). Therefore, injury biomarkers have potential in conjunction with 
functional markers such as serum creatinine and urine output. Furthermore, in our clinical 
practice serum creatinine is measured at admission and at least once daily at 6.00 AM 
thereafter. While serum creatinine may take up to 24 hours to increase after a reduction in 
glomerular filtration (24), measuring serum creatinine once daily could delay the recognition 
of AKIsCr. Moreover, since we did not correct the measured serum creatinine concentration 
for the cumulative fluid balance in the first 72 hours of ICU admission (25), it is possible that 
some patients were incorrectly classified as not having AKIsCr. Thirdly, to calculate hourly 
urine output from irregular collection intervals, we assumed that urine flow was constant 
during each interval, which ignores any effects of treatment or disease progression during a 
single period of variable length which could increase or decrease urine output. Additionally, 
collecting enough urine to measure urinary NGAL is difficult in patients with very low urine 
output, which may explain some of the missing values for urinary NGAL. The missing data 
rate for plasma and urinary NGAL measurements was 8.5% and 12% respectively, due 
to interventional procedures or transport at the time of collection. We used multiple 
imputations using predictive mean matching of NGAL at admission, 4 hours and 8 hours 
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after admission to gather valid data to use as a surrogate. Lastly, we did not normalize 
urinary NGAL concentrations for urinary creatinine concentration, since urinary creatinine 
data was not available, and doubts remain about the necessity for such a correction (26,27).
The main clinical application of our findings is that it provides early awareness which 
should trigger interventions to stop further renal injury in oliguric patients with NGAL 
above the cutoff value. Decision algorithms similar to the one proposed for cardiac-surgery-
associated-AKI could be used to triage patients and resources (28). In this population 
with possible AKIsCr, fluid resuscitation should be limited to the restoration of systemic 
hemodynamic variables, and nephrotoxic agents should be discontinued. In a research 
setting, NGAL is able to adjust the inclusion criteria to create early intervention studies 
similar to the STOP-AKI trial (29) currently including patients only after serum creatinine 
starts to increase, reducing the lag-time before interventions are started. 
More importantly, measuring NGAL may lead to differentiation between structural renal 
injury and functional adaptation. Patients with higher NGAL but without an increase in 
serum creatinine should be classified as subclinical AKIsCr (23). These patients have worse 
outcomes than those with a low NGAL value and no increase in serum creatinine most 
likely due to adequate renal reserves (30), suggesting that subclinical AKIsCr should be 
considered similar to AKIsCr with elevated NGAL levels. Conversely, patients with AKIsCr may 
have relatively low NGAL levels due to glomerular impairment without tubular injury which 
is associated with worse outcomes than those with low NGAL and no serum creatinine 
increase (23,30). Whether these patients should be treated as AKIsCr or as a third entity in 
the AKI spectrum remains to be determined.
conclUsion
In summary, NGAL is able to discriminate between critically ill patients with oliguria 
associated with AKIsCr and those with oliguria due to functional adaptation. More specifically, 
NGAL as part of a multivariate model is able to exclude AKIsCr whereas NGAL as a single 
marker can identify oliguric patients at risk for AKIsCr. Thus, NGAL could be used to aid 
clinical management in patients presenting with early oliguria. Guided by NGAL, clinicians 
can reduce further renal injury and identify patients with subclinical AKIsCr. However, since 
serum creatinine is an imperfect diagnostic standard for factual renal cellular injury, further 
prospective studies are needed to confirm our findings.
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Consequences of fluid management
There appears to be a mismatch between intravenous fluid administration and fluid loss via 
urine output in the critically ill patient, which leads to fluid overload and related adverse 
events. Although commonly assumed, it has never been shown that patients who are still 
fluid responsive have a lower risk to develop tissue edema. Therefore, in chapter 2, we 
hypothesized that excessive fluid administration in the first days of intensive care admission 
is associated with higher extravascular lung water index (EVLWI), but not in fluid responsive 
patients. The main finding of this retrospective study was that a higher fluid balance was 
associated with an increase in EVLWI. However, increases in EVLWI were independent from 
the presence of fluid responsiveness, which may be due to fluid responsiveness not being a 
factor in fluid extravasation. More importantly, patients showed poorer oxygenation despite 
higher FiO2 when EVLWI increased. Preventing fluid overload may therefore lead to adequate 
oxygenation, less ventilatory support, and shorter length of stay. In chapter 3, we investigated 
whether high early fluid intake and fluid balances after admission were associated with the 
occurrence of delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid 
hemorrhage (aSAH), and the feasibility of decreasing fluid input guided by cardiac output 
monitoring with transpulmonary thermodilution (TPT). In this retrospective study of two 
separate aSAH cohorts, early high daily fluid input was independently associated with 
DCI and poor outcome in one cohort, and fluid loading beyond normal preload occurred 
in the both cohorts. It was nevertheless feasible to significantly restrict fluid intake while 
maintaining adequate preload with TPT in selected high-risk patients with aSAH. 
Taking both chapters together, these results corroborate the potential harm from fluid 
overload in patients and support further study on potential benefit of fluid restriction 
guided by cardiac output-based hemodynamic monitoring. While decreasing fluid intake 
may not necessarily directly improve outcome, it is likely that it will prevent adverse effects 
negatively impacting outcome.
Fluid management guided by targeting urine output
One of the main focuses of this thesis was to investigate whether additional fluid 
administration aimed at improving urine output had the desired effect of protecting against 
acute kidney injury (AKI) or other adverse outcomes. In chapter 4 and 5, both systematic 
reviews with meta-analyses, we focused on whether including urine output as a target in 
the protocols of studies comparing goal-directed therapy (GDT) with conventional fluid 
management (CFM) strategies in surgical and critically ill patients reduced the incidence of 
AKI and mortality, respectively. In chapter 4, while GDT was superior to CFM in preventing 
AKI, the addition of urine output as a target in either protocol appeared to increase the 
occurrence of AKI. In chapter 5, the principal finding was that while GDT might decrease 
30-day mortality, including urine output as a target may increase 30-day mortality. However, 
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after adjusting for confounders, there was insufficient evidence to associate targeting urine 
output with an effect on 30-day mortality. Additionally, using the common urine output 
threshold of 0.5 ml/kg/h, there was insufficient evidence to suggest that targeting urine 
output affected 30-day mortality. In chapter 6, we investigated whether perioperative 
restrictive fluid management influenced the occurrence of oliguria, AKI, fluid intake and fluid 
balance. We also investigated whether targeting urine output influenced these parameters. In 
this meta-analysis, we found insufficient evidence to associate restrictive fluid management 
with an increase in oliguria and AKI occurrence. The difference in intraoperative fluid intake 
between conventional and restrictive fluid management was similar whether urine output 
was targeted or not, and excluding urine output as a target in a restrictive fluid management 
protocol did not seem to be associated with an increase in AKI occurrence.
Summarizing these three chapters, at best, targeting urine output does not influence AKI 
or mortality, and at worst, the addition of urine output as a target in a fluid management 
protocol increases the risk for AKI and mortality. The difficulty in interpreting the findings 
from these meta-analyses lies in the high variability between studies and the lack of 
any direct comparison between targeting and not targeting urine output. Nevertheless, 
there appears to be no clear benefit of incorporating urine output as a target in any fluid 
management strategy. Overall, the findings in these chapters support the removal of urine 
output as a target in any fluid management protocol due to the lack of the desired effect 
on AKI.
Fluid management in oliguria
Another aim of this thesis was to assess whether the urine output response after a fluid 
challenge can be predicted, and whether this effect impacts patients’ outcome. We used 
neutrophil gelatinase associated lipocalin (NGAL) as a marker for renal damage and in 
chapter 7, we performed a post-hoc analysis in a cohort of critically ill patients with oliguria 
occurring within 6 h of intensive care unit (ICU) admission. Our hypothesis was that low 
NGAL concentrations in oliguric critically patients are most likely due to hemodynamic or 
hormonal compensation mechanisms, whereas a high NGAL concentration heralded AKI by 
a rise in serum creatinine within the first 72 hours. The main finding was that NGAL can be 
used in a clinical setting to discriminate between oliguric critically ill patients with AKI from 
oliguric patients with a functional, reversible adaptation. In an oliguric patient with known 
risk factors, the addition of NGAL improved the ability to rule out AKI. Furthermore, NGAL by 
itself was not inferior to a multivariate model of known risk factors, and NGAL can be used 
to identify or exclude AKI in oliguric patients even when pre-admission serum creatinine 
value and other risk factors are unknown. 
The supposed protective effects of renal fluid responsiveness (RFR) against AKI and renal 
damage have not been proven. In chapter 8, we performed a prospective interventional 
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study in critically ill patients with isolated oliguria for at least 2 hours to test whether 
cardiac fluid responsiveness (CFR) is associated with RFR, whether RFR protects against 
AKI occurrence or renal damage as assessed by NGAL, and whether there are predictors 
for RFR and AKI in this population. We found that CFR in critically ill patients with isolated 
oliguria was not associated with RFR, and the development of AKI was not influenced by 
RFR, though urinary NGAL after the fluid challenge - as a sign of tubular injury - was lower in 
RFR+ patients than in RFR- patients. Nevertheless, there were no good, specific predictors 
for RFR or AKI.
Summarizing both chapters, clinicians can use NGAL to identify patients with oliguria 
due to functional adaptation during the early ICU admission. Additionally, oliguria is not a 
reliable indicator of inadequate cardiac output, and RFR is difficult to predict. Simply put, 
when oliguria occurs, low NGAL values may rule out structural cellular damage and no 
additional fluid boluses aimed at improving urine output should be given in the absence 
of other signs of hemodynamic instability. These chapters findings support the paradigm 
that urine output should never be a goal onto itself, but should be viewed as a sign of an 
underlying problem.
Future perspectives
In this thesis, we showed the adverse effects of inappropriate fluid loading on tissue edema 
and outcome, while hemodynamic monitoring using TPT may be able to safely reduce 
fluid intake without negatively impacting cardiac output. Additionally, contrary to current 
practice, targeting urine output and a subsequent improvement in urine output do not 
protect against AKI either due to the resolution of hypovolemia through other resuscitation 
targets or because the cause of oliguria does not respond to fluids. Nevertheless, several 
questions remain.
Though hemodynamic monitoring – either by TPT or other methods – has become 
commonplace in the ICU for certain populations, its use in the general ICU population is 
limited. While the need for and beneficial effects of hemodynamic monitoring in sepsis 
and high-risk surgical patients are well documented, guiding fluid intake by hemodynamic 
monitoring tools other than conventional measures remains to be explored. For example, 
the cost-effectiveness of using TPT in patients with respiratory insufficiency necessitating 
mechanical ventilation to prevent increases in extravascular volume is an interesting topic. 
Although conventional hemodynamic parameters may be adequate to hypovolemia, it is 
the ability of hemodynamic monitoring tools such as TPT to signal hypervolemia which is of 
interest even outside the traditional target groups.
While we advocate the use of permissive oliguria in this thesis due to the lack of effect 
when targeting urine output, its impact on patient outcome needs to be investigated further. 
This is of increased importance when considering the use of early renal replacement therapy 
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during the deresuscitation phase when urine output is unable to adequately clear the fluid 
excess cumulated during the resuscitation phase. It is not only important to investigate 
when to start renal replacement therapy, but also how to monitor its effect on renal 
recovery and when to discontinue it. While the interventional burden of renal replacement 
therapy on this new group of patients may seem disproportionate, the expected benefits 
from reducing the effects of fluid overload would most likely outweigh it.
Lastly, further investigation into the underlying etiology of oliguria is needed. In this 
thesis, we showed that not all oliguric patients with elevated NGAL as a sign of tubular 
damage had an increase in serum creatinine and vice versa. Similarly, NGAL was elevated in 
patients with persistent oliguria who were cardiac fluid responsive, but not in patients who 
did not have an increase in stroke volume after a fluid challenge. The former is assumed 
to be due to microcirculatory dysfunction with inflammatory stress, while the latter could 
be considered a form of functional adaptation with glomerular dysfunction. It would be 
interesting to see whether the underlying etiology further influences the clinical course and 
long-term outcome, as well as finding new avenues for early interventions.
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Consequenties van intraveneus vochtbeleid
Er lijkt een dissociatie te zijn tussen het intraveneus toegediende vocht en het vochtverlies 
via de urineproductie in ernstig zieke patiënten, wat leidt tot overvulling en daaraan 
gerelateerde complicaties. Alhoewel het algemeen aangenomen wordt, is het nog niet 
bewezen dat patiënt die reageren op een intraveneuze vochtbolus een lagere kans hebben 
op het ontwikkelen van weefseloedeem. Daarom is onze hypothese in hoofdstuk 2 dat 
te veel intraveneuze vochttoediening in de eerste dagen van de intensive care opname 
geassocieerd is met een hogere extravasculair longwater index (EVLWI), maar niet in 
vochtresponsieve patiënten. De voornaamste bevinding in deze retrospectieve studie was 
dat een hogere vochtbalans geassocieerd was met een stijging in EVLWI. Maar stijgingen 
in EVLWI waren onafhankelijk van vochtresponsiviteit, wat verklaard kan worden doordat 
vochtresponsiviteit niet een bepalende factor is in het ontstaan van vochtlekkage uit de 
bloedvaten. Belangrijker was de bevinding dat, wanneer EVLWI toenam, patiënten een lagere 
arteriële zuurstofconcentratie hadden ondanks meer zuurstofaanbod via de beademing. 
Het voorkomen van overvulling zou daardoor kunnen leiden tot betere zuurstofopname, 
lagere beademingsvoorwaarden en een kortere opnameduur.
In hoofdstuk 3 onderzochten wij of hoge vochtintake en vochtbalansen kort na 
de opname geassocieerd zijn met cerebrale ischemie (DCI) in patiënten met een 
aneurysmatisch subarachnoïdale bloeding (aSAH) en of hemodynamische monitoring 
middels de transpulmonale thermodilutie techniek (TPT) kan leiden tot het veilig verlagen 
van de vochtintake. In deze retrospectieve studie van twee verschillende aSAH cohorten 
was hoge vochtintake onafhankelijk gerelateerd met DCI en slechte uitkomst in een 
cohort. Daarnaast was de vochtintake hoger dan normaal in beide cohorten. Desondanks 
was het mogelijk om de vochtintake significant te verlagen met behoud van adequate 
hemodynamiek middels TPT in geselecteerde hoog risicopatiënten met aSAH.
Als beide artikelen samengenomen worden, dan zijn deze resultaten in overeenstemming 
met de mogelijke schade van overvulling in patiënten die in eerder studies zijn gezien. 
Daarnaast ondersteunen beide studies de noodzaak van verder onderzoek naar het 
potentiele voordeel van vochtbeperking middels hemodynamische monitoring. Alhoewel 
het verlagen van de vochtintake wellicht niet direct leidt tot betere uitkomsten, is het 
waarschijnlijk dat het nadelige effecten voorkomt.
Urineproductie gestuurde vochtbeleid
Een van de kernpunten van dit proefschrift was om te onderzoeken of extra vochttoedieningen 
gericht op het verbeteren van de urineproductie het gewenste effect bereiken, beschermen 
tegen acute nierschade (AKI) of het voorkomen van ongewenste uitkomsten. In hoofdstuk 
4 en 5, beiden systematische review artikelen met meta-analyses, focusten we op of 
het toevoegen van urineproductie als een doel in behandelprotocollen leidde tot een 
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respectievelijke verlaging in het voorkomen van AKI en sterfte in studies die goal-directed 
therapy (GDT) vergelijken met conventioneel vochtbeleid (CFM) in chirurgische en 
ernstig zieke patiënten. In hoofdstuk 4 was GDT superieur ten opzichte van CFM in het 
beschermen tegen AKI, maar het toevoegen van urineproductie als een behandeldoel in 
beide protocollen lijkt te leiden tot een hoger risico op het krijgen van AKI. De voornaamste 
bevinding in hoofdstuk 5 was dat het toevoegen van urineproductie als een behandeldoel 
30-dagen sterfte leek te verhogen, ondanks een risico reductie in 30-dagen sterfte door GDT. 
Desondanks was er na correctie voor vertroebelende factoren onvoldoende aanwijzingen 
dat urineproductie-gestuurd vochtbeleid de 30-dagen sterfte beïnvloedde. Daarnaast was 
er gebruikmakend van de standaard afkapwaarde van 0,5 ml/kg/uur voor urineproductie 
eveneens onvoldoende aanwijzingen dat urineproductie-gestuurd vochtbeleid de 30-dagen 
sterfte beïnvloedde. In hoofdstuk 6 onderzochten wij of restrictief vochtbeleid tijdens de 
perioperatieve fase invloed had op het krijgen van oligurie, het ontstaan van AKI, vochtintake 
en vochtbalans. We onderzochten ook of urineproductie-gestuurde vochtbeleid invloed 
had op deze waarden. In deze meta-analyse vonden we onvoldoende aanwijzingen om een 
terughoudend vochtbeleid te associëren met een toename in oligurie en AKI. Het verschil 
in intra-operatieve vochtintake tussen een conventionele en restrictieve vochtbeleid was 
hetzelfde ongeacht of urineproductie als een behandeldoel werd gebruikt. Het ontbreken 
van urineproductie als een behandeldoel in een restrictief vochtbeleid leek niet geassocieerd 
met een toename in AKI.
Samenvattend lijkt het gebruik van urineproductie als behandeldoel in het beste geval 
niet van invloed op het ontstaan van AKI of sterfte, maar in het slechtste geval verhoogt 
het juist de kans op AKI of sterfte. De moeilijkheid in het interpreteren van de bevindingen 
uit deze meta-analyses komt door de grote verschillen in de gebruikte studies om het 
effect uit de beschreven literatuur te analyseren en het gebrek aan studies die een directe 
vergelijking maken tussen het gebruiken en het niet gebruiken van urineproductie als een 
behandeldoel. Desalniettemin lijkt er geen duidelijk voordeel te zijn aan het gebruik van 
urineproductie als behandeldoel. Al met al ondersteunen deze hoofdstukken het laten 
vallen van urineproductie als een doel in elke vochtbeleidsprotocol gezien het gebrek van 
enig gewenst effect op AKI.
Vochtbeleid in oligurie
Een ander kernpunt van dit proefschrift was het vaststellen of een stijging in urineproductie 
na een vochtbolus te voorspelling is en of dit effect van invloed is op de uitkomst van een 
patiënt. We gebruikten neutrophil gelatinase associated lipocalin (NGAL) als een marker 
voor nierschade en in hoofdstuk 7 lieten we een post-hoc analyse zien van een cohort van 
ernstig zieke patiënten met oligurie in de eerste zes uur van de intensive care opname. 
Onze hypothese was dat een lage NGAL-waarde in oligure, ernstig zieke patiënten meest 
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waarschijnlijk door hemodynamische of hormonale compensatiemechanismen komt, 
terwijl een hoge NGAL-waarde een teken is van het krijgen van AKI in de eerste 72 uur 
van de opname. De voornaamste bevinding was dat NGAL in een klinische setting gebruikt 
kan worden om AKI in oligure, ernstig zieke patiënten te onderscheiden van functionele 
adaptatie als oorzaak voor de oligurie. In een oligure patiënt verbeterde de toevoeging van 
NGAL aan een voorspellingsmodel op basis van bekende risicofactoren de capaciteit om AKI 
uit te sluiten. Daarnaast was het voorspellend vermogen van enkel NGAL niet inferieur aan 
die van een model met bekende risicofactoren. NGAL kan zelfs gebruikt worden om AKI aan 
te tonen of uit te sluiten in oligure patiënten als serum creatinine waarden voor opname of 
andere risicofactoren niet bekend zijn. 
De veronderstelde beschermende effecten van renale vochtresponsiviteit (RFR) op AKI 
en nierschade zijn niet bewezen. In hoofdstuk 8 voerden wij een prospectieve interventie 
studie uit in ernstig zieke patiënten met oligurie gedurende tenminste 2 uur om te testen 
of cardiale vochtresponsiviteit (CFR) geassocieerd is met RFR, of RFR beschermt tegen 
het ontstaan van AKI of nierschade uitgedrukt in NGAL-expressie, en of er voorspellende 
factoren zijn voor RFR en AKI in deze patiëntenpopulatie. We vonden dat CFR in ernstig 
zieke patiënten met oligurie niet geassocieerd was met RFR en dat het ontstaan van AKI 
niet beïnvloed werd door RFR. Daarnaast was urine NGAL, als teken voor nierschade, lager 
in de RFR+ groep na de vochtbolus dan in de RFR- patiënten, maar er waren geen goede, 
specifieke voorspellers voor RFR en AKI. 
Samenvattend kunnen artsen NGAL gebruiken om aan te tonen dat oligurie in de vroege 
intensive care opname veroorzaakt wordt door functionele adaptatie. Daarnaast is oligurie 
geen goede indicator voor een inadequate hemodynamiek en RFR is moeilijk te voorspellen. 
Simpel gezegd, als oligurie zich voordoet, sluit een lage NGAL-waarde nierschade uit en 
hebben extra vochttoedieningen gericht op het verbeteren van de urineproductie geen 
zin als andere tekenen van hemodynamische instabiliteit afwezig zijn. Deze hoofdstukken 
ondersteunen de zienswijze dat urineproductie niet een doel op zich moet zijn, maar dat 
het gezien moet worden als een teken van een onderliggend probleem.
Toekomstperspectieven
In dit proefschrift toonden wij de effecten van ongepaste vochttoedieningen op 
weefseloedeem en uitkomst, terwijl hemodynamische monitoring middels TPT mogelijk kan 
leiden tot het veilig verlagen van de vochtintake. In tegenstelling tot wat in het algemeen 
gedacht werd, beschermen het gebruik van urineproductie als een behandeldoel en een 
stijging van de urineproductie na een vochtbolus niet tegen AKI. Dit is of vanwege het 
verbeteren van de ondervulling door andere behandeldoelen of doordat de oorzaak van de 
oligurie niet reageert op vulling. Desalniettemin blijven er vragen onbeantwoord.
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Alhoewel hemodynamische monitoring door middel van TPT of andere methoden 
ondertussen gemeengoed is geworden in bepaalde patiëntengroepen op de intensive care, 
is het gebruik ervan in de algemene intensive care populatie beperkt. De noodzaak voor 
en de voordelen van hemodynamische monitoring in sepsis en hoog-risico chirurgische 
patiënten zijn goed gedocumenteerd, maar het sturen van de vochtintake op geleide van 
hemodynamische monitoringstechnieken anders dan conventionele methoden moet nog 
uitgezocht worden. Een interessant onderwerp is bijvoorbeeld de kosteneffectiviteit van 
het gebruik van TPT ter voorkoming van stijging in EVLWI in patiënten met noodzaak tot 
mechanische beademing. Terwijl traditionele hemodynamische parameters adequaat 
genoeg zijn om ondervulling te beoordelen, is de toegevoegde waarde van technieken 
zoals TPT dat hiermee ook overvulling beoordeeld kan worden - ook buiten de gebruikelijk 
patiëntengroepen.
Alhoewel wij in dit proefschrift een voorstander zijn van het accepteren van oligurie 
gezien het gebrek aan effect als urineproductie als behandeldoel wordt gezien, moet 
de invloed van het accepteren van oligurie op uitkomstparameters verder onderzocht 
worden. Dit is vooral van belang vanwege het vroege gebruik van nierfunctie-vervangende 
therapie zoals tijdelijke dialyse tijdens de vroege deresuscitatie fase als de urineproductie 
niet in staat is om het ontstane vochtoverschot te kunnen verminderen. Het is niet alleen 
belangrijk om uit te zoeken wanneer er met nierfunctie-vervangende therapie gestart 
moet worden, maar ook het bijhouden van het effect op het herstel van de nierfunctie 
en wanneer er gestopt kan worden met nierfunctie vervangende therapie. De toename in 
het gebruik van nierfunctie vervangende therapie in deze nieuwe patiëntenpopulatie zou 
kunnen leiden tot een onevenredige behandelbelasting, maar de verwachte voordelen van 
het verminderen van de complicaties van overvulling zullen hier waarschijnlijk meer dan 
voldoende voor compenseren.
Als laatste is er verder onderzoek nodig naar de onderliggende ontstaanswijze van 
oligurie. In dit proefschrift toonden we dat niet alle oligure patiënten met een verhoogd 
NGAL-waarde als teken van nierschade een stijging van het serum creatinine doormaakte 
en omgekeerd. Daarnaast was NGAL hoger in patiënten met aanhoudende oligurie die 
wel cardiaal vocht responsief waren in tegenstelling tot patiënten die geen stijging van 
hun slagvolume lieten zien na een vochtbolus.  Het eerste kan passen bij microcirculatoire 
dysfunctie met inflammatoire stress, terwijl het laatste gezien kan worden als een soort 
functionele adaptatie met glomerulaire dysfunctie. Het zou zeer interessant zijn om te 
onderzoeken of de onderliggende oorzaak ook invloed heeft op het klinische beloop en de 
uitkomst op lange termijn. Daarnaast zou verder onderzoek naar de onderliggende oorzaak 
ook nieuwe aanwijzingen kunnen geven voor vroege interventies.
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